PMID- 95914 OWN - NLM STAT- MEDLINE DA - 19780814 DCOM- 19780814 LR - 20091118 IS - 0009-9104 (Print) IS - 0009-9104 (Linking) VI - 31 IP - 3 DP - 1978 Mar TI - Protection of mice against haemoprotozoan Babesia microti with Brucella abortus strain 19. PG - 518-23 AB - When Brucella abortus strain 19 is given intraperitoneally to mice it protects them against subsequent infection with large doses of Babesia microti. The protection obtained was more effective when B. abortus was given intraperitoneally than when it was injected subcutaneously. This non-specific protection seems to be best explained by the stimulation of macrophages so as to release a mediator which limits the intracellular replication of the parasites. FAU - Herod, E AU - Herod E FAU - Clark, I A AU - Clark IA FAU - Allison, A C AU - Allison AC LA - eng PT - Journal Article PL - ENGLAND TA - Clin Exp Immunol JT - Clinical and experimental immunology JID - 0057202 RN - 0 (Antibodies) RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Antibodies/analysis MH - Babesiosis/*prevention & control MH - *Brucella Vaccine/administration & dosage MH - Brucella abortus/immunology MH - Female MH - Injections, Intraperitoneal MH - Injections, Subcutaneous MH - Mice MH - Mice, Inbred CBA MH - Time Factors PMC - PMC1541244 OID - NLM: PMC1541244 EDAT- 1978/03/01 MHDA- 1978/03/01 00:01 CRDT- 1978/03/01 00:00 PST - ppublish SO - Clin Exp Immunol. 1978 Mar;31(3):518-23. PMID- 415406 OWN - NLM STAT- MEDLINE DA - 19780417 DCOM- 19780417 LR - 20031114 IS - 0042-4900 (Print) IS - 0042-4900 (Linking) VI - 101 IP - 26-27 DP - 1977 Dec 24-31 TI - Protective effects of colostral antibodies to Br abortus on strain 19 vaccination and field injection. PG - 521-4 AB - Calves which have received no antibodies against Br abortus in their colostrum may respond to strain 19 vaccination even on the first day of life. However, calves with such antibodies may completely suppress any response to S19 vaccination. In calves which have received very high titres of passive antibodies from their dams complete suppresson of vaccinal response may be expected to occur up to about 153 days of age. Thus, if vaccination is restricted to between 90 and 180 days many calves in infected herds will not be protected by routine vaccination with S19. In calves born of and reared on infected dams the colostral antibodies also have a marked protective effect. In spite of heavy exposure to Br abortus at birth and later from infected milk only six out of 64 calves (9.4 per cent) developed persistent positive titres. The remaining calves reverted to zero titres within 12 months and an anamnestic test indicated that of these up to 15 per cent may have been latent carriers but even more remarkably, 85 per cent of such calves were not even "primed" by such heavy exposure. FAU - Cunningham, B AU - Cunningham B LA - eng PT - Journal Article PL - ENGLAND TA - Vet Rec JT - The Veterinary record JID - 0031164 RN - 0 (Antibodies, Bacterial) SB - IM MH - Agglutination Tests MH - Animals MH - *Antibodies, Bacterial/analysis MH - Brucella abortus/*immunology MH - Cattle/*immunology MH - Colostrum/*immunology MH - Complement Fixation Tests MH - Immunity, Maternally-Acquired MH - Vaccination/*veterinary EDAT- 1977/12/24 MHDA- 1977/12/24 00:01 CRDT- 1977/12/24 00:00 PST - ppublish SO - Vet Rec. 1977 Dec 24-31;101(26-27):521-4. PMID- 825014 OWN - NLM STAT- MEDLINE DA - 19770103 DCOM- 19770103 LR - 20031114 IS - 0003-4193 (Print) IS - 0003-4193 (Linking) VI - 7 IP - 1 DP - 1976 TI - Vaccination against bovine brucellosis with a low dose of strain 19 administered by the conjunctival route. PG - 1-8 AB - Eighteen 25 month old cows were vaccinated once either with 10(6) to 10(10) living bacteria of Brucella abortus B 19 by the conjunctival route, or with 2.5 to 5 X 10(10) formalin-killed bacteria of the same strain by subcutaneous injection. Fifteen days post-vaccination, low but definite agglutination titers were present in sera of cattle receiving 10(10) living bacteria by the conjunctival route, whereas high titers were observed in the control group given subcutaneous injection of killed bacteria (table I). Agglutination reactions were negative in sera from all cattle receiving less than 10(10) bacteria, and complement fixation tests were negative with all sera. Seventy-one 4 month old claves were vaccinated by the conjunctival route with different doses (10(6) to 10(10)) of living bacteria, either freshly prepared or lyophilized. At autopsy about 15 or about 30 days later, the parotid, submaxillary and retropharyngeal lymph nodes were removed and cultured on Brucella selective medium. Blood samples were taken at autopsy for testing by agglutination, complement fixation, Coombs test and (for some samples) by the Rose Bengal plate test. Colonization of at least one lymph node was observed in 26 of 34 calves given 10(9) bacteria, in all 9 calves given 5 X 10(9) bacteria and in all 12 calves given 10(10) bacteria. Serological responses were demonstrated rarely, and then only in agglutination and Coombs tests. The 5 X 10(9) dose, wich following conjunctival inoculation consistently colonized the regional lymph nodes without inducing significant serological response, would be the most suitable dose for the vaccination of calves and cows. FAU - Plommet, M AU - Plommet M FAU - Plommet, A M AU - Plommet AM LA - eng PT - Journal Article PL - FRANCE TA - Ann Rech Vet JT - Annales de recherches veterinaires. Annals of veterinary research JID - 1267230 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Brucella Vaccine/*administration & dosage MH - Brucella abortus/isolation & purification MH - Brucellosis, Bovine/immunology/microbiology/*prevention & control MH - Cattle MH - Conjunctiva MH - Female MH - Injections MH - Lymph Nodes/*microbiology MH - Male MH - Vaccination/veterinary EDAT- 1976/01/01 MHDA- 1976/01/01 00:01 CRDT- 1976/01/01 00:00 PST - ppublish SO - Ann Rech Vet. 1976;7(1):1-8. PMID- 1306918 OWN - NLM STAT- MEDLINE DA - 19930813 DCOM- 19930813 LR - 20061115 IS - 0049-4747 (Print) IS - 0049-4747 (Linking) VI - 24 IP - 1 DP - 1992 Feb TI - Control of brucellosis in Kuwait by vaccination of cattle, sheep and goats with Brucella abortus strain 19 or Brucella melitensis strain Rev. 1. PG - 45-9 AB - In Kuwait, approximately 12,000 dairy cows were vaccinated with a reduced dose of 3 x 10(9) Brucella abortus strain 19 and approximately 350,000 sexually mature sheep and goats with a reduced dose of 10(7) B. melitensis strain Rev. 1. Using the criteria of prevaccinal and postvaccinal incidences of antibodies, abortions, and human cases of brucellosis, the programme was very successful. Widespread vaccination of adult animals is the most effective method of controlling brucellosis among cattle, sheep and goats in many countries. AD - Animal Health Department, Public Authority for Agriculture Affairs and Fish Resources, Kuwait. FAU - al-Khalaf, S A AU - al-Khalaf SA FAU - Mohamad, B T AU - Mohamad BT FAU - Nicoletti, P AU - Nicoletti P LA - eng PT - Comparative Study PT - Journal Article PL - SCOTLAND TA - Trop Anim Health Prod JT - Tropical animal health and production JID - 1277355 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - *Brucella Vaccine MH - Brucella abortus/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/immunology/prevention & control/*veterinary MH - Brucellosis, Bovine/immunology/prevention & control MH - Cattle MH - Female MH - Goat Diseases/immunology/*prevention & control MH - Goats MH - Kuwait MH - Sheep MH - Sheep Diseases/immunology/*prevention & control MH - Species Specificity MH - Vaccination/*veterinary EDAT- 1992/02/01 MHDA- 1992/02/01 00:01 CRDT- 1992/02/01 00:00 PST - ppublish SO - Trop Anim Health Prod. 1992 Feb;24(1):45-9. PMID- 1439207 OWN - NLM STAT- MEDLINE DA - 19921209 DCOM- 19921209 LR - 20061115 IS - 0034-5288 (Print) IS - 0034-5288 (Linking) VI - 53 IP - 2 DP - 1992 Sep TI - Comparative behaviour of Brucella abortus strains 19 and RB51 in the pregnant mouse. PG - 179-83 AB - Pregnant BALB/c mice received various doses of either Brucella abortus strain 19, a smooth vaccine strain, or B abortus strain RB51, a stable rough organism, intraperitoneally on day 9 of gestation to compare the relative pathogenicity of the two attenuated strains. Nine days after inoculation, spleens and placentas were collected for bacteriological and histopathological examination. A dose of 10(7.5) and strain 19 organisms produced a severe necrosuppurative placentitis occasionally accompanied by fetal death. This dose resulted in a 10-fold higher level of splenic infection than did a dose of 10(9.5) strain RB51 organisms, which produced only mild to minimal placentitis not associated with fetal death. Strain 19 infected mice showed seroconversion in the standard tube agglutination test in contrast to the seronegative titre of strain RB51 infected mice. The results of this study corroborate previous investigations on the relative pathogenicity and the serological response of the non-pregnant mouse to strain RB51. AD - Department of Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg 24061. FAU - Tobias, L AU - Tobias L FAU - Schurig, G G AU - Schurig GG FAU - Cordes, D O AU - Cordes DO LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Res Vet Sci JT - Research in veterinary science JID - 0401300 SB - IM MH - Animals MH - Brucella abortus/*pathogenicity MH - Brucellosis, Bovine/microbiology MH - Cattle MH - Disease Models, Animal MH - Female MH - Mice MH - Mice, Inbred BALB C MH - Pregnancy MH - Pregnancy, Animal/*physiology EDAT- 1992/09/01 MHDA- 1992/09/01 00:01 CRDT- 1992/09/01 00:00 AID - 0034-5288(92)90107-D [pii] PST - ppublish SO - Res Vet Sci. 1992 Sep;53(2):179-83. PMID- 1612769 OWN - NLM STAT- MEDLINE DA - 19920724 DCOM- 19920724 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 60 IP - 7 DP - 1992 Jul TI - Survival of virulent and attenuated strains of Brucella abortus in normal and gamma interferon-activated murine peritoneal macrophages. PG - 3011-4 AB - Virulent Brucella abortus 2308 was phagocytized more readily than attenuated strain 19 following opsonization and survived at significantly higher levels in normal murine peritoneal macrophages and in macrophages treated with gamma interferon. Activation of macrophages with gamma interferon greatly inhibited intracellular replication of strain 2308 but did not result in its elimination. These data support the hypothesis that persistent infection of the host requires the ability of antibody-opsonized B. abortus to survive in activated macrophages. AD - Department of Microbiology, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853. FAU - Jones, S M AU - Jones SM FAU - Winter, A J AU - Winter AJ LA - eng PT - Comparative Study PT - In Vitro PT - Journal Article PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Animals MH - Brucella abortus/*pathogenicity MH - Cell Survival/immunology MH - Female MH - Immunity, Cellular MH - Interferon-gamma/immunology MH - Macrophage Activation/*immunology MH - Macrophages/*immunology MH - Mice MH - Mice, Inbred BALB C MH - Phagocytosis MH - Time Factors PMC - PMC257269 OID - NLM: PMC257269 EDAT- 1992/07/01 MHDA- 1992/07/01 00:01 CRDT- 1992/07/01 00:00 PST - ppublish SO - Infect Immun. 1992 Jul;60(7):3011-4. PMID- 1908158 OWN - NLM STAT- MEDLINE DA - 19910918 DCOM- 19910918 LR - 20061115 IS - 0378-1135 (Print) IS - 0378-1135 (Linking) VI - 28 IP - 2 DP - 1991 Jul TI - Biological properties of RB51; a stable rough strain of Brucella abortus. PG - 171-88 AB - A rifampin-resistant mutant of Brucella abortus, designated RB51, was derived by repeated passage of strain 2308 on Trypticase soy supplemented with 1.5% agar and varying concentrations rifampin or penicillin. The RB51 colonies absorbed crystal violet and RB51 cell suspensions autoagglutinated, indicating a rough type colonial morphology for this strain. No O-chain component was detected in lipopolysaccharide (LPS) extracted from RB51 on SDS-PAGE gels stained with silver. Western blot analysis with the monoclonal antibody BRU 38, which is specific for the perosamine homopolymer O-chain of smooth Brucella LPS, indicated that the LPS of RB51 is highly deficient in O-chain when compared with the parenteral smooth strain 2308 or rough strain 45/20. Biochemically, RB51 resembles parental strain 2308 in its ability to utilize erythritol. Intraperitoneal inoculation of RB51 into mice results in a splenic colonization which is cleared within four weeks post infection. RB51 does not revert to smooth colony morphology upon passage in vivo (mice) or in vitro. Mice infected with RB51 produce antibodies against B. abortus antigens including class 2 and 3 outer membrane proteins but not against the O-chain. Furthermore, rabbits, goats and cattle hyperimmunized with sonicates of RB51 develop antibodies to B. abortus cellular antigens but do not develop antibodies specific for the O-chain. Immunization of mice with 1 x 10(8) viable RB51 organisms confers significant protection against challenge with virulent B. abortus strain 2308. AD - Department of Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, VA 24061. FAU - Schurig, G G AU - Schurig GG FAU - Roop, R M 2nd AU - Roop RM 2nd FAU - Bagchi, T AU - Bagchi T FAU - Boyle, S AU - Boyle S FAU - Buhrman, D AU - Buhrman D FAU - Sriranganathan, N AU - Sriranganathan N LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - NETHERLANDS TA - Vet Microbiol JT - Veterinary microbiology JID - 7705469 RN - 0 (Antigens, Bacterial) RN - 13292-46-1 (Rifampin) SB - IM MH - Animals MH - Antigens, Bacterial/immunology MH - Blotting, Western MH - Brucella abortus/drug effects/*physiology MH - Brucellosis/microbiology MH - Brucellosis, Bovine/microbiology MH - Cattle MH - Drug Resistance, Microbial MH - Goats MH - Mice MH - Mice, Inbred BALB C MH - Rabbits MH - Rifampin/pharmacology EDAT- 1991/07/01 MHDA- 1991/07/01 00:01 CRDT- 1991/07/01 00:00 AID - 0378-1135(91)90091-S [pii] PST - ppublish SO - Vet Microbiol. 1991 Jul;28(2):171-88. PMID- 2844673 OWN - NLM STAT- MEDLINE DA - 19881123 DCOM- 19881123 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 56 IP - 11 DP - 1988 Nov TI - Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. PG - 2808-17 AB - A single vaccination of mice with a complex of porin and smooth lipopolysaccharide (porin-S-LPS) extracted from virulent Brucella abortus 2308 provided significant protection (P less than 0.01 to P less than 0.001) against challenge with the same strain, equivalent to that achieved by vaccination with living attenuated B. abortus 19. The porin-S-LPS vaccine given without adjuvant or in several adjuvants (trehalose dimycolate and muramyl dipeptide; the pluronic polymer L-121 and muramyl dipeptide; or complexed with Quil A in immunostimulating complexes) provided equivalent protection. In contrast, one vaccination with porin complexed with rough LPS (porin-R-LPS) from a rough mutant of strain 2308 provided no protection with any adjuvant tested. In one experiment, two inoculations with the porin-R-LPS resulted in a low level of protection, probably owing to priming of the animals for production of O-polysaccharide-specific antibodies. However, one vaccination with rough-strain porin covalently bound to purified O polysaccharide conferred protection equal to that obtained with natural complexes of porin-S-LPS or with living strain 19. A synthetic vaccine containing long chains of O polysaccharide was more effective than one prepared with short chains. Protective vaccines caused the formation of increased concentrations of circulating O-polysaccharide-specific antibodies, although there were individual exceptions to the quantitative association between O-polysaccharide-specific antibodies and protection. Antibodies specific for porin or R-LPS were found in negligible quantities in vaccinated mice. These results provide additional evidence that the O polysaccharide will constitute an essential component of an effective subcellular vaccine against B. abortus and that O-polysaccharide-specific antibodies play an important role in protective immunity in brucellosis. AD - Department of Veterinary Microbiology, Cornell University, Ithaca, New York 14853. FAU - Winter, A J AU - Winter AJ FAU - Rowe, G E AU - Rowe GE FAU - Duncan, J R AU - Duncan JR FAU - Eis, M J AU - Eis MJ FAU - Widom, J AU - Widom J FAU - Ganem, B AU - Ganem B FAU - Morein, B AU - Morein B LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Bacterial Vaccines) RN - 0 (Glycolipids) RN - 0 (Polysaccharides, Bacterial) RN - 0 (Porins) RN - 0 (Vaccines) RN - 0 (Vaccines, Synthetic) SB - IM MH - Adjuvants, Immunologic MH - Animals MH - Antibodies, Bacterial/biosynthesis MH - Antigens, Bacterial/immunology MH - Bacterial Outer Membrane Proteins/*immunology MH - Bacterial Vaccines/*immunology MH - Brucella abortus/*immunology MH - Brucellosis/immunology/microbiology/*prevention & control MH - Glycolipids/immunology MH - Mice MH - Polysaccharides, Bacterial/*immunology MH - Porins MH - Structure-Activity Relationship MH - Vaccination MH - Vaccines/*immunology MH - Vaccines, Synthetic/*immunology PMC - PMC259654 OID - NLM: PMC259654 EDAT- 1988/11/01 MHDA- 1988/11/01 00:01 CRDT- 1988/11/01 00:00 PST - ppublish SO - Infect Immun. 1988 Nov;56(11):2808-17. PMID- 3451685 OWN - NLM STAT- MEDLINE DA - 19880714 DCOM- 19880714 LR - 20061115 IS - 0003-4193 (Print) IS - 0003-4193 (Linking) VI - 18 IP - 4 DP - 1987 TI - Conjunctival vaccination of young goats with Brucella melitensis strain Rev 1. PG - 397-403 AB - Three groups each of 15 four-month old female kids were vaccinated with Brucella melitensis strain Rev 1 either conjunctivally (1.1 x 10(7) or 1.1 x 10(9) CFU) or subcutaneously (1.1 x 10(9) CFU). One group of 15 kids remained unvaccinated as control. All kids were mated when 9.5 month old. Three months later, they were challenged conjunctivally with B melitensis strain H38 at a dose of 5.1 x 10(6) CFU. Blood samples collected before vaccination and throughout the experiment were subjected to Rose Bengal (RBPT) and Complement Fixation (CFT) tests. Allergy was tested both after vaccination and after challenge. Milk, uterine discharge as well as tissues from aborted foetuses and dead kids and from goats slaughtered 4-6 weeks after abortion or full-term kidding, were cultured on Farrell's medium. A serological response was shown in most kids vaccinated conjunctivally. However, 4 months after vaccination with either 1.1 x 10(7) or 1.1 x 10(9) CFU Rev 1, all animals were negative whereas some positive RBPT or CFT titres were still observed after the classical subcutaneous vaccination. There were more allergic reactions among subcutaneously than conjunctivaly vaccinated animals, but sensitization was shown long-lasting in all vaccinated groups, excluding allergic testing as a screening method in vaccinated flocks. Against a challenge which led all controls to abort, conjunctival vaccination was slightly better with 1.1 x 10(9) than with 1.1 x 10(7) CFU and almost as effective than that given by the subcutaneous one. These differences however were not statistically significant. These results quite agree with those previously recorded for ewes.(ABSTRACT TRUNCATED AT 250 WORDS) AD - INRA, Centre de Tours-Nouzilly, Station de Pathologie de la Reproduction, Monnaie, France. FAU - Fensterbank, R AU - Fensterbank R FAU - Verger, J M AU - Verger JM FAU - Grayon, M AU - Grayon M LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - FRANCE TA - Ann Rech Vet JT - Annales de recherches veterinaires. Annals of veterinary research JID - 1267230 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Brucella Vaccine/*administration & dosage MH - Brucellosis/prevention & control/*veterinary MH - Conjunctiva MH - Female MH - Goats/*immunology MH - Injections, Subcutaneous EDAT- 1987/01/01 MHDA- 1987/01/01 00:01 CRDT- 1987/01/01 00:00 PST - ppublish SO - Ann Rech Vet. 1987;18(4):397-403. PMID- 4622856 OWN - NLM STAT- MEDLINE DA - 19720620 DCOM- 19720620 LR - 20001218 IS - 0002-9645 (Print) IS - 0002-9645 (Linking) VI - 33 IP - 4 DP - 1972 Apr TI - Characterization of Brucella abortus strain 19. PG - 759-64 FAU - Brown, G M AU - Brown GM FAU - Love, E L AU - Love EL FAU - Pietz, D E AU - Pietz DE FAU - Ranger, C R AU - Ranger CR LA - eng PT - Journal Article PL - UNITED STATES TA - Am J Vet Res JT - American journal of veterinary research JID - 0375011 RN - 0 (Aniline Compounds) RN - 0 (Culture Media) RN - 0 (Glutamates) RN - 0 (Penicillins) RN - 0 (Thiazines) RN - 124-38-9 (Carbon Dioxide) RN - 149-32-6 (Erythritol) RN - 26566-61-0 (Galactose) RN - 50-69-1 (Ribose) RN - 56-41-7 (Alanine) SB - IM MH - Alanine/metabolism MH - Aniline Compounds/pharmacology MH - Brucella abortus/classification/drug effects/growth & development/immunology/*isolation & purification/metabolism MH - Carbon Dioxide/metabolism MH - Culture Media MH - Erythritol/metabolism/pharmacology MH - Galactose/metabolism MH - Glutamates/metabolism MH - Penicillin Resistance MH - Penicillins/pharmacology MH - Ribose/metabolism MH - Thiazines/pharmacology EDAT- 1972/04/01 MHDA- 1972/04/01 00:01 CRDT- 1972/04/01 00:00 PST - ppublish SO - Am J Vet Res. 1972 Apr;33(4):759-64. PMID- 6436092 OWN - NLM STAT- MEDLINE DA - 19841214 DCOM- 19841214 LR - 20081121 IS - 0301-5149 (Print) IS - 0301-5149 (Linking) VI - 56 DP - 1984 TI - Properties of an immunogenic fraction from Brucella abortus 45/20. PG - 159-68 AB - Hot saline extracts of Brucella abortus strain 45/20 contain up to 4 protein components. Some of these components are shared with other Brucella strains but one appears specific to B. abortus 45/20 or possibly other non-smooth Brucella strains. The extracts are antigenic in guinea-pigs and evoke protective immunity against virulent B. abortus. The rough antigen specific activity appears to be associated with a protein component rather than lipopolysaccharide. FAU - Corbel, M J AU - Corbel MJ FAU - Redwood, D W AU - Redwood DW LA - eng PT - Journal Article PL - SWITZERLAND TA - Dev Biol Stand JT - Developments in biological standardization JID - 0427140 RN - 0 (Antigens, Bacterial) SB - IM MH - Animals MH - Antigens, Bacterial/analysis/*immunology/isolation & purification MH - Brucella abortus/*immunology MH - Chemical Phenomena MH - Chemistry MH - Guinea Pigs MH - Immunization MH - Immunologic Techniques MH - Rabbits MH - Species Specificity EDAT- 1984/01/01 MHDA- 1984/01/01 00:01 CRDT- 1984/01/01 00:00 PST - ppublish SO - Dev Biol Stand. 1984;56:159-68. PMID- 7622248 OWN - NLM STAT- MEDLINE DA - 19950825 DCOM- 19950825 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 63 IP - 8 DP - 1995 Aug TI - Comparison of spleen cell proliferation in response to Brucella abortus 2308 lipopolysaccharide or proteins in mice vaccinated with strain 19 or RB51. PG - 3199-205 AB - Mice vaccinated with Brucella abortus 19 (S19) or RB51 (SRB51) had spleen cells which proliferated in response to proteins of 32, 27, 18, and < 18 kDa but not in response to proteins of 106, 80, and 49 kDa from B. abortus 2308 (S2308) following vaccination and challenge infection with S2308. Spleen cells from mice vaccinated with S19 but not with SRB51 had increased proliferation in response to S2308 lipopolysaccharide (LPS) following challenge infection with S2308. We previously reported that mice vaccinated with S19 or SRB51, which were analyzed in the current study, have increased resistance to infection with S2308 and that only mice vaccinated with S19 produce antibody to S2308 LPS (M. Stevens, S. Olsen, G. Pugh, Jr., and D. Brees, Infect. Immun. 63:264-270, 1995). The results from our current and previous studies support the contention that vaccination of mice with S19 or SRB51 induces protection from infection with S2308 by cell-mediated immune responses to the same immunodominant (32, 27, 18, and < 18 kDa) protein antigens of S2308. In addition, the absence of S2308 LPS-responsive spleen cells and antibody to S2308 LPS in mice vaccinated with SRB51 suggests that immune responses to LPS have no role in SRB51-induced protective immunity. AD - Brucellosis Research Unit, U.S. Department of Agriculture, Agriculture Research Service, Ames, Iowa 50010, USA. FAU - Stevens, M G AU - Stevens MG FAU - Olsen, S C AU - Olsen SC FAU - Pugh, G W Jr AU - Pugh GW Jr LA - eng PT - Journal Article PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antigens, Bacterial) RN - 0 (Bacterial Proteins) RN - 0 (Bacterial Vaccines) RN - 0 (Lipopolysaccharides) SB - IM MH - Animals MH - Antigens, Bacterial/*immunology MH - Bacterial Proteins/*immunology MH - Bacterial Vaccines/immunology MH - Brucella abortus/*immunology MH - Female MH - Lipopolysaccharides/*immunology MH - *Lymphocyte Activation MH - Mice MH - Mice, Inbred BALB C MH - Spleen/immunology MH - Vaccination PMC - PMC173437 OID - NLM: PMC173437 EDAT- 1995/08/01 MHDA- 2001/03/28 10:01 CRDT- 1995/08/01 00:00 PST - ppublish SO - Infect Immun. 1995 Aug;63(8):3199-205. PMID- 7625115 OWN - NLM STAT- MEDLINE DA - 19950831 DCOM- 19950831 LR - 20061115 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 13 IP - 2 DP - 1995 Feb TI - Comparison of the efficacy of Brucella suis strain 2 and Brucella melitensis Rev. 1 live vaccines against a Brucella melitensis experimental infection in pregnant ewes. PG - 191-6 AB - The comparative efficacy of Brucella suis strain 2 (S2) and Brucella melitensis strain Rev. 1 (Rev. 1) live vaccines in protecting sheep against B. melitensis infection was evaluated by clinical and bacteriological examination of ewes vaccinated conjunctivally with a dose of 1 x 10(9) c.f.u. when 4 months old and then challenged with 5 x 10(7) c.f.u. of the B. melitensis virulent strain 53H38 (H38) at the middle of the first or second pregnancy following vaccination. Animals were considered to be protected when no abortion, no excretion of the challenge strain and no infection at slaughter occurred. The percentages of protection in Rev. 1-vaccinated groups challenged during either first (80%) or second (62%) pregnancy were significantly different (p < 0.001 and p < 0.05, respectively) compared with those of the relevant unvaccinated control groups. In contrast no significant difference in protection was found between the S2-vaccinated and control groups. AD - Laboratoire de Pathologie Infectieuse et d'Immunologie, INRA, Nouzilly, France. FAU - Verger, J M AU - Verger JM FAU - Grayon, M AU - Grayon M FAU - Zundel, E AU - Zundel E FAU - Lechopier, P AU - Lechopier P FAU - Olivier-Bernardin, V AU - Olivier-Bernardin V LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Brucella/*immunology MH - Brucella Vaccine/*therapeutic use MH - Brucella melitensis/*immunology MH - Brucellosis/immunology/prevention & control/*veterinary MH - Conjunctiva MH - Dose-Response Relationship, Drug MH - Drug Administration Routes MH - Female MH - Pregnancy MH - Pregnancy Complications, Infectious/immunology/prevention & control/*veterinary MH - Sheep MH - Sheep Diseases/immunology/*prevention & control EDAT- 1995/02/01 MHDA- 1995/02/01 00:01 CRDT- 1995/02/01 00:00 AID - 0264410X9593135V [pii] PST - ppublish SO - Vaccine. 1995 Feb;13(2):191-6. PMID- 7806364 OWN - NLM STAT- MEDLINE DA - 19950202 DCOM- 19950202 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 63 IP - 1 DP - 1995 Jan TI - Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51. PG - 264-70 AB - Immune responses and resistance to infection with Brucella abortus 2308 (S2308) were measured in mice following vaccination with B. abortus 19 (S19) or the lipopolysaccharide (LPS) O-antigen-deficient mutant, strain RB51 (SRB51). Live bacteria persisted for 8 weeks in spleens of mice vaccinated with 5 x 10(6) or 5 x 10(8) CFU of SRB51, whereas bacteria persisted for 12 weeks in mice vaccinated with 5 x 10(6) CFU of S19. Mice vaccinated with 5 x 10(6) or 5 x 10(8) CFU of SRB51 had increased resistance to infection with S2308 at 12, 16, and 20 weeks after vaccination, but the resistance was lower than that induced by vaccinating mice with 5 x 10(6) CFU of S19. Spleen cells obtained from mice vaccinated with S19 or SRB51 generally exhibited similar proliferative responses to S2308 bacteria or bacterial proteins (106 to 18 kDa) following challenge of mice with S2308 at 12, 16, or 20 weeks after vaccination. Mice vaccinated with S19 had antibody to S2308 bacteria and S2308 smooth LPS at 4, 8, and 12 weeks after vaccination. In contrast, mice vaccinated with either dose of SRB51 did not produce antibody to S2308 smooth LPS. In addition, only mice vaccinated with the highest dose of SRB51 (5 x 10(8) CFU) had antibody responses to S2308 bacteria, although the responses were lower and less persistent than those in mice vaccinated with S19. Collectively, these results indicate that SRB51-vaccinated mice have similar cell-mediated immune responses to S2308 but lower resistance to infection with S2308 compared with S19-vaccinated mice. The lower resistance in SRB51-vaccinated mice probably resulted from a combination of rapid clearance of SRB51 and an absence of antibodies to S2308 LPS. AD - Brucellosis Research Unit, National Animal Disease Center, Agriculture Research Service, U.S. Department of Agriculture, Ames, Iowa 50010. FAU - Stevens, M G AU - Stevens MG FAU - Olsen, S C AU - Olsen SC FAU - Pugh, G W Jr AU - Pugh GW Jr FAU - Brees, D AU - Brees D LA - eng PT - Comparative Study PT - Journal Article PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Lipopolysaccharides) SB - IM MH - Animals MH - *Antibody Formation MH - Bacterial Proteins/immunology MH - Brucella Vaccine/*therapeutic use MH - Brucella abortus/classification/*immunology MH - Brucellosis/immunology/*prevention & control MH - Cell Division MH - Female MH - Lipopolysaccharides/immunology MH - Mice MH - Mice, Inbred BALB C MH - Organ Size MH - Species Specificity MH - Spleen/cytology/microbiology/pathology MH - Time Factors MH - *Vaccination PMC - PMC172987 OID - NLM: PMC172987 EDAT- 1995/01/01 MHDA- 2001/03/28 10:01 CRDT- 1995/01/01 00:00 PST - ppublish SO - Infect Immun. 1995 Jan;63(1):264-70. PMID- 7927779 OWN - NLM STAT- MEDLINE DA - 19941122 DCOM- 19941122 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 62 IP - 11 DP - 1994 Nov TI - Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis. PG - 4990-6 AB - Vaccination of BALB/c mice with live Brucella abortus RB51, a stable rough mutant, produced protection against challenge with virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis. Passive-transfer experiments indicated that vaccinated mice were protected against B. abortus 2308 through cell-mediated immunity, against B. ovis PA through humoral immunity, and against B. melitensis 16M through both forms of immunity. Live bacteria were required for the induction of protective cell-mediated immunity; vaccination with whole killed cells of strain RB51 failed to protect mice against B. abortus 2308 despite development of good delayed-type hypersensitivity reactions. Protective antibodies against the heterologous species were generated in vaccinated mice primarily through anamnestic responses following challenge infections. Growth of the antigenically unrelated bacterium Listeria monocytogenes in the spleens of vaccinated mice indicated that nonspecific killing by residual activated macrophages contributed minimally to protection. These results encourage the continued investigation of strain RB51 as an alternative vaccine against heterologous Brucella species. However, its usefulness against B. ovis would be limited if, as suggested here, epitopes critical for protective cell-mediated immunity are not shared between B. abortus and B. ovis. AD - College of Veterinary Medicine, Cornell University, Ithaca, New York 14853. FAU - Jimenez de Bagues, M P AU - Jimenez de Bagues MP FAU - Elzer, P H AU - Elzer PH FAU - Jones, S M AU - Jones SM FAU - Blasco, J M AU - Blasco JM FAU - Enright, F M AU - Enright FM FAU - Schurig, G G AU - Schurig GG FAU - Winter, A J AU - Winter AJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Bacterial Vaccines) SB - IM MH - Animals MH - Bacterial Vaccines/immunology MH - Brucella/*immunology MH - Brucella abortus/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/*prevention & control MH - Dose-Response Relationship, Immunologic MH - Female MH - Hypersensitivity, Delayed/immunology MH - Immunization, Passive MH - Mice MH - Mice, Inbred BALB C MH - Vaccination PMC - PMC303217 OID - NLM: PMC303217 EDAT- 1994/11/01 MHDA- 1994/11/01 00:01 CRDT- 1994/11/01 00:00 PST - ppublish SO - Infect Immun. 1994 Nov;62(11):4990-6. PMID- 8039890 OWN - NLM STAT- MEDLINE DA - 19940824 DCOM- 19940824 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 62 IP - 8 DP - 1994 Aug TI - Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308. PG - 3206-12 AB - Immune and pathologic responses were measured for 20 weeks after infection of mice with Brucella abortus 19, RB51, or 2308. Live bacteria and bacterial antigens of 19 and RB51 persisted in spleens for 10 and 4 weeks after infection, respectively, whereas 2308 bacteria and bacterial antigens persisted for at least 20 weeks. Small germinal centers and profound lymphoid depletion occurred in spleens of mice during the first 4 weeks of infection with strain 19 or 2308; however, mice infected with strain RB51 had much larger germinal centers but no lymphoid depletion. At 4 weeks, only spleen cells from RB51-infected mice proliferated when incubated with 2308 bacteria. Large germinal centers in the spleen and spleen cell proliferative responses to 2308 did not appear in strain 19-infected mice until 6 weeks or in strain 2308-infected mice until 10 weeks. Similar proliferative responses to 2308 occurred in mice infected with strain 19 or RB51 at 6 weeks and in mice infected with strain 19, RB51, or 2308 at 10 weeks. However, at 20 weeks, spleen cell proliferative responses to 2308 occurred in mice infected with strain 19 or 2308 but not in mice infected with strain RB51. Mice infected with strain RB51 had lower and less persistent antibody titers to 2308 than did mice infected with strain 19 or 2308. Collectively, these results indicate that RB51-infected mice have less persistent immune responses to 2308 than do mice infected with 19 or 2308. The shorter duration of the responses probably resulted because RB51 is considerably less pathogenic and is cleared more rapidly from mice than are 19 and 2308. AD - Brucellosis Research Unit, National Animal Disease Center, USDA Agricultural Research Service, Ames, Iowa 50010. FAU - Stevens, M G AU - Stevens MG FAU - Olsen, S C AU - Olsen SC FAU - Pugh, G W Jr AU - Pugh GW Jr FAU - Palmer, M V AU - Palmer MV LA - eng PT - Journal Article PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - *Brucella abortus MH - Brucellosis/*immunology/pathology MH - Female MH - Immunoenzyme Techniques MH - Mice MH - Mice, Inbred BALB C MH - Spleen/microbiology/pathology PMC - PMC302947 OID - NLM: PMC302947 EDAT- 1994/08/01 MHDA- 2001/03/28 10:01 CRDT- 1994/08/01 00:00 PST - ppublish SO - Infect Immun. 1994 Aug;62(8):3206-12. PMID- 8236802 OWN - NLM STAT- MEDLINE DA - 19931214 DCOM- 19931214 LR - 20071115 IS - 0165-2427 (Print) IS - 0165-2427 (Linking) VI - 37 IP - 3-4 DP - 1993 Aug TI - Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams. PG - 257-70 AB - Five antigen preparations from Brucella ovis strain REO 198 were incorporated with the pluronic polymer L-121 and muramyl dipeptide and tested as vaccines against B. ovis infection of rams. The antigenic preparations were: (1) a fraction enriched in outer membrane proteins and rough lipopolysaccharide (hot saline extract, HS); (2) the proteins from HS substantially free of lipopolysaccharide; (3) outer membrane blebs; (4) outer membrane-peptidoglycan complexes extracted with detergent; (5) killed whole cells. The experimental vaccines were compared with two standard vaccines, rough Brucella abortus 45/20 whole killed cells in an oil based adjuvant, and live Brucella melitensis Rev 1. Immunizations with non-living vaccines were performed on two occasions, 18 weeks apart. The rams were challenged with a virulent strain of B. ovis 31 weeks after the second vaccination and slaughtered 15 weeks thereafter. Rates of infection in groups vaccinated with Rev 1 (33%), and HS (40%) were significantly lower (P < 0.005 and P < 0.025, respectively) than that in the non-vaccinated control group (87%). Strain 45/20 was the only other vaccine that conferred a significant level of protection (50%) (P < 0.05). The organ distribution of the infection and the level of colonization of infected organs did not differ significantly between infected animals in the various vaccine groups and those in the unvaccinated control group. No statistically significant relationship was detected between the magnitude of the antibody responses to the HS extract, to outer membrane proteins, or to the rough lipopolysaccharide, and freedom from infection. The results indicate that the HS extract of B. ovis may represent a useful alternative to B. melitensis Rev 1 or B. abortus 45/20 as a vaccine against B. ovis. AD - Servicio de Investigacion Agraria, Diputacion General de Aragon, Zaragoza, Spain. FAU - Blasco, J M AU - Blasco JM FAU - Gamazo, C AU - Gamazo C FAU - Winter, A J AU - Winter AJ FAU - Jimenez de Bagues, M P AU - Jimenez de Bagues MP FAU - Marin, C AU - Marin C FAU - Barberan, M AU - Barberan M FAU - Moriyon, I AU - Moriyon I FAU - Alonso-Urmeneta, B AU - Alonso-Urmeneta B FAU - Diaz, R AU - Diaz R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - NETHERLANDS TA - Vet Immunol Immunopathol JT - Veterinary immunology and immunopathology JID - 8002006 RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Vaccines, Attenuated) RN - 0 (Vaccines, Inactivated) SB - IM MH - Animals MH - Antibodies, Bacterial/*biosynthesis MH - Antigens, Bacterial/immunology MH - Brucella/*immunology MH - Brucella Vaccine/*immunology MH - Brucella melitensis/immunology MH - Brucellosis/immunology/prevention & control/*veterinary MH - Evaluation Studies as Topic MH - Male MH - Sheep MH - Sheep Diseases/*immunology/prevention & control MH - Subcellular Fractions/*immunology MH - Vaccines, Attenuated/immunology MH - Vaccines, Inactivated/immunology EDAT- 1993/08/01 MHDA- 1993/08/01 00:01 CRDT- 1993/08/01 00:00 PST - ppublish SO - Vet Immunol Immunopathol. 1993 Aug;37(3-4):257-70. PMID- 8260964 OWN - NLM STAT- MEDLINE DA - 19940125 DCOM- 19940125 LR - 20031114 IS - 0928-4249 (Print) IS - 0928-4249 (Linking) VI - 24 IP - 5 DP - 1993 TI - Field-oriented trial of the Chinese Brucella suis strain 2 vaccine on sheep and goats in Libya. PG - 422-9 AB - The Chinese Brucella suis S2 vaccine was studied in a flock of sheep and goats in field conditions. The locally-produced vaccine was orally administered in the form of a drench to 446 ewes, 50 lambs and 20 adult goats. After vaccination, abortion and excretion of the vaccine strain in vaginal discharges or in milk did not occur. Serological tests became positive in 92% of animals at 4 wk post-vaccination and declined to near nil after 1 yr. The protection conferred by the vaccine against a double virulent B melitensis conjunctival challenge which infected 10/10 control ewes was on average 53% in ewes (32/60) and 71% in goats (5/7). Abortion rates were respectively 100% (7/7) in control ewes versus 44% (25/57) and 28% (2/7) in vaccinated ewes and goats. The vaccine was thus found to be safe, antigenic and reasonably protective against the challenge dose used. AD - FAO Representative, Khartoum, Sudan. FAU - Mustafa, A A AU - Mustafa AA FAU - Abusowa, M AU - Abusowa M LA - eng PT - Clinical Trial PT - Journal Article PL - FRANCE TA - Vet Res JT - Veterinary research JID - 9309551 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) SB - IM MH - Abortion, Veterinary/chemically induced/prevention & control MH - Administration, Oral MH - Animals MH - Antibodies, Bacterial/biosynthesis MH - *Brucella Vaccine/administration & dosage/adverse effects/immunology MH - Brucellosis/prevention & control/*veterinary MH - Female MH - Goat Diseases/*prevention & control MH - Goats MH - Libya MH - Male MH - Pregnancy MH - Sheep MH - Sheep Diseases/*prevention & control MH - Vaccination/*veterinary EDAT- 1993/01/01 MHDA- 1993/01/01 00:01 CRDT- 1993/01/01 00:00 PST - ppublish SO - Vet Res. 1993;24(5):422-9. PMID- 8296481 OWN - NLM STAT- MEDLINE DA - 19940225 DCOM- 19940225 LR - 20061115 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 11 IP - 13 DP - 1993 Oct TI - Efficacy of Brucella suis strain 2 vaccine against Brucella ovis in rams. PG - 1291-4 AB - The protective efficacy against Brucella ovis of live vaccine Brucella suis strain 2 (S2) and Brucella melitensis strain Rev 1 has been evaluated in rams. Fourteen 4-month-old Brucella-free Aragonesa rams were vaccinated conjunctivally with 2 x 10(9) c.f.u. S2. Sixteen rams of the same breed, condition and age were conjunctivally vaccinated the same day with 1.6 x 10(9) Rev 1. Thirteen rams were unvaccinated controls. Eight months after vaccination all rams were challenged with 6 x 10(9) c.f.u. B. ovis and slaughtered 2 months thereafter for bacteriological and pathological studies. The percentage of infection in the group vaccinated with Rev 1 (43.7%) was significantly lower (p < 0.05) than that of the S2-vaccinated animals (78.6%) and unvaccinated controls (84.6%). No significant differences were found when comparing the percentages of infection corresponding to S2-vaccinated and control groups. The degree of infection (percentage of necropsy samples infected) was significantly lower in Rev 1-vaccinated (13%) than in S2-vaccinated (36.9%) or control groups (47.4%) (p < 0.001). However, no significant differences were found when comparing S2-vaccinated and control groups. AD - Servicio de Investigacion Agraria, Diputacion General de Aragon, Zaragoza, Spain. FAU - Blasco, J M AU - Blasco JM FAU - Marin, C AU - Marin C FAU - Jimenez de Bagues, M P AU - Jimenez de Bagues MP FAU - Barberan, M AU - Barberan M LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Antibody Formation/immunology MH - Brucella/*immunology MH - Brucella Vaccine/*pharmacology MH - Brucellosis/immunology/*prevention & control/*veterinary MH - Male MH - Sheep MH - Sheep Diseases/immunology/*microbiology/*prevention & control MH - Vaccination EDAT- 1993/10/01 MHDA- 1993/10/01 00:01 CRDT- 1993/10/01 00:00 AID - 0264-410X(93)90097-H [pii] PST - ppublish SO - Vaccine. 1993 Oct;11(13):1291-4. PMID- 8427038 OWN - NLM STAT- MEDLINE DA - 19930226 DCOM- 19930226 LR - 20071115 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 11 IP - 1 DP - 1993 TI - Evaluation of vaccines and of antigen therapy in a mouse model for Brucella ovis. PG - 61-6 AB - A mouse model was developed to study Brucella ovis infection. The evolution of the number of B. ovis per spleen of mice inoculated intravenously, intraperitoneally or subcutaneously was found to be independent of the sex of the mice. The number of B. ovis increased in the spleen when increasing the challenge dose up to 1.7 x 10(7). At higher doses of challenge, the response remained constant. In this model it was observed that the inoculation of Brucella melitensis Rev 1 vaccine or subcellular B. ovis hot saline antigens during both the acute and chronic phases did not modify the time course of B. ovis infection. Finally, the model was found suitable to determine the efficacy of anti-B. ovis vaccines. B. melitensis Rev 1 (2.2 x 10(5) c.f.u.) and B. suis strain 2 (1.2 x 10(7) c.f.u.) live vaccines but not the inactivated B. melitensis H38 vaccine conferred protection against B. ovis. AD - Departamento de Produccion Animal, SIA/DGA, Zaragoza, Spain. FAU - Jimenez de Bagues, M P AU - Jimenez de Bagues MP FAU - Marin, C M AU - Marin CM FAU - Barberan, M AU - Barberan M FAU - Blasco, J M AU - Blasco JM LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antigens, Bacterial) RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Antigens, Bacterial/*administration & dosage MH - Brucella/immunology MH - Brucella Vaccine/*administration & dosage MH - Brucellosis/immunology/*prevention & control/*therapy MH - Disease Models, Animal MH - Dose-Response Relationship, Immunologic MH - Evaluation Studies as Topic MH - Female MH - Male MH - Mice EDAT- 1993/01/01 MHDA- 1993/01/01 00:01 CRDT- 1993/01/01 00:00 PST - ppublish SO - Vaccine. 1993;11(1):61-6. PMID- 8723881 OWN - NLM STAT- MEDLINE DA - 19961022 DCOM- 19961022 LR - 20061115 IS - 0002-9645 (Print) IS - 0002-9645 (Linking) VI - 57 IP - 5 DP - 1996 May TI - Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. PG - 677-83 AB - OBJECTIVE--To evaluate stable rough mutants derived from Brucella melitensis 16M and B suis 2579 (biovar 4) as vaccines against homologous and heterologous Brucella spp in the BALB/c mouse model. DESIGN, ANIMALS, AND PROCEDURE--Rough mutants VTRM1 and VTRS1 were obtained from B melitensis 16M and B suis 2579, respectively, by allelic exchange of rfbU gene encoding mannosyltransferase with a Tn5-disrupted rfbU gene. Mice were vaccinated with VTRM1 or VTRS1 and challenge exposed 8 weeks later. RESULTS--VTRM1 and VTRS1 replicated extensively in the spleen during the first 3 weeks of infection, then decreased rapidly. Antibodies specific for the O polysaccharide were not detected in sera of mice inoculated with either rough strain. Vaccination with VTRM1 or VTRS1 induced protection against virulent strains of B abortus (2308), B melitensis (16M), B suis biovar 1 (750), and B suis biovar 4 (2579). VTRM1 also protected against B ovis (PA) and against 4 field isolates of B abortus from bison or elk. VTRS1 conferred protection against 4 field isolates of B suis biovar 4 from reindeer. Vaccines prepared from live VTRM1 or VTRS1 provided significantly greater protection than that afforded by vaccines of killed cells in QS-21 adjuvant. Vaccination with VTRM1 containing VTRS1 gave minimal protection against the antigenically unrelated Listeria monocytogenes, thus demonstrating the immunologic specificity of protection against Brucella spp. CONCLUSIONS AND CLINICAL RELEVANCE--Results encourage evaluation, in primary host species, of VTRM1 and VTRS1, along with RB51, as alternative vaccines to strain 19, Rev 1, or other smooth phase vaccines. AD - Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA. FAU - Winter, A J AU - Winter AJ FAU - Schurig, G G AU - Schurig GG FAU - Boyle, S M AU - Boyle SM FAU - Sriranganathan, N AU - Sriranganathan N FAU - Bevins, J S AU - Bevins JS FAU - Enright, F M AU - Enright FM FAU - Elzer, P H AU - Elzer PH FAU - Kopec, J D AU - Kopec JD LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - UNITED STATES TA - Am J Vet Res JT - American journal of veterinary research JID - 0375011 RN - 0 (Antibodies, Viral) RN - 0 (Antigens, Viral) RN - 0 (Brucella Vaccine) RN - 0 (Vaccines, Attenuated) SB - IM MH - Alleles MH - Animals MH - Antibodies, Viral/analysis/immunology MH - Antigens, Viral/analysis/immunology MH - Bison MH - Blotting, Western/veterinary MH - Brucella/genetics/*immunology MH - Brucella Vaccine/*immunology MH - Brucella melitensis/genetics/*immunology MH - Brucellosis/immunology/prevention & control/*veterinary MH - Cattle MH - Deer MH - Female MH - Listeria monocytogenes/immunology MH - Mice MH - Mice, Inbred BALB C/*immunology MH - Mutation MH - Reindeer MH - Rodent Diseases/immunology/*prevention & control MH - Swine MH - Vaccines, Attenuated/pharmacology EDAT- 1996/05/01 MHDA- 1996/05/01 00:01 CRDT- 1996/05/01 00:00 PST - ppublish SO - Am J Vet Res. 1996 May;57(5):677-83. PMID- 8740701 OWN - NLM STAT- MEDLINE DA - 19961017 DCOM- 19961017 LR - 20031114 IS - 0300-9858 (Print) IS - 0300-9858 (Linking) VI - 33 IP - 3 DP - 1996 May TI - Morphometric and histopathologic analysis of lymphoid depletion in murine spleens following infection with Brucella abortus strains 2308 or RB51 or an htrA deletion mutant. PG - 282-9 AB - BALB/C mice were inoculated intraperitoneally with suspensions of Brucella abortus strains 2308 or RB51 or an htrA mutant. Spleens were examined on postinoculation day (PID) 2, 4, 7, 10, 15, 21, 30, and 60. Brucellae were cultured in high numbers from the spleens of mice infected with strains 2308 or htrA through PID 60; however, mice infected with strain RB51 cleared the infection between PID 30 and PID 60. Histopathologic changes in spleens from 2308-infected mice were characterized by marked accumulations of macrophages, which expanded marginal zones beginning as early as PID 7 and persisting through PID 60. Morphometric analysis showed a decrease in splenic white pulp in 2308-infected mice at PID 10, which correlated with the peak of bacterial infection. Although this decrease was significant (P < 0.05) when compared with values at the previous (PID 7) and the following (PID 15) time periods, it was not significantly different from white pulp values noted at PID 2 or PID 4 or the values for control spleens. Spleens from RB51-infected mice showed only mild to moderate accumulations of macrophages in marginal zone areas during the peak of RB51 infection (PID 7-10). Morphometric analysis of RB51-infected spleens showed a decrease in white pulp area, which coincided with peak bacterial numbers. However, this decrease was not significant (P > 0.05). Spleens from mice infected with the htrA mutant showed moderate to marked accumulations of macrophages in marginal zone areas, which persisted through PID 60. Multifocal necrosis in lymphoid follicles as early as PID 4 was seen in both htrA and 2308 infection. Morphometric analysis of htrA-infected spleens revealed no significant decrease in white pulp and no obvious correlation with bacterial numbers in the spleen. These results suggest that virulent B. abortus does not induce lymphoid depletion significantly below those values seen in noninfected mice; thus, the possible role of lymphoid depletion in the pathogenesis of brucellosis remains questionable. AD - National Animal Disease Center, US Department of Agriculture, Agriculture Research Service, Ames, IA, USA. FAU - Palmer, M V AU - Palmer MV FAU - Cheville, N F AU - Cheville NF FAU - Tatum, F M AU - Tatum FM LA - eng PT - Journal Article PL - UNITED STATES TA - Vet Pathol JT - Veterinary pathology JID - 0312020 SB - IM MH - Animals MH - Brucella abortus/*genetics MH - Brucellosis/microbiology/pathology/*veterinary MH - Gene Deletion MH - Lymphoid Tissue/microbiology/*pathology MH - Macrophages/pathology MH - Male MH - Mice MH - Mice, Inbred BALB C MH - Mutation MH - Rodent Diseases/microbiology/*pathology MH - Spleen/microbiology/*pathology EDAT- 1996/05/01 MHDA- 1996/05/01 00:01 CRDT- 1996/05/01 00:00 PST - ppublish SO - Vet Pathol. 1996 May;33(3):282-9. PMID- 8810948 OWN - NLM STAT- MEDLINE DA - 19961122 DCOM- 19961122 LR - 20061115 IS - 0022-2615 (Print) IS - 0022-2615 (Linking) VI - 45 IP - 3 DP - 1996 Sep TI - Production and characterisation of monoclonal antibodies to Brucella melitensis cytosoluble proteins that are able to differentiate antibody responses of infected sheep from Rev. 1 vaccinated sheep. PG - 206-13 AB - Monoclonal antibodies (MAbs) were produced to Brucella melitensis cytosoluble proteins (CP) with apparent molecular masses of 12, 24 and 28 kDa (CP12, CP24 and CP28) which were previously shown by immunoblotting to differentiate antibody responses of infected sheep from those of B. melitensis strain Rev. 1 vaccinated sheep. These MAbs were derived from mice infected with virulent smooth (S) B. melitensis strain H38. Most MAbs obtained were directed to CP28, which indicated (as was shown in infected sheep) that this protein was also highly immunogenic in mice. A large number of MAbs that showed reactivity to CP in ELISA but did not show reactivity in immunoblotting of CP were also obtained and might recognise conformational epitopes of these proteins. MAbs were used to localise CP12, CP24 and CP28. None of the MAbs reacted with whole B. melitensis cells in ELISA but showed reactivity with sonicated bacteria in ELISA, which indicated an internal localisation of these proteins. Among several B. melitensis B115 subcellular fractions tested, the anti-CP12 and anti-CP28 MAbs reacted essentially with the CP extract (CPE) in both ELISA and immunoblotting, whereas the anti-CP24 MAbs reacted with both CPE and cell envelope fraction (CEF)-although with lower intensity to the latter fraction. The internal localisation of these proteins was confirmed by immuno-electron microscopy of thin-sectioned B. melitensis B115 or B. melitensis 16M cells. Immunogold labelling was mainly observed in the cytoplasm and, consequently, CP12, CP24 and CP28 are probably cytoplasmic proteins. Immunoblotting of whole cell lysates with the MAbs also showed the presence of these proteins in all Brucella species and biovars, including the vaccine strains B. melitensis Rev. 1 and B. abortus B19. The use of these MAbs should help further study of antibody responses in sheep and other hosts and may be of considerable value for developing new diagnostic tests for ovine brucellosis. AD - Laboratoire de Pathologie Infectieuse et Immunologie, Institut National de la Recherche Agronomique, Nouzilly, France. FAU - Cloeckaert, A AU - Cloeckaert A FAU - Debbarh, H S AU - Debbarh HS FAU - Zygmunt, M S AU - Zygmunt MS FAU - Dubray, G AU - Dubray G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - J Med Microbiol JT - Journal of medical microbiology JID - 0224131 RN - 0 (Antibodies, Monoclonal) RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Antibodies, Monoclonal/*biosynthesis/*immunology MH - Bacterial Proteins/*immunology MH - Brucella Vaccine/immunology MH - Brucella melitensis/*immunology MH - Brucellosis/*immunology/*veterinary MH - Cell Wall/immunology MH - Cytosol/immunology MH - Female MH - Immunoblotting MH - Mice MH - Mice, Inbred BALB C MH - Microscopy, Immunoelectron MH - Sheep MH - Sheep Diseases/*immunology EDAT- 1996/09/01 MHDA- 1996/09/01 00:01 CRDT- 1996/09/01 00:00 PST - ppublish SO - J Med Microbiol. 1996 Sep;45(3):206-13. PMID- 8873388 OWN - NLM STAT- MEDLINE DA - 19970122 DCOM- 19970122 LR - 20061115 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 14 IP - 10 DP - 1996 Jul TI - Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. PG - 959-62 AB - BALB/c mice were immunized with the recombinant Brucella abortus L7/L12 ribosomal protein fused to maltose binding protein (MBP). Vaccinated animals mounted a specific immune response to the recombinant fusion protein as demonstrated by immunoblot analyses. Additionally, B. abortus L7/L12 ribosomal protein conferred a significant degree of protection when compared to mice vaccinated with adjuvant alone, adjuvant plus MBP or B. abortus. These results indicate that a recombinant B. abortus protein, previously identified as T-cell-reactive, engendered protective immunity to mice against brucellosis. AD - Department of Animal Health and Biomedical Sciences, University of Wisconsin, Madison 53706, USA. FAU - Oliveira, S C AU - Oliveira SC FAU - Splitter, G A AU - Splitter GA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - ENGLAND TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Vaccines) RN - 0 (Ribosomal Proteins) RN - 0 (Rpl7 protein, mouse) RN - 0 (Vaccines, Synthetic) RN - 70815-33-7 (ribosomal protein L7-L12) SB - IM MH - Animals MH - Antibodies, Bacterial/biosynthesis MH - Bacterial Vaccines/*immunology MH - Brucella abortus/isolation & purification MH - Brucellosis/immunology/*prevention & control MH - Female MH - Immunity, Cellular MH - Mice MH - Mice, Inbred BALB C MH - Ribosomal Proteins/*immunology MH - Vaccines, Synthetic/*immunology EDAT- 1996/07/01 MHDA- 1996/07/01 00:01 CRDT- 1996/07/01 00:00 AID - 0264410X96000187 [pii] PST - ppublish SO - Vaccine. 1996 Jul;14(10):959-62. PMID- 8890203 OWN - NLM STAT- MEDLINE DA - 19970106 DCOM- 19970106 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 64 IP - 11 DP - 1996 Nov TI - Immune responses and resistance to brucellosis in mice vaccinated orally with Brucella abortus RB51. PG - 4534-41 AB - Immune responses and resistance to infection with Brucella abortus 2308 (S2308) were measured in mice following oral or intraperitoneal (i.p.) vaccination with strain RB51 (SRB51). Bacteria persisted in the parotid lymph node for 4 weeks following oral vaccination of mice with 5 x 10(8) or 5 x 10(6) CFU of SRB51. Bacteria did not appear in the spleen during 12 weeks after oral vaccination, whereas they did appear in the spleen for 8 weeks following i.p. vaccination of mice with SRB51 (5 x 10(8) or 5 x 10(6) CFU). Increased resistance to S2308 infection occurred at 12 to 20 weeks in mice vaccinated i.p. with SRB51 (5 x 10(8) or 5 x 10(6) CFU) but occurred at 12 weeks only in mice vaccinated orally with SRB51 (5 x 10(8) CFU). Oral SRB51 vaccination induced lower levels of antibodies to the surface antigens of intact SRB51 bacteria than did i.p. vaccination. However, neither route of vaccination induced anamnestic antibody responses to the surface antigens of intact S2308 bacteria after challenge infection of the vaccinated mice with S2308. Mice vaccinated orally with SRB51 and challenged with S2308 at 12 to 20 weeks had lower and less persistent spleen cell proliferation and production of gamma interferon in response to S2308 and certain immunodominant S2308 proteins (32 to < or = 18 kDa) than did mice vaccinated i.p. with SRB51. However, mice vaccinated orally or i.p. with SRB51 and challenged with S2308 had similar spleen cell tumor necrosis factor alpha production. These results indicate that oral vaccination of mice with SRB51 was effective in inducing protective immunity to S2308 infection, although the immunity was lower and less persistent than that induced by i.p. vaccination. The lower protective immunity induced by oral vaccination may have resulted from lower and less persistent cell-mediated immunity and gamma interferon production in response to S2308 and S2308 proteins. AD - Zoonotic Diseases Research Unit, National Animal Disease Center, USDA Agriculture Research Service, Ames, Iowa 50010, USA. FAU - Stevens, M G AU - Stevens MG FAU - Olsen, S C AU - Olsen SC FAU - Palmer, M V AU - Palmer MV FAU - Pugh, G W Jr AU - Pugh GW Jr LA - eng PT - Comparative Study PT - Journal Article PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 0 (Antigens, Surface) RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Tumor Necrosis Factor-alpha) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Administration, Oral MH - Animals MH - Antibodies, Bacterial/*biosynthesis/blood MH - Antigens, Bacterial/immunology MH - Antigens, Surface/immunology MH - Bacterial Proteins/immunology MH - Brucella Vaccine/administration & dosage/*immunology MH - Brucella abortus/*immunology/isolation & purification MH - Brucellosis/*immunology MH - Colony Count, Microbial MH - Female MH - Injections, Intraperitoneal MH - Interferon-gamma/biosynthesis MH - Lymph Nodes/immunology MH - Lymphocyte Activation MH - Mice MH - Mice, Inbred BALB C MH - Organ Size MH - Spleen/immunology/microbiology/pathology MH - Tumor Necrosis Factor-alpha/biosynthesis MH - *Vaccination PMC - PMC174409 OID - NLM: PMC174409 EDAT- 1996/11/01 MHDA- 2001/03/28 10:01 CRDT- 1996/11/01 00:00 PST - ppublish SO - Infect Immun. 1996 Nov;64(11):4534-41. PMID- 8953530 OWN - NLM STAT- MEDLINE DA - 19970314 DCOM- 19970314 LR - 20031114 IS - 1040-6387 (Print) IS - 1040-6387 (Linking) VI - 8 IP - 4 DP - 1996 Oct TI - Serologic responses of Brucella abortus strain 19 calfhood-vaccinated cattle following adult vaccination with strain RB51. PG - 451-4 AB - This study was designed to determine if Brucella abortus strain RB51, which expresses small amounts of the lipopolysaccharide O side chain, would cause positive responses on brucellosis serologic surveillance tests when given to adult cattle that were vaccinated as calves with B. abortus strain 19. Cattle vaccinated as adults with strain RB51 that had been vaccinated as calves with strain 19 (n = 40) had significantly greater antibody titers (P < 0.05) against strain RB51 at 4 and 8 weeks postvaccination in the dot blot assay than did animals (n = 10) not vaccinated with strain RB51. When evaluated using the card or buffered acid plate agglutination presumptive tests, 7 strain RB51 vaccinates tested positive at either 4 or 8 weeks following vaccination as compared with 4 cattle in the control group that were not vaccinated with strain RB51. One strain RB51 vaccinate was scored as suspect on the standard tube agglutination (STA) test at 8 weeks following vaccination. Remaining samples from strain RB51 vaccinates tested negative on the STA, complement fixation (CF), rivanol, and particle concentration fluorescence immunoassay (PCFIA) confirmatory tests. Samples from 2 control cattle were PCFIA positive at time 0; 1 of these animals was CF positive throughout the study. This study suggests that use of strain RB51 in cattle vaccinated with strain 19 as calves will not cause positive responses on confirmatory tests and will not impair brucellosis serologic surveillance efforts. AD - USDA, National Animal Disease Center, Ames, IA 50010, USA. FAU - Olsen, S C AU - Olsen SC FAU - Evans, D AU - Evans D FAU - Hennager, S G AU - Hennager SG FAU - Cheville, N F AU - Cheville NF FAU - Stevens, M G AU - Stevens MG LA - eng PT - Journal Article PL - UNITED STATES TA - J Vet Diagn Invest JT - Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc JID - 9011490 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Vaccines) SB - IM MH - Animals MH - Antibodies, Bacterial/*blood MH - *Bacterial Vaccines MH - Brucella abortus/*immunology MH - Brucellosis, Bovine/diagnosis/*immunology MH - Cattle MH - Time Factors MH - Vaccination/veterinary EDAT- 1996/10/01 MHDA- 1996/10/01 00:01 CRDT- 1996/10/01 00:00 PST - ppublish SO - J Vet Diagn Invest. 1996 Oct;8(4):451-4. PMID- 9234451 OWN - NLM STAT- MEDLINE DA - 19970909 DCOM- 19970909 LR - 20061115 IS - 0167-5877 (Print) IS - 0167-5877 (Linking) VI - 31 IP - 3-4 DP - 1997 Aug TI - A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. PG - 275-83 AB - The live Brucella melitensis Rev 1 strain is considered the best vaccine available for the prophylaxis of brucellosis in small ruminants. The classically recommended exclusive vaccination of young replacement animals has failed to control brucellosis in some developed countries and is frequently inapplicable in the developing world. Accordingly, whole-flock vaccination is the only feasible alternative to control B. melitensis infection in small ruminants under the extensive management conditions characteristic of these countries. This review describes the practical problems encountered and the experience acquired over the past decade (particularly in Spain) using the Rev 1 based control strategy. The vaccination of pregnant animals with full standard doses of Rev 1 administered subcutaneously is followed by abortion in most vaccinated animals. Reducing the dose of vaccine has been suggested as a method of avoiding this problem and, accordingly, a reduced-dose vaccination strategy has been widely used and has been reported as a safe and effective method of controlling small ruminant brucellosis. However, we reviewed field and experimental results supporting the fact that as a result of the induction of abortion in pregnant animals and the low degree of immunity conferred, reduced doses of Rev 1 should not be recommended as an alternative to the full standard doses. When tested in a mouse model, differences in residual virulence and immunogenicity have been demonstrated between the different Rev 1 vaccines produced world-wide. These differences could account for the discrepancies in safety results obtained in mass vaccination trials in different countries. The induction of abortions when vaccinating pregnant animals means that there is no entirely safe strategy for Rev 1 vaccination. Conjunctival vaccination is safer than subcutaneous vaccination but is not safe enough to be applied regardless of the pregnancy status of the animals, and should be used only under restricted conditions. For sheep, conjunctival administration of standard doses of Rev 1 during the late lambing season or during lactation is recommended as a whole-flock vaccination strategy. AD - Dpt. Sanidad Animal, SIA/DGA, Zaragoza, Spain. jblasco@posta.unizar.es FAU - Blasco, J M AU - Blasco JM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - NETHERLANDS TA - Prev Vet Med JT - Preventive veterinary medicine JID - 8217463 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - *Brucella Vaccine/administration & dosage/immunology MH - Brucella melitensis/*immunology MH - Brucellosis/immunology/prevention & control/*veterinary MH - Disease Models, Animal MH - Dose-Response Relationship, Drug MH - Female MH - Goat Diseases/epidemiology/immunology/*prevention & control MH - Goats MH - Injections, Subcutaneous/methods/veterinary MH - Mice MH - Pregnancy MH - Sheep MH - Sheep Diseases/epidemiology/immunology/*prevention & control MH - Spain/epidemiology MH - Vaccination/methods/veterinary RF - 37 EDAT- 1997/08/01 MHDA- 1997/08/01 00:01 CRDT- 1997/08/01 00:00 AID - S0167-5877(96)01110-5 [pii] PST - ppublish SO - Prev Vet Med. 1997 Aug;31(3-4):275-83. PMID- 9690613 OWN - NLM STAT- MEDLINE DA - 19981009 DCOM- 19981009 LR - 20031114 IS - 0034-5288 (Print) IS - 0034-5288 (Linking) VI - 64 IP - 3 DP - 1998 May-Jun TI - Evaluation of a rough mutant of Brucella melitensis in pregnant goats. PG - 259-60 AB - Brucella melitensis strain VTRM1, a rough derivative of B melitensis strain 16M, is able to colonise the lymph nodes of goats, does not induce abortion in pregnant goats when used at doses leading to abortions with virulent strain 16M, and does not induce anti-O chain antibodies. However, strain VTRM1 as a single dose vaccine induces only partial protection against both infection and abortion following challenge. AD - Department of Veterinary Science, Louisiana State University Agricultural Center, Baton Rouge 70803, USA. Pelzer@unix1.sncc.lsu.edu FAU - Elzer, P H AU - Elzer PH FAU - Enright, F M AU - Enright FM FAU - McQuiston, J R AU - McQuiston JR FAU - Boyle, S M AU - Boyle SM FAU - Schurig, G G AU - Schurig GG LA - eng PT - Journal Article PL - ENGLAND TA - Res Vet Sci JT - Research in veterinary science JID - 0401300 RN - 0 (Antibodies, Bacterial) SB - IM MH - Abortion, Veterinary/*microbiology MH - Animals MH - Antibodies, Bacterial/biosynthesis MH - *Brucella melitensis/genetics/pathogenicity MH - Brucellosis/immunology/physiopathology/*veterinary MH - Female MH - Goat Diseases/immunology/*microbiology/physiopathology MH - Goats MH - Pregnancy MH - Species Specificity EDAT- 1998/08/05 MHDA- 1998/08/05 00:01 CRDT- 1998/08/05 00:00 PST - ppublish SO - Res Vet Sci. 1998 May-Jun;64(3):259-60. PMID- 9784574 OWN - NLM STAT- MEDLINE DA - 19981123 DCOM- 19981123 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 66 IP - 11 DP - 1998 Nov TI - Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice. PG - 5561-4 AB - The 39-kilodalton protein (P39) has previously been shown to be an immunodominant protein in Brucella infections. P39 gene deletion mutants of vaccine strains Brucella abortus S19 and Brucella melitensis Rev.1 were constructed by gene replacement. This deletion did not significantly modify the residual virulence of both vaccine strains in CD-1 mice. CD-1 mice vaccinated with the parent or mutant strains were protected against a virulent challenge. Mutant vaccine strains devoid of P39 could provide a means for differentiating vaccinated from infected animals. AD - Laboratoire de Microbiologie et d'Immunologie, Facultes Universitaires Notre-Dame de la Paix, B-5000 Namur, Belgium. anne.tibor@fundp.ac.be FAU - Tibor, A AU - Tibor A FAU - Jacques, I AU - Jacques I FAU - Guilloteau, L AU - Guilloteau L FAU - Verger, J M AU - Verger JM FAU - Grayon, M AU - Grayon M FAU - Wansard, V AU - Wansard V FAU - Letesson, J J AU - Letesson JJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antigens, Bacterial) RN - 0 (Brucella Vaccine) RN - 11028-17-4 (brucellin) SB - IM MH - Animals MH - Antigens, Bacterial/*genetics/*immunology MH - Brucella Vaccine/genetics/*immunology MH - Brucella abortus/genetics/*immunology/pathogenicity MH - Brucella melitensis/genetics/*immunology/pathogenicity MH - Brucellosis/immunology/*prevention & control MH - Disease Models, Animal MH - Female MH - *Gene Deletion MH - Mice MH - Virulence/genetics/immunology PMC - PMC108700 OID - NLM: PMC108700 EDAT- 1998/10/24 MHDA- 1998/10/24 00:01 CRDT- 1998/10/24 00:00 PST - ppublish SO - Infect Immun. 1998 Nov;66(11):5561-4. PMID- 10445249 OWN - NLM STAT- MEDLINE DA - 19990930 DCOM- 19990930 LR - 20031114 IS - 0049-4747 (Print) IS - 0049-4747 (Linking) VI - 31 IP - 3 DP - 1999 Jun TI - Use of mass vaccination with a reduced dose of REV 1 vaccine for Brucella melitensis control in a population of small ruminants. PG - 135-41 AB - Mass vaccination with reduced dose 1/50 Rev 1 strain live vaccine (1-2 10(9) colony forming units), administered subcutaneously, over a four and a half year period reduced the prevalence of Brucella melitensis in Kuwait's small ruminant population from 5.8% in 1993 to 2.02% in 1997. Serological test results using the Rose Bengal Plate Test, Rivanol Agglutination Test and Complement Fixation showed no evidence of persistence of positive serology in animals nine or more months after vaccination. Questionnaires and post-vaccination flock inspections found that the effects on gestation (abortions) were minimal--and not proven to be due to the vaccine. The conclusion from these findings is that mass vaccination with reduced dose Rev 1 administered by the subcutaneous route is a practical field strategy for control of Brucella melitensis. AD - GRM International Pty Ltd, Brisbane, Queensland, Australia. FAU - Scharp, D W AU - Scharp DW FAU - al Khalaf, S A AU - al Khalaf SA FAU - al Muhanna, M W AU - al Muhanna MW FAU - Cheema, R A AU - Cheema RA FAU - Godana, W AU - Godana W LA - eng PT - Journal Article PL - SCOTLAND TA - Trop Anim Health Prod JT - Tropical animal health and production JID - 1277355 RN - 0 (Anti-Infective Agents, Local) RN - 0 (Brucella Vaccine) RN - 0 (Fluorescent Dyes) RN - 0 (Vaccines, Attenuated) RN - 11121-48-5 (Rose Bengal) RN - 442-16-0 (Ethacridine) SB - IM MH - Abortion, Veterinary/epidemiology MH - Agglutination Tests/veterinary MH - Animals MH - Anti-Infective Agents, Local/chemistry MH - *Brucella Vaccine/administration & dosage MH - Brucella melitensis/*immunology MH - Brucellosis/epidemiology/prevention & control/*veterinary MH - Complement Fixation Tests/veterinary MH - Ethacridine/chemistry MH - Female MH - Fluorescent Dyes/chemistry MH - Goat Diseases/epidemiology/*prevention & control MH - Goats MH - Injections, Subcutaneous/veterinary MH - Kuwait/epidemiology MH - Pregnancy MH - Questionnaires MH - Rose Bengal/chemistry MH - Seroepidemiologic Studies MH - Sheep MH - Sheep Diseases/epidemiology/*prevention & control MH - Vaccination/*veterinary MH - Vaccines, Attenuated/administration & dosage EDAT- 1999/08/13 MHDA- 1999/08/13 00:01 CRDT- 1999/08/13 00:00 PST - ppublish SO - Trop Anim Health Prod. 1999 Jun;31(3):135-41. PMID- 10531243 OWN - NLM STAT- MEDLINE DA - 19991116 DCOM- 19991116 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 67 IP - 11 DP - 1999 Nov TI - Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK). PG - 5877-84 AB - Human brucellosis can be acquired from infected animal tissues by ingestion, inhalation, or contamination of the conjunctiva or traumatized skin by infected animal products. A vaccine to protect humans from occupational exposure or from zoonotic infection in areas where the disease is endemic would reduce an important cause of morbidity worldwide. Vaccines currently used in animals are unsuitable for human use. We tested a live, attenuated, purine-auxotrophic mutant strain of Brucella melitensis, WR201, for its ability to elicit cellular and humoral immune responses and to protect mice against intranasal challenge with B. melitensis 16M. Mice inoculated intraperitoneally with WR201 made serum antibody to lipopolysaccharide and non-O-polysaccharide antigens. Splenocytes from immunized animals released interleukin-2 (IL-2), gamma interferon, and IL-10 when cultured with Brucella antigens. Immunization led to protection from disseminated infection but had only a slight effect on clearance of the challenge inoculum from the lungs. These studies suggest that WR201 should be further investigated as a vaccine to prevent human brucellosis. AD - Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, D.C. 20307-5100, USA. david.hoover@na.amedd.army.mil FAU - Hoover, D L AU - Hoover DL FAU - Crawford, R M AU - Crawford RM FAU - Van De Verg, L L AU - Van De Verg LL FAU - Izadjoo, M J AU - Izadjoo MJ FAU - Bhattacharjee, A K AU - Bhattacharjee AK FAU - Paranavitana, C M AU - Paranavitana CM FAU - Warren, R L AU - Warren RL FAU - Nikolich, M P AU - Nikolich MP FAU - Hadfield, T L AU - Hadfield TL LA - eng PT - Journal Article PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Lipopolysaccharides) RN - 82115-62-6 (Interferon-gamma) RN - EC 2.8.3.- (Coenzyme A-Transferases) RN - EC 2.8.3.- (RfbL protein, Vibrio cholerae) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Bacterial Proteins/immunology MH - Brucella Vaccine/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/*prevention & control MH - Coenzyme A-Transferases/immunology MH - Female MH - Interferon-gamma/biosynthesis MH - Lipopolysaccharides/immunology MH - Mice MH - Mice, Inbred BALB C MH - Vaccination PMC - PMC96969 OID - NLM: PMC96969 EDAT- 1999/10/26 MHDA- 1999/10/26 00:01 CRDT- 1999/10/26 00:00 PST - ppublish SO - Infect Immun. 1999 Nov;67(11):5877-84. PMID- 10534009 OWN - NLM STAT- MEDLINE DA - 19991116 DCOM- 19991116 LR - 20091118 IS - 0830-9000 (Print) IS - 0830-9000 (Linking) VI - 63 IP - 4 DP - 1999 Oct TI - The adjuvant effect of a single dose of interleukin-12 on murine immune responses to live or killed Brucella abortus strain RB51. PG - 284-7 AB - This study was designed to determine if a single 0.5 microg administration of recombinant murine interleukin-12 (IL-12) would influence immune responses of mice vaccinated with live or killed Brucella abortus strain RB51 (SRB51). Mice were vaccinated intraperitoneally with 5 x 10(8) cfu of live or gamma-irradiated SRB51 bacteria alone, or in combination with 0.5 microg of IL-12. Control mice received saline or 0.5 microg of IL-12. Serologic responses and spleen weights after vaccination were greater in mice vaccinated with live SRB51 when compared to mice receiving killed SRB51 or control treatments. Administration of a single dose of IL-12 as a vaccine adjuvant did not influence immune responses, clearance of live SRB51, or resistance against B. abortus strain 2308 (S2308) challenge. The results of this study suggest that a single administration of 0.5 microg of IL-12 at the time of vaccination does not have significant adjuvant effects on vaccine-induced immune responses against live or killed Brucella. AD - National Animal Disease Center, Agriculture Research Service, United States Department of Agriculture, Ames, Iowa 50010, USA. FAU - Lee, I K AU - Lee IK FAU - Olsen, S C AU - Olsen SC FAU - Kehrli, M AU - Kehrli M FAU - Bolin, C A AU - Bolin CA LA - eng PT - Journal Article PL - CANADA TA - Can J Vet Res JT - Canadian journal of veterinary research = Revue canadienne de recherche veterinaire JID - 8607793 RN - 0 (Adjuvants, Immunologic) RN - 0 (Bacterial Vaccines) RN - 0 (Recombinant Proteins) RN - 0 (Vaccines, Inactivated) RN - 187348-17-0 (Interleukin-12) SB - IM MH - Adjuvants, Immunologic MH - Animals MH - Bacterial Vaccines/*administration & dosage MH - Brucella abortus/*pathogenicity MH - Brucellosis, Bovine/*prevention & control MH - Cattle MH - Drug Administration Schedule MH - Interleukin-12/*administration & dosage/pharmacology MH - Male MH - Mice MH - Mice, Inbred BALB C MH - Recombinant Proteins MH - Vaccines, Inactivated PMC - PMC1189566 OID - NLM: PMC1189566 EDAT- 1999/10/26 MHDA- 1999/10/26 00:01 CRDT- 1999/10/26 00:00 PST - ppublish SO - Can J Vet Res. 1999 Oct;63(4):284-7. PMID- 10816475 OWN - NLM STAT- MEDLINE DA - 20000623 DCOM- 20000623 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 68 IP - 6 DP - 2000 Jun TI - Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. PG - 3286-9 AB - Brucella abortus strain RB51 is an attenuated rough strain that is currently being used as the official live vaccine for bovine brucellosis in the United States and several other countries. We reasoned that overexpression of a protective antigen(s) of B. abortus in strain RB51 should enhance its vaccine efficacy. To test this hypothesis, we overexpressed Cu/Zn superoxide dismutase (SOD) protein of B. abortus in strain RB51. This was accomplished by transforming strain RB51 with a broad-host-range plasmid, pBBR1MCS, containing the sodC gene along with its promoter. Strain RB51 overexpressing SOD (RB51SOD) was tested in BALB/c mice for its ability to protect against challenge infection with virulent strain 2308. Mice vaccinated with RB51SOD, but not RB51, developed antibodies and cell-mediated immune responses to Cu/Zn SOD. Strain RB51SOD vaccinated mice developed significantly (P < 0.05) more resistance to challenge than those vaccinated with strain RB51 alone. The presence of the plasmid alone in strain RB51 did not alter its vaccine efficacy. Also, overexpression of SOD did not alter the attenuation characteristic of strain RB51. AD - Department of Biomedical Sciences, Center for Molecular Medicine and Infectious Diseases, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA. rvemulap@vt.edu FAU - Vemulapalli, R AU - Vemulapalli R FAU - He, Y AU - He Y FAU - Cravero, S AU - Cravero S FAU - Sriranganathan, N AU - Sriranganathan N FAU - Boyle, S M AU - Boyle SM FAU - Schurig, G G AU - Schurig GG LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antigens, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Recombinant Proteins) RN - 0 (Vaccines, Attenuated) RN - 82115-62-6 (Interferon-gamma) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - Antigens, Bacterial/*therapeutic use MH - Brucella Vaccine/*therapeutic use MH - Brucella abortus/genetics/*immunology MH - Brucellosis/*prevention & control MH - Brucellosis, Bovine/prevention & control MH - Cattle MH - Interferon-gamma/secretion MH - Mice MH - Mice, Inbred BALB C MH - Recombinant Proteins/immunology/therapeutic use MH - Spleen/cytology/immunology MH - Superoxide Dismutase/genetics/immunology/*therapeutic use MH - Vaccination MH - Vaccines, Attenuated/therapeutic use PMC - PMC97582 OID - NLM: PMC97582 EDAT- 2000/05/19 09:00 MHDA- 2000/07/06 11:00 CRDT- 2000/05/19 09:00 PST - ppublish SO - Infect Immun. 2000 Jun;68(6):3286-9. PMID- 10858205 OWN - NLM STAT- MEDLINE DA - 20000720 DCOM- 20000720 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 68 IP - 7 DP - 2000 Jul TI - Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation. PG - 3927-32 AB - Brucella abortus RB51 is a stable rough, attenuated mutant vaccine strain derived from the virulent strain 2308. Recently, we demonstrated that the wboA gene in RB51 is disrupted by an IS711 element (R. Vemulapalli, J. R. McQuiston, G. G. Schurig, N. Srirauganathan, S. M. Halling, and S. M. Boyle, Clin. Diagn. Lab. Immunol. 6:760-764, 1999). Disruption of the wboA gene in smooth, virulent B. abortus, Brucella melitensis, and Brucella suis results in rough, attenuated mutants which fail to produce the O polysaccharide (O antigen). In this study, we explored whether the wboA gene disruption is responsible for the rough phenotype of RB51. We complemented RB51 with a functional wboA gene, and the resulting strain was designated RB51WboA. Colony and Western blot analyses indicated that RB51WboA expressed the O antigen; immunoelectron microscopy revealed that the O antigen was present in the cytoplasm. Crystal violet staining, acryflavin agglutination, and polymyxin B sensitivity studies indicated that RB51WboA had rough phenotypic characteristics similar to those of RB51. Bacterial clearance studies of BALB/c mice indicated no increase in the survival ability of RB51WboA in vivo compared to that of RB51. Vaccination of mice with live RB51WboA induced antibodies to the O antigen which were predominantly of the immunoglobulin G2a (IgG2a) and IgG3 isotypes. After in vitro stimulation of splenocytes with killed bacterial cells, quantitation of gamma interferon in the culture supernatants indicated that RB51WboA immunization induced higher levels of gamma interferon than immunization with RB51. Mice vaccinated with RB51WboA were better protected against a challenge infection with the virulent strain 2308 than those vaccinated with RB51. These studies indicate that in addition to the disruption of the wboA gene there is at least one other mutation in RB51 responsible for its rough phenotype. These studies also suggest that the expressed O antigen in RB51WboA is responsible either directly or indirectly for the observed enhancement in the T-cell response. AD - Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061-0342, USA. rvemulap@vt.edu FAU - Vemulapalli, R AU - Vemulapalli R FAU - He, Y AU - He Y FAU - Buccolo, L S AU - Buccolo LS FAU - Boyle, S M AU - Boyle SM FAU - Sriranganathan, N AU - Sriranganathan N FAU - Schurig, G G AU - Schurig GG LA - eng PT - Journal Article PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Vaccines) RN - 0 (O Antigens) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Animals MH - Antibodies, Bacterial/biosynthesis/classification MH - Bacterial Vaccines/genetics/immunology MH - Brucella abortus/*genetics/*immunology/pathogenicity MH - Female MH - *Genes, Bacterial MH - Genetic Complementation Test MH - Interferon-gamma/secretion MH - Mice MH - Mice, Inbred BALB C MH - Microscopy, Immunoelectron MH - O Antigens/*biosynthesis/*genetics MH - Phenotype MH - Virulence/genetics/immunology PMC - PMC101669 OID - NLM: PMC101669 EDAT- 2000/06/17 09:00 MHDA- 2000/07/25 11:00 CRDT- 2000/06/17 09:00 PST - ppublish SO - Infect Immun. 2000 Jul;68(7):3927-32. PMID- 11058778 OWN - NLM STAT- MEDLINE DA - 20001226 DCOM- 20010111 LR - 20061115 IS - 0167-5877 (Print) IS - 0167-5877 (Linking) VI - 47 IP - 3 DP - 2000 Nov 16 TI - Response of Bali cattle (Bos javanicus) to vaccination with Brucella abortus strain 19 in West Timor. PG - 177-86 AB - A trial was conducted in two villages (one containing cattle infected with brucellosis and one not containing infected cattle) in Timor, Indonesia to determine the serological response to vaccination with Brucella abortus strain 19 in Bali cattle (Bos javanicus) (n = 599). Mature female cattle were immunised with low-dose strain 19 (2x10(8)-6x10(8) colony forming units) and calves (6-12 months) with high-dose strain 19 (4x10(10)-12x10(10) colony forming units). Other mature females and calves were inoculated with sterile vaccine diluent and formed a non-vaccinated in-contact control group. The seroprevalence and mean titres were highest in the vaccinated cattle 3 months after vaccination. These then receded, however, 1% of vaccinated calves and 1.9% of vaccinated cows from the village without infected cattle were still seropositive on the complement-fixation test (CFT) 24 months after vaccination. Non-vaccinated seropositive animals were more likely to have aborted or had a stillbirth and were less likely to have produced a calf than were seronegative cows from the village containing infected animals. We concluded that strain 19 vaccine induced protection in Bali cattle and that this vaccine might play an important role in the control of bovine brucellosis in Timor. AD - Division of Veterinary and Biomedical Sciences, Murdoch University, Murdoch, WA 6150, Perth, Australia. FAU - Geong, M AU - Geong M FAU - Robertson, I D AU - Robertson ID LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - NETHERLANDS TA - Prev Vet Med JT - Preventive veterinary medicine JID - 8217463 SB - IM MH - Abortion, Veterinary/immunology/microbiology/*prevention & control MH - Animals MH - Antibody Formation MH - Brucella abortus/*immunology MH - Brucellosis, Bovine/immunology/*prevention & control MH - Cattle MH - Cattle Diseases/immunology/microbiology/*prevention & control MH - Female MH - Seroepidemiologic Studies MH - Vaccination/*veterinary EDAT- 2000/11/04 11:00 MHDA- 2001/02/28 10:01 CRDT- 2000/11/04 11:00 AID - S0167-5877(00)00174-4 [pii] PST - ppublish SO - Prev Vet Med. 2000 Nov 16;47(3):177-86. PMID- 11107632 OWN - NLM STAT- MEDLINE DA - 20010112 DCOM- 20020207 LR - 20031114 IS - 0253-1933 (Print) IS - 0253-1933 (Linking) VI - 19 IP - 3 DP - 2000 Dec TI - Immune response of buffaloes to vaccination with Brucella abortus strain 19. PG - 867-70 AB - The immune response of buffalo calves and heifers to a full or half dose of Brucella abortus strain 19 vaccine was studied. Buffalo calves developed high serum agglutination test (SAT) titres following full dose vaccination. These titres declined more rapidly in calves of six months of age than in calves of eleven to twelve months of age. Specific immunoglobulin G titres, as measured by 2-mercaptoethanol-treated serum agglutination, declined much earlier than SAT titres. Buffalo heifers vaccinated with a full or half dose developed high SAT titres. The rate of decline of SAT titres in heifers was much slower than in calves. Vaccination with a half dose did not appear to offer any advantage in terms of disappearance of SAT titres. AD - Animal Sciences Institute, National Agricultural Research Centre, Pakistan Agricultural Research Council, Islamabad, Pakistan. FAU - Afzal, M AU - Afzal M FAU - Ashraf Mirza, M AU - Ashraf Mirza M FAU - Jahangir, M AU - Jahangir M LA - eng PT - Journal Article PL - FRANCE TA - Rev Sci Tech JT - Revue scientifique et technique (International Office of Epizootics) JID - 8712301 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) SB - IM MH - Agglutination Tests/veterinary MH - Animals MH - Antibodies, Bacterial/*biosynthesis MH - Brucella Vaccine/administration & dosage/*immunology MH - Brucella abortus/*immunology MH - Buffaloes/*immunology MH - Dose-Response Relationship, Immunologic MH - Female MH - Male MH - Vaccination/*veterinary EDAT- 2000/01/11 19:15 MHDA- 2002/02/08 10:01 CRDT- 2000/01/11 19:15 PST - ppublish SO - Rev Sci Tech. 2000 Dec;19(3):867-70. PMID- 11193615 OWN - NLM STAT- MEDLINE DA - 20010117 DCOM- 20010201 LR - 20041117 IS - 0077-8923 (Print) IS - 0077-8923 (Linking) VI - 916 DP - 2000 TI - Development, testing and commercialization of a new brucellosis vaccine for cattle. PG - 147-53 AB - Vaccines used against brucellosis do not generally protect completely against infection or abortion. Genetic analysis has revealed differences in arrangements of DNA sequences between these vaccine strains and the virulent parent strain and permits the specific identification of field isolates of B. abortus as wild-type or vaccine strain. B. abortus strain 19 is a low-virulence, live vaccine developed for use in cattle. Although it is effective, strain 19 vaccine had a tropism for the placenta and caused abortion when given to pregnant cows, was infectious for humans, and caused serologic responses in calves that could not be differentiated from those in cattle infected with natural field strains. In the mid-1980s the need for a new vaccine emerged when the USDA increased its efforts in brucellosis eradication. In the 1990s, research on biosafety, vaccine efficacy and field application rapidly established the fact that strain RB51 is protective in cattle at doses comparable to those of strain 19. Thus, Brucella abortus strain RB51 is the vaccine of choice against brucellosis of cattle in the United States. Studies have established the relative efficacy of strain RB51 vaccine on bison, and the vaccine has also been accepted for use in commercial bison herds in the U.S. AD - Department of Veterinary Pathology, Iowa State University, Ames, Iowa 50011, USA. nchevill@iastate.edu FAU - Cheville, N F AU - Cheville NF LA - eng PT - Journal Article PL - United States TA - Ann N Y Acad Sci JT - Annals of the New York Academy of Sciences JID - 7506858 RN - 0 (Bacterial Vaccines) RN - 0 (Vaccines, Attenuated) SB - IM MH - Abortion, Veterinary MH - Animals MH - *Bacterial Vaccines/therapeutic use MH - Brucella abortus/genetics/*immunology/isolation & purification MH - Brucellosis, Bovine/*immunology/*prevention & control/transmission MH - Cattle MH - Drug Industry MH - Female MH - Humans MH - Kansas MH - Lymph Nodes/microbiology MH - Placenta/microbiology MH - Pregnancy MH - Safety MH - *Vaccines, Attenuated/therapeutic use EDAT- 2001/02/24 12:00 MHDA- 2001/02/28 10:01 CRDT- 2001/02/24 12:00 PST - ppublish SO - Ann N Y Acad Sci. 2000;916:147-53. PMID- 11447155 OWN - NLM STAT- MEDLINE DA - 20010711 DCOM- 20010823 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 69 IP - 8 DP - 2001 Aug TI - Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. PG - 4816-22 AB - The P39 and the bacterioferrin (BFR) antigens of Brucella melitensis 16M were previously identified as T dominant antigens able to induce both delayed-type hypersensivity in sensitized guinea pigs and in vitro gamma interferon (IFN-gamma) production by peripheral blood mononuclear cells from infected cattle. Here, we analyzed the potential for these antigens to function as a subunitary vaccine against Brucella abortus infection in BALB/c mice, and we characterized the humoral and cellular immune responses induced. Mice were injected with each of the recombinant proteins alone or adjuvanted with either CpG oligodeoxynucleotides (CpG ODN) or non-CpG ODN. Mice immunized with the recombinant antigens with CpG ODN were the only group demonstrating both significant IFN-gamma production and T-cell proliferation in response to either Brucella extract or to the respective antigen. The same conclusion holds true for the antibody response, which was only demonstrated in mice immunized with recombinant antigens mixed with CpG ODN. The antibody titers (both immunoglobulin G1 [IgG1] and IgG2a) induced by P39 immunization were higher than the titers induced by BFR (only IgG2a). Using a B. abortus 544 challenge, the level of protection was analyzed and compared to the protection conferred by one immunization with the vaccine strain B19. Immunization with P39 and CpG ODN gave a level of protection comparable to the one conferred by B19 at 4 weeks postchallenge, and the mice were still significantly protected at 8 weeks postchallenge, although to a lesser extent than the B19-vaccinated group. Intriguingly, no protection was detected after BFR vaccination. All other groups did not demonstrate any protection. AD - Unite de Recherche en Biologie Moleculaire, Laboratoire d'Immunologie et de Microbiologie, Facultes Universitaires Notre-Dame de la Paix, B-5000 Namur, Belgium. FAU - Al-Mariri, A AU - Al-Mariri A FAU - Tibor, A AU - Tibor A FAU - Mertens, P AU - Mertens P FAU - De Bolle, X AU - De Bolle X FAU - Michel, P AU - Michel P FAU - Godefroid, J AU - Godefroid J FAU - Walravens, K AU - Walravens K FAU - Letesson, J J AU - Letesson JJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Carrier Proteins) RN - 0 (CpG ODN 1826) RN - 0 (Cytochrome b Group) RN - 0 (Interleukin-5) RN - 0 (Membrane Proteins) RN - 0 (Periplasmic Binding Proteins) RN - 0 (Recombinant Fusion Proteins) RN - 0 (Vaccines, Synthetic) RN - 0 (p39 protein, Brucella) RN - 82115-62-6 (Interferon-gamma) RN - 9007-49-2 (DNA) RN - 9007-73-2 (Ferritins) RN - 9035-38-5 (bacterioferritin) SB - IM MH - *Adjuvants, Immunologic MH - Animals MH - Antibodies, Bacterial/immunology MH - Antigens, Bacterial/genetics/*immunology/isolation & purification MH - *Bacterial Proteins MH - Brucella Vaccine/genetics/*immunology/isolation & purification MH - Brucella abortus/*immunology MH - Brucellosis/immunology/*prevention & control MH - Carrier Proteins/genetics/*immunology/isolation & purification MH - Cell Division MH - Cells, Cultured MH - Chickens MH - Cytochrome b Group/genetics/*immunology/isolation & purification MH - DNA/*immunology MH - Female MH - Ferritins/genetics/*immunology/isolation & purification MH - Gene Expression MH - Interferon-gamma/biosynthesis MH - Interleukin-5/biosynthesis MH - Membrane Proteins/genetics/*immunology/isolation & purification MH - Mice MH - Mice, Inbred BALB C MH - *Periplasmic Binding Proteins MH - Recombinant Fusion Proteins/genetics/immunology/isolation & purification MH - Spleen/cytology MH - Vaccination MH - Vaccines, Synthetic/genetics/*immunology/isolation & purification PMC - PMC98569 OID - NLM: PMC98569 EDAT- 2001/07/12 10:00 MHDA- 2001/08/24 10:01 CRDT- 2001/07/12 10:00 AID - 10.1128/IAI.69.8.4816-4822.2001 [doi] PST - ppublish SO - Infect Immun. 2001 Aug;69(8):4816-22. PMID- 11500423 OWN - NLM STAT- MEDLINE DA - 20010813 DCOM- 20010913 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 69 IP - 9 DP - 2001 Sep TI - Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51. PG - 5502-8 AB - A safe, more sensitive, nonradioactive, neutral red uptake assay was adopted to replace the traditional 51Cr release assay for detection of Brucella-specific cytotoxic T lymphocyte (CTL) activity. Our studies indicated that Brucella abortus strain RB51 vaccination of mice induced specific CTLs against both strain RB51- and strain 2308-infected J774.A1 macrophages but not against Listeria monocytogenes-infected J774.A1 cells. The antigen-specific cytotoxic activity was exerted by T lymphocytes but not by NK cells. CD3+ CD4+ T cells secreted the highest level of gamma interferon (IFN-gamma) and were able to exert a low but significant level of specific lysis of Brucella-infected macrophages. They also exerted a low level of nonspecific lysis of noninfected macrophages. In contrast, CD3+ CD8+ T cells secreted low levels of IFN-gamma but demonstrated high levels of specific lysis of Brucella-infected macrophages with no nonspecific lysis. These findings indicate that B. abortus strain RB51 vaccination of mice induces specific CTLs and suggest that CD3+ CD4+ and CD3+ CD8+ T cells play a synergistic role in the anti-Brucella activity. AD - Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, VA-MD Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061-0342, USA. FAU - He, Y AU - He Y FAU - Vemulapalli, R AU - Vemulapalli R FAU - Zeytun, A AU - Zeytun A FAU - Schurig, G G AU - Schurig GG LA - eng SI - GENBANK/L06299 SI - GENBANK/L06302 PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antigens, CD3) RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Antigens, CD3/metabolism MH - Brucella Vaccine/*immunology MH - Brucella abortus/*immunology MH - Brucellosis/immunology/*prevention & control MH - Female MH - Mice MH - Mice, Inbred BALB C MH - Molecular Sequence Data MH - T-Lymphocytes, Cytotoxic/*immunology MH - Vaccination PMC - PMC98663 OID - NLM: PMC98663 EDAT- 2001/08/14 10:00 MHDA- 2001/09/14 10:01 CRDT- 2001/08/14 10:00 PST - ppublish SO - Infect Immun. 2001 Sep;69(9):5502-8. PMID- 11504226 OWN - NLM STAT- MEDLINE DA - 20010815 DCOM- 20020221 LR - 20051117 IS - 0090-3558 (Print) IS - 0090-3558 (Linking) VI - 37 IP - 3 DP - 2001 Jul TI - Experimental infection of nontarget species of rodents and birds with Brucella abortus strain RB51 vaccine. PG - 532-7 AB - The Brucella abortus vaccine strain RB51 (SRB51) is being considered for use in the management of bnucellosis in wild bison (Bison bison) and elk (Cervus elaphus) populations in the Greater Yellowstone Area (USA). Evaluation of the vaccines safety in non-target species was considered necessary prior to field use. Between June 1998 and December 1999, ground squirrels (Spermophilus richardsonii, n = 21), deer mice (Peromyscus maniculatus, n = 14), prairie voles (Microtus ochrogaster, n = 21), and ravens (Corvus corax, n = 13) were orally inoculated with SRB51 or physiologic saline. Oral and rectal swabs and blood samples were collected for bacteriologic evaluation. Rodents were necropsied at 8 to 10 wk and 12 to 21 wk post inoculation (PI), and ravens at 7 and 11 wk PI. Spleen, liver and reproductive tissues were collected for bacteriologic and histopathologic evaluation. No differences in clinical signs, appetite, weight loss or gain, or activity were observed between saline- and SRB51-inoculated animals in all four species. Oral and rectal swabs from all species were negative throughout the study. In tissues obtained from SRB51-inoculated animals, the organism was isolated from six of seven (86%) ground squirrels, one of six (17%) deer mice, none of seven voles, and one of five (20%) ravens necropsied at 8, 8, 10, and 7 wk PI, respectively. Tissues from four of seven (57%) SRB51-inoculated ground squirrels were culture positive for the organism 12 wk PI; SRB51 was not recovered from deer mice, voles. or ravens necropsied 12, 21, or 11 wk, respectively, PI. SRB51 was not recovered from saline-inoculated ground squirrels, deer mice, or voles at any time but was recovered from one saline-inoculated raven at necropsy, 7 wk PI, likely attributable to contact with SRB51-inoculated ravens in an adjacent aviary room. Spleen was time primary tissue site of colonization in ground squirrels, followed by the liver and reproductive organs. The results indicate oral exposure to SRB51 does not produce morbidity or mortality in ravens, ground squirrels, deer mice, or prairie voles. AD - US Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, National Wildlife Research Center, Fort Collins, Colorado 80521, USA. FAU - Januszewski, M C AU - Januszewski MC FAU - Olsen, S C AU - Olsen SC FAU - McLean, R G AU - McLean RG FAU - Clark, L AU - Clark L FAU - Rhyan, J C AU - Rhyan JC LA - eng PT - Journal Article PL - United States TA - J Wildl Dis JT - Journal of wildlife diseases JID - 0244160 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Arvicolinae MH - Bird Diseases/etiology/*prevention & control MH - Brucella Vaccine/*administration & dosage/adverse effects MH - Brucella abortus/*immunology/isolation & purification MH - Brucellosis/etiology/prevention & control/*veterinary MH - Colony Count, Microbial MH - Female MH - Liver/microbiology/pathology MH - Male MH - Peromyscus MH - Rodent Diseases/etiology/*prevention & control MH - Safety MH - Sciuridae MH - Songbirds MH - Spleen/microbiology/pathology MH - Treatment Outcome EDAT- 2001/08/16 10:00 MHDA- 2002/02/22 10:01 CRDT- 2001/08/16 10:00 PST - ppublish SO - J Wildl Dis. 2001 Jul;37(3):532-7. PMID- 11504238 OWN - NLM STAT- MEDLINE DA - 20010815 DCOM- 20020221 LR - 20061115 IS - 0090-3558 (Print) IS - 0090-3558 (Linking) VI - 37 IP - 3 DP - 2001 Jul TI - Safety of Brucella abortus strain RB51 in deer mice. PG - 621-5 AB - Brucella abortus strain RB51 is an approved brucellosis vaccine for use in cattle that may have potential as an oral vaccine for use in elk (Cervus elaphus) and/or bison (Bison bison). This study was designed to determine effects of strain RB51 on deer mice (Peromyscus maniculatus), a nontarget species that could have access to treated baits in a field situation. In February 1994, 90 mice were orally dosed or intraperitoneally injected with 1 x 10(8) colony forming units strain RB51 and 77 controls were similarly dosed with sterile saline. At weekly intervals through early April 1994, 4 to 6 mice from each group were euthanized, gross necropsies performed, spleens and uteruses cultured, and tissues examined histologically. All orally inoculated mice cleared the infection by 6 wk post-inoculation (PI). While most of the injected mice cleared the infection by 7 wk PI, a few required 9 wk. There were minimal adverse effects attributable to strain RB51. Apparently, strain RB51 would not negatively impact P. maniculatus populations if it were used in a field situation. Also, deer mice appear to be able to clear the vaccine in 6 to 9 wk, thus the probability of these mice transmitting the vaccine to other animals is low. AD - School of Veterinary Medicine, University of California, Davis 95617, USA. wecook@uwyo.edu FAU - Cook, W E AU - Cook WE FAU - Williams, E S AU - Williams ES FAU - Thorne, E T AU - Thorne ET FAU - Taylor, S K AU - Taylor SK FAU - Anderson, S AU - Anderson S LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Wildl Dis JT - Journal of wildlife diseases JID - 0244160 RN - 0 (Brucella Vaccine) SB - IM MH - Administration, Oral MH - Animals MH - Brucella Vaccine/administration & dosage/pharmacokinetics/*standards MH - Brucella abortus/*immunology MH - Brucellosis/pathology/prevention & control/*veterinary MH - Colony Count, Microbial MH - Female MH - Injections, Intraperitoneal/veterinary MH - Male MH - Peromyscus/*immunology MH - Random Allocation MH - Safety MH - Spleen/microbiology/pathology MH - Uterus/microbiology/pathology EDAT- 2001/08/16 10:00 MHDA- 2002/02/22 10:01 CRDT- 2001/08/16 10:00 PST - ppublish SO - J Wildl Dis. 2001 Jul;37(3):621-5. PMID- 11553603 OWN - NLM STAT- MEDLINE DA - 20010912 DCOM- 20011025 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 69 IP - 10 DP - 2001 Oct TI - Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection. PG - 6541-4 AB - This study indicated that mice immunized with Brucella abortus RB51 bacteria and subsequently challenged with B. abortus 2308 were protected from reinfection. After vaccination, both Th1 and Th2 cytokine patterns were observed. Of those, the early production of gamma interferon seems to have the prominent role in inducing an immunologically based protection. AD - Laboratory of Veterinary Medicine, Istituto Superiore di Sanita, 00161 Rome, Italy. pasquali@iss.it FAU - Pasquali, P AU - Pasquali P FAU - Adone, R AU - Adone R FAU - Gasbarre, L C AU - Gasbarre LC FAU - Pistoia, C AU - Pistoia C FAU - Ciuchini, F AU - Ciuchini F LA - eng PT - Journal Article PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 130068-27-8 (Interleukin-10) RN - 187348-17-0 (Interleukin-12) RN - 207137-56-2 (Interleukin-4) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Animals MH - Brucella abortus/*immunology/isolation & purification MH - Brucellosis/*immunology/prevention & control MH - Cells, Cultured MH - Disease Models, Animal MH - Interferon-gamma/*biosynthesis MH - Interleukin-10/*biosynthesis MH - Interleukin-12/*biosynthesis MH - Interleukin-4/*biosynthesis MH - Mice MH - Mice, Inbred BALB C MH - Organ Size MH - Spleen/cytology/immunology MH - Time Factors MH - *Vaccination/methods PMC - PMC98794 OID - NLM: PMC98794 EDAT- 2001/09/13 10:00 MHDA- 2001/10/26 10:01 CRDT- 2001/09/13 10:00 AID - 10.1128/IAI.69.10.6541-6544.2001 [doi] PST - ppublish SO - Infect Immun. 2001 Oct;69(10):6541-4. PMID- 11732416 OWN - NLM STAT- MEDLINE DA - 20011204 DCOM- 20020516 LR - 20061115 IS - 0253-1933 (Print) IS - 0253-1933 (Linking) VI - 20 IP - 3 DP - 2001 Dec TI - Comparison of the efficacy of Brucella abortus strain RB51 and Brucella melitensis Rev. 1 live vaccines against experimental infection with Brucella melitensis in pregnant ewes. PG - 741-7 AB - To test the efficacy of rough Brucella strain vaccines in sheep, a vaccine recently developed in cattle (Brucella abortus strain RB51) was assessed in comparison with the conventional Rev. 1 vaccine. Forty-five ewes from twelve to fourteen months of age, from brucellosis-free flocks, were allotted to three groups of fifteen ewes each. Group one was vaccinated by the conjunctival route with 1.73 x 10(8) colony forming units (CFU) of Rev. 1 vaccine. Group two was vaccinated subcutaneously with 11 x 10(9) CFU of RB51 vaccine and group three was considered as a control. All sheep were challenged at two to three months of gestation with 5 x 10(7) CFU of virulent B. melitensis H38. Vaccination with RB51 vaccine did not result in the production of any antibodies against the O-side chain of lipopolysaccharide, as measured by conventional serological tests (Rose Bengal plate test and complement fixation test). Protection of sheep against abortion and excretion of virulent Brucella strain in vaginal fluid, aborted foetuses and/or non viable lambs at parturition and abortion was significantly lower than that afforded by Rev. 1 vaccine. The difference compared to the control group was not significant. Data from this study suggest that the RB51 vaccine used for cattle vaccination does not provide effective protection of sheep against abortion induced by B. melitensis. AD - Departement de Microbiologie et Maladies Contagieuses, Institut Agronomique et Veterinaire Hassan II, Rabat-Instituts B.P. 6202, Rabat, Morocco. FAU - el Idrissi, A H AU - el Idrissi AH FAU - Benkirane, A AU - Benkirane A FAU - el Maadoudi, M AU - el Maadoudi M FAU - Bouslikhane, M AU - Bouslikhane M FAU - Berrada, J AU - Berrada J FAU - Zerouali, A AU - Zerouali A LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - France TA - Rev Sci Tech JT - Revue scientifique et technique (International Office of Epizootics) JID - 8712301 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Ophthalmic Solutions) SB - IM MH - Abortion, Veterinary/prevention & control MH - Animals MH - Antibodies, Bacterial/blood MH - *Brucella Vaccine/administration & dosage/immunology/standards MH - Brucella abortus/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/prevention & control/*veterinary MH - Female MH - Injections, Subcutaneous/veterinary MH - Ophthalmic Solutions MH - Pregnancy MH - Pregnancy Complications, Infectious/prevention & control/*veterinary MH - Sheep MH - Sheep Diseases/*prevention & control MH - Vaccination/veterinary EDAT- 2001/12/06 10:00 MHDA- 2002/05/17 10:01 CRDT- 2001/12/06 10:00 PST - ppublish SO - Rev Sci Tech. 2001 Dec;20(3):741-7. PMID- 11768128 OWN - NLM STAT- MEDLINE DA - 20011220 DCOM- 20020423 LR - 20091118 IS - 0830-9000 (Print) IS - 0830-9000 (Linking) VI - 65 IP - 4 DP - 2001 Oct TI - Effects of exogenous recombinant interleukin-12 on immune responses and protection against Brucella abortus in a murine model. PG - 223-8 AB - This study determined if murine interleukin-12 (IL-12) would influence immunity in mice vaccinated with live or killed Brucella abortus strain RB51 (SRB51). Mice received live or gamma-irradiated SRB51 bacteria alone, or with IL-12 (0.5 or 1.0 microg, 2x or 3x), whereas other mice received saline or IL-12 alone. Post-vaccination antibody responses to live or killed SRB51 and clearance of live SRB51 from splenic tissue were not influenced by IL-12 treatments. Mice were challenged at 12 weeks with 4 x 10(4) cfu of B. abortus strain 2308 (S2308) and were euthanized 2 weeks later. The highest IL-12 treatment increased (P < 0.05) post-challenge antibody responses when co-administered with killed SRB51. Co-administration of 1.0 microg of IL-12 with live SRB51, but not killed SRB51, reduced (P < 0.05) S2308 colonization of splenic tissues. Our data suggest that although IL-12 may augment protective immunity induced by live SRB51, it does not influence protection induced by vaccination with killed SRB51. AD - Bacterial Diseases Research Unit, National Animal Disease Center, Agriculture Research Service, United States Department of Agriculture, Ames, Iowa 50010, USA. FAU - Lee, I K AU - Lee IK FAU - Olsen, S C AU - Olsen SC FAU - Bolin, C A AU - Bolin CA LA - eng PT - Journal Article PL - Canada TA - Can J Vet Res JT - Canadian journal of veterinary research = Revue canadienne de recherche veterinaire JID - 8607793 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Vaccines) RN - 0 (Vaccines, Inactivated) RN - 187348-17-0 (Interleukin-12) SB - IM MH - Adjuvants, Immunologic/*administration & dosage MH - Animals MH - Antibodies, Bacterial/*blood MH - Bacterial Vaccines/*administration & dosage/immunology MH - Brucella abortus/*immunology/pathogenicity MH - Brucellosis/prevention & control/*veterinary MH - Colony Count, Microbial MH - Disease Models, Animal MH - Female MH - Interleukin-12/*administration & dosage MH - Liver/microbiology/pathology MH - Mice MH - Mice, Inbred BALB C MH - Spleen/microbiology/pathology MH - Vaccines, Inactivated/administration & dosage/immunology PMC - PMC1189683 OID - NLM: PMC1189683 EDAT- 2002/01/05 10:00 MHDA- 2002/04/24 10:01 CRDT- 2002/01/05 10:00 PST - ppublish SO - Can J Vet Res. 2001 Oct;65(4):223-8. PMID- 11953389 OWN - NLM STAT- MEDLINE DA - 20020415 DCOM- 20020508 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 70 IP - 5 DP - 2002 May TI - A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. PG - 2507-11 AB - This study was conducted to evaluate the immunogenicity of the Brucella abortus lumazine synthase (BLS) gene cloned into the pcDNA3 plasmid, which is driven by the cytomegalovirus promoter. Injection of plasmid DNA carrying the BLS gene (pcDNA-BLS) into BALB/c mice elicited both humoral and cellular immune responses. Antibodies to the encoded BLS included immunoglobulin G1 (IgG1) IgG2a, IgG2b, IgG3, and IgM isotypes. Animals injected with pcDNA-BLS exhibited a dominance of IgG2a over IgG1. In addition, spleen cells from vaccinated animals produced interleukin-2 and gamma interferon but not IL-10 or IL-4 after in vitro stimulation with recombinant BLS (rBLS), suggesting the induction of a Th1 response. Protection was evaluated by comparing the levels of infection in the spleens of vaccinated mice challenged with B. abortus 544. Immunization with pcDNA-BLS- reduced the bacterial burden relative to those in the control groups. Mice immunized with rBLS produced a significant humoral response but did not show a specific cellular response or any protection from challenge. Altogether, these data suggest that pcDNA-BLS is a good immunogen for the production of humoral and cell-mediated responses in mice and is a candidate for use in future studies of vaccination against brucellosis. AD - Facultad de Farmacia y Bioquimica Instituto de Estudios de la Inmunidad Humoral, UNICEN, Tandil, Argentina. FAU - Velikovsky, Carlos A AU - Velikovsky CA FAU - Cassataro, Juliana AU - Cassataro J FAU - Giambartolomei, Guillermo H AU - Giambartolomei GH FAU - Goldbaum, Fernando A AU - Goldbaum FA FAU - Estein, Silvia AU - Estein S FAU - Bowden, Raul A AU - Bowden RA FAU - Bruno, Laura AU - Bruno L FAU - Fossati, Carlos A AU - Fossati CA FAU - Spitz, Moises AU - Spitz M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Immunoglobulin G) RN - 0 (Multienzyme Complexes) RN - 0 (Recombinant Proteins) RN - 0 (Vaccines, DNA) RN - 0 (Vaccines, Synthetic) RN - 89287-46-7 (6,7-dimethyl-8-ribityllumazine synthase) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Brucella Vaccine/*immunology MH - Brucella abortus/enzymology/*immunology MH - Brucellosis/*prevention & control MH - Female MH - Immunization MH - Immunoglobulin G/blood/classification MH - Mice MH - Mice, Inbred BALB C MH - Multienzyme Complexes/*genetics/immunology MH - Recombinant Proteins/immunology MH - Th1 Cells/immunology MH - Vaccines, DNA/*immunology MH - Vaccines, Synthetic/immunology PMC - PMC127889 OID - NLM: PMC127889 EDAT- 2002/04/16 10:00 MHDA- 2002/05/09 10:01 CRDT- 2002/04/16 10:00 PST - ppublish SO - Infect Immun. 2002 May;70(5):2507-11. PMID- 11953393 OWN - NLM STAT- MEDLINE DA - 20020415 DCOM- 20020508 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 70 IP - 5 DP - 2002 May TI - Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. PG - 2535-43 AB - The members of the genus Brucella are gram-negative, facultatively intracellular bacterial pathogens that cause brucellosis in many animal species and humans. Although live, attenuated vaccines are available to protect several animal species from the disease, there is no safe and effective vaccine for human use. Here we report that a bacterium that is closely related to Brucella species, Ochrobactrum anthropi, can be used as a vaccine vector for the delivery of Brucella antigens to mice, leading to the elicitation of protective immunity against brucellosis. Brucella abortus Cu,Zn superoxide dismutase (SOD), a protective Brucella antigen, was expressed in large amounts in O. anthropi strain 49237 by use of the broad-host-range plasmid pBBR1MCS. Neither O. anthropi strain 49237 nor the recombinant O. anthropi strain 49237SOD, expressing B. abortus Cu,Zn SOD, provided protection against virulent Brucella infection in mice. Analysis of immune responses indicated that strains 49237 and 49237SOD stimulated a mix of Th1 and Th2 type responses in the mice. After the immune response was switched to a Th1-biased response by addition of oligonucleotides containing unmethylated CpG motifs, both O. anthropi strain 49237 and the recombinant O. anthropi strain 49237SOD induced protection in mice. However, the protection conferred by strain 49237SOD was significantly better than that induced by the parental strain, 49237. AD - Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061-0342, USA. FAU - He, Yongqun AU - He Y FAU - Vemulapalli, Ramesh AU - Vemulapalli R FAU - Schurig, Gerhardt G AU - Schurig GG LA - eng PT - Journal Article PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Brucella Vaccine) RN - 0 (CPG-oligonucleotide) RN - 0 (Immunoglobulin G) RN - 0 (Oligodeoxyribonucleotides) RN - 0 (Vaccines, Synthetic) RN - 207137-56-2 (Interleukin-4) RN - 82115-62-6 (Interferon-gamma) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - Brucella Vaccine/*immunology MH - Brucella abortus/*immunology MH - Brucellosis/microbiology/*prevention & control MH - Female MH - Immunization MH - Immunoglobulin G/blood/classification MH - Interferon-gamma/biosynthesis MH - Interleukin-4/biosynthesis MH - Mice MH - Mice, Inbred BALB C MH - Ochrobactrum anthropi/*genetics MH - Oligodeoxyribonucleotides/pharmacology MH - Superoxide Dismutase/genetics/*immunology MH - Th1 Cells/*immunology MH - Vaccines, Synthetic/*immunology PMC - PMC127893 OID - NLM: PMC127893 EDAT- 2002/04/16 10:00 MHDA- 2002/05/09 10:01 CRDT- 2002/04/16 10:00 PST - ppublish SO - Infect Immun. 2002 May;70(5):2535-43. PMID- 12057611 OWN - NLM STAT- MEDLINE DA - 20020611 DCOM- 20021127 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 20 IP - 19-20 DP - 2002 Jun 7 TI - Identification of Brucella melitensis vaccine strain Rev.1 by PCR-RFLP based on a mutation in the rpsL gene. PG - 2546-50 AB - The live attenuated strain B. melitensis Rev.1 is considered the best vaccine available for the prophylaxis of brucellosis in sheep and goats. The Rev.1 vaccine was obtained in the 1950s by a two-step selection involving firstly streptomycin resistance and dependence and secondly reversion of dependence but keeping streptomycin resistance. Chromosomally acquired streptomycin resistance is frequently due to mutations in the gene encoding the ribosomal protein S12, rpsL. Nucleotide sequencing revealed one mutation in the rpsL gene of vaccine strain Rev.1 compared to that of reference strain 16M leading to an amino acid Pro-to-Leu change at codon position 91 (Pro91Leu). This mutation resulted also in the lack of a NciI restriction site in the gene. PCR-restriction fragment length polymorphism (PCR-RFLP) using NciI applied to a large number of Brucella reference and field strains showed that the mutation detected was specific of vaccine strain Rev.1. AD - Unite de Pathologie Aviaire et Parasitologie, Institut National de la Recherche Agronomique, 37380 Nouzilly, France. cloeckae@tours.inra.fr FAU - Cloeckaert, Axel AU - Cloeckaert A FAU - Grayon, Maggy AU - Grayon M FAU - Grepinet, Olivier AU - Grepinet O LA - eng SI - GENBANK/AE008917 SI - GENBANK/AF448459 PT - Journal Article PL - England TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Bacterial Vaccines) RN - 0 (DNA Primers) RN - 0 (Ribosomal Proteins) RN - 0 (ribosomal protein S12) SB - IM MH - Bacterial Vaccines/*immunology MH - Base Sequence MH - Brucella melitensis/*immunology MH - DNA Primers MH - Molecular Sequence Data MH - *Mutation MH - Polymerase Chain Reaction MH - Polymorphism, Restriction Fragment Length MH - Ribosomal Proteins/*genetics EDAT- 2002/06/12 10:00 MHDA- 2002/11/28 04:00 CRDT- 2002/06/12 10:00 AID - S0264410X02001597 [pii] PST - ppublish SO - Vaccine. 2002 Jun 7;20(19-20):2546-50. PMID- 12065469 OWN - NLM STAT- MEDLINE DA - 20020614 DCOM- 20020730 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 70 IP - 7 DP - 2002 Jul TI - Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. PG - 3324-9 AB - Intranasal immunization of mice with purified Brucella melitensis lipopolysaccharide (LPS) as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (GBOMP) elicited a high-titer anti-LPS systemic antibody response and a significant mucosal antibody response. The anti-LPS immunoglobulin G (IgG) antibody was predominantly of the IgG1 subtype, although there was some response of the IgG2a, IgG2b, and IgG3 subtypes. The antibody titer remained high for 16 weeks postimmunization. Immunized mice and sham-immunized control mice were challenged intranasally with 10(4) CFU of virulent B. melitensis strain 16 M 4 weeks after the second dose of vaccine. The numbers of bacteria in lungs, livers, and spleens at 3 days, 9 days, and 8 weeks postchallenge were determined. Bacteria were found in lungs of all mice on day 3, but there was no disseminated infection of liver or spleen. By day 9, 40% of the mice had infected spleens and livers. At 8 weeks postchallenge, spleens of 25 of 62 immunized mice were infected, compared to 61 of 62 control mice (P < 0.0001). The livers of 12 of 43 immunized mice were infected, compared to 22 of 36 control mice (P = 0.005). In contrast, the lungs of 26 of 46 immunized mice were still infected, compared to 27 of 44 control mice. The numbers of bacterial CFU in lungs of immunized and control animals were identical. These studies show that intranasal immunization with B. melitensis LPS-GBOMP subunit vaccine significantly protects mice against intranasal challenge with virulent B. melitensis. Vaccination reduces bacterial dissemination to spleen and liver but has no effect on the course of lung infection. AD - Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, D.C. 20307-5100, USA. Apurba.Bhattacharjee2@na.amedd.army.mil FAU - Bhattacharjee, Apurba K AU - Bhattacharjee AK FAU - Van de Verg, Lillian AU - Van de Verg L FAU - Izadjoo, Mina J AU - Izadjoo MJ FAU - Yuan, Liang AU - Yuan L FAU - Hadfield, Ted L AU - Hadfield TL FAU - Zollinger, Wendell D AU - Zollinger WD FAU - Hoover, David L AU - Hoover DL LA - eng PT - Journal Article PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Lipopolysaccharides) SB - IM MH - Administration, Intranasal MH - Animals MH - Antibodies, Bacterial/biosynthesis MH - Bacterial Outer Membrane Proteins/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/immunology/*prevention & control MH - Female MH - Lipopolysaccharides/*immunology MH - Liver/immunology/microbiology MH - Lung/immunology/microbiology MH - Mice MH - Mice, Inbred BALB C MH - Neisseria meningitidis/*immunology MH - Spleen/immunology/microbiology MH - Vaccination PMC - PMC128042 OID - NLM: PMC128042 EDAT- 2002/06/18 10:00 MHDA- 2002/07/31 10:01 CRDT- 2002/06/18 10:00 PST - ppublish SO - Infect Immun. 2002 Jul;70(7):3324-9. PMID- 12119140 OWN - NLM STAT- MEDLINE DA - 20020716 DCOM- 20020924 LR - 20061115 IS - 0378-1135 (Print) IS - 0378-1135 (Linking) VI - 88 IP - 1 DP - 2002 Aug 2 TI - Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev. 1 vaccines and challenged with Brucella melitensis bv. 3. PG - 85-94 AB - BALB/c mice were immunized with live rough Brucella abortus RB51 or smooth Brucella melitensis Rev. 1 vaccines and challenged with a B. melitensis field strain. Protection was assessed by a variety of serological tests and recovery of vaccinal and challenge strains by culture. Mice vaccinated with RB51 gave negative results in the conventional serological tests prior to challenge, namely; standard tube agglutination test (SAT), Rose Bengal plate test (RBPT), buffered acidified plate antigen test (BAPAT), and mercaptoethanol test (MET). Sero-conversion took place to a whole-cell bacterial buffered RB51 antigen after vaccination and persisted for 7 weeks post-vaccination. Mice challenged with B. melitensis were assessed for bacterial load and immune response for 12 weeks after challenge. Protection units were showed that Rev. 1 vaccine was superior to RB51 vaccine in protection of mice against B. melitensis. However, RB51 vaccine has the advantage that it would not elicit antibodies to standard serological tests based on the LPS O antigen. RB51 vaccine could therefore be used for control of B. melitensis infection and avoid confusion in the use of standard sero-diagnostic tests. AD - Department of Brucellosis Research, Animal Health Research Institute, Dokki, Giza, Egypt. merhamdy@hotmail.com FAU - Hamdy, M E R AU - Hamdy ME FAU - El-Gibaly, S M AU - El-Gibaly SM FAU - Montasser, A M AU - Montasser AM LA - eng PT - Comparative Study PT - Journal Article PL - Netherlands TA - Vet Microbiol JT - Veterinary microbiology JID - 7705469 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Antibodies, Bacterial/biosynthesis MH - Brucella Vaccine/*immunology/standards/therapeutic use MH - Brucella melitensis/*immunology MH - Brucellosis/*immunology/prevention & control MH - Female MH - Liver/microbiology MH - Lung/microbiology MH - Mice MH - Mice, Inbred BALB C MH - Spleen/microbiology MH - Vaccination/*veterinary EDAT- 2002/07/18 10:00 MHDA- 2002/09/25 06:00 CRDT- 2002/07/18 10:00 AID - S0378113502000883 [pii] PST - ppublish SO - Vet Microbiol. 2002 Aug 2;88(1):85-94. PMID- 12193611 OWN - NLM STAT- MEDLINE DA - 20020823 DCOM- 20021004 LR - 20091118 IS - 0021-9193 (Print) IS - 0021-9193 (Linking) VI - 184 IP - 18 DP - 2002 Sep TI - Comparative proteome analysis of Brucella melitensis vaccine strain Rev 1 and a virulent strain, 16M. PG - 4962-70 AB - The genus Brucella consists of bacterial pathogens that cause brucellosis, a major zoonotic disease characterized by undulant fever and neurological disorders in humans. Among the different Brucella species, Brucella melitensis is considered the most virulent. Despite successful use in animals, the vaccine strains remain infectious for humans. To understand the mechanism of virulence in B. melitensis, the proteome of vaccine strain Rev 1 was analyzed by two-dimensional gel electrophoresis and compared to that of virulent strain 16M. The two strains were grown under identical laboratory conditions. Computer-assisted analysis of the two B. melitensis proteomes revealed proteins expressed in either 16M or Rev 1, as well as up- or down-regulation of proteins specific for each of these strains. These proteins were identified by peptide mass fingerprinting. It was found that certain metabolic pathways may be deregulated in Rev 1. Expression of an immunogenic 31-kDa outer membrane protein, proteins utilized for iron acquisition, and those that play a role in sugar binding, lipid degradation, and amino acid binding was altered in Rev 1. AD - Institute of Molecular Biology and Medicine, The University of Scranton, Scranton, Pennsylvania 18510, USA. FAU - Eschenbrenner, Michel AU - Eschenbrenner M FAU - Wagner, Mary Ann AU - Wagner MA FAU - Horn, Troy A AU - Horn TA FAU - Kraycer, Jo Ann AU - Kraycer JA FAU - Mujer, Cesar V AU - Mujer CV FAU - Hagius, Sue AU - Hagius S FAU - Elzer, Philip AU - Elzer P FAU - DelVecchio, Vito G AU - DelVecchio VG LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - J Bacteriol JT - Journal of bacteriology JID - 2985120R RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Proteome) SB - IM MH - Bacterial Proteins/genetics/*metabolism MH - *Brucella Vaccine MH - Brucella melitensis/genetics/growth & development/*metabolism/pathogenicity MH - Electrophoresis, Gel, Two-Dimensional MH - Gene Expression Regulation, Bacterial MH - Hydrogen-Ion Concentration MH - Image Processing, Computer-Assisted MH - Proteome/*analysis MH - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization MH - Virulence PMC - PMC135307 OID - NLM: PMC135307 EDAT- 2002/08/24 10:00 MHDA- 2002/10/09 04:00 CRDT- 2002/08/24 10:00 PST - ppublish SO - J Bacteriol. 2002 Sep;184(18):4962-70. PMID- 12414167 OWN - NLM STAT- MEDLINE DA - 20021104 DCOM- 20030303 LR - 20061115 IS - 0378-1135 (Print) IS - 0378-1135 (Linking) VI - 90 IP - 1-4 DP - 2002 Dec 20 TI - Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: laboratory aspects and field observations. PG - 497-519 AB - Brucellosis vaccines are essential elements in control programs. Since first developed in the mid-1950s, the Brucella melitensis vaccine strain Rev.1 has been used worldwide and its significant value in protecting sheep and goats in endemic areas recognized. This review provides historical background on the development of the vaccine, its use and field complications arising in Israel following changes in the strain's pathogenicity. The urgent need for resolving cases of vaccine strain excretion in the milk, horizontal transfer and a unique case of human infection has led to identification of an atypical B. melitensis biovar 1 strain that resembles strain Rev.1 in susceptibility to penicillin and dyes. An omp2 based PCR method has been developed that traced the lineage of Israeli B. melitensis biovar 1 strains. This locus serves as an epidemiological tag for the Rev.1 vaccine strain. Despite the rapid development of new approaches in the field of vaccination, it is anticipated that in the near future the Rev.1 vaccine would remain the only accepted vaccine in national control programs. CI - Copyright 2002 Elsevier Science B.V. AD - Department of Bacteriology, Kimron Veterinary Institute, PO Box 12, Bet Dagan 50250, Israel. mbana_vs@netvision.net.il FAU - Banai, Menachem AU - Banai M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Review PL - Netherlands TA - Vet Microbiol JT - Veterinary microbiology JID - 7705469 RN - 0 (Bacterial Vaccines) RN - 0 (Rev.1 vaccine, Brucella melitensis) SB - IM MH - Animals MH - *Bacterial Vaccines/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/*immunology/prevention & control/*veterinary MH - Ruminants RF - 49 EDAT- 2002/11/05 04:00 MHDA- 2003/03/04 04:00 CRDT- 2002/11/05 04:00 AID - S0378113502002316 [pii] PST - ppublish SO - Vet Microbiol. 2002 Dec 20;90(1-4):497-519. PMID- 12438380 OWN - NLM STAT- MEDLINE DA - 20021119 DCOM- 20030107 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 70 IP - 12 DP - 2002 Dec TI - Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice. PG - 7004-12 AB - Interferon regulatory factor 1-deficient (IRF-1(-/-)) mice infected with virulent Brucella abortus 2308 at 5 x 10(5) CFU developed acute hepatitis similar to many natural hosts but, unlike natural hosts, IRF-1(-/-) mice were unable to resolve infection and died. In contrast, IRF-1(-/-) mice survived when infected at 5 x 10(5) CFU with several attenuated Brucella strains (S19, RB51, cbp, and cyd). The survival of infected IRF-1(-/-) mice is likely a function of the level of virulence of each Brucella strain and the extent of retained immunity. Further, these findings suggest that adaptive immunity may be important to the survival of IRF-1(-/-) mice since attenuated Brucella strains can protect IRF-1(-/-) mice against lethal challenge with virulent Brucella: Using the IRF-1(-/-) mouse model, the following set of criteria were identified to define Brucella virulence: (i) the day of death for 50% of mice infected with 5 x 10(5)CFU of Brucella, (ii) the extent of liver toxicity, and (iii) the minimum immunizing dose of Brucella to protect against challenge with virulent S2308. Thus, IRF-1(-/-) mice are important to determining the level of Brucella virulence, to evaluating Brucella mutants for attenuation, and to investigating adaptive immunity in brucellosis. AD - Laboratory of Cellular and Molecular Immunology, Department of Animal Health and Biomedical Sciences, University of Wisconsin, Madison 53706, USA. FAU - Ko, Jinkyung AU - Ko J FAU - Gendron-Fitzpatrick, Annette AU - Gendron-Fitzpatrick A FAU - Ficht, Thomas A AU - Ficht TA FAU - Splitter, Gary A AU - Splitter GA LA - eng GR - R01-AI48490/AI/NIAID NIH HHS/United States PT - Evaluation Studies PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Bacterial Proteins) RN - 0 (DNA-Binding Proteins) RN - 0 (Interferon Regulatory Factor-1) RN - 0 (Irf1 protein, mouse) RN - 0 (Phosphoproteins) SB - IM MH - Animals MH - Bacterial Proteins/*genetics/metabolism MH - Brucella abortus/genetics/immunology/*pathogenicity MH - *Brucellosis/microbiology/mortality/pathology/physiopathology MH - DNA-Binding Proteins/*deficiency/genetics MH - *Disease Models, Animal MH - Immunization MH - Interferon Regulatory Factor-1 MH - Liver/microbiology/pathology MH - Mice MH - Mice, Inbred C57BL MH - Phosphoproteins/*deficiency/genetics MH - Spleen/microbiology MH - Virulence/genetics PMC - PMC132959 OID - NLM: PMC132959 EDAT- 2002/11/20 04:00 MHDA- 2003/01/08 04:00 CRDT- 2002/11/20 04:00 PST - ppublish SO - Infect Immun. 2002 Dec;70(12):7004-12. PMID- 12704101 OWN - NLM STAT- MEDLINE DA - 20030421 DCOM- 20030515 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 71 IP - 5 DP - 2003 May TI - Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308. PG - 2326-30 AB - Brucellae are gram-negative, facultative intracellular bacteria which are one of the most common causes of abortion in animals. In addition, they are the source of a severe zoonosis. In this trial, we evaluated the effect of oral inoculation of Brucella abortus RB51 in mice against a challenge infection with B. abortus 2308. First, we showed that a gastric acid neutralization prior to the oral inoculation contributed to a more homogeneous and consistent infection with both vaccine strain B. abortus RB51 and virulent strain B. abortus 2308. Successively, we assessed the clearance and the immune response following an oral infection with B. abortus RB51. Oral inoculation gave a mild infection which was cleared 42 days after infection, and it induced a delayed humoral and cell-mediated immune response. Finally, we immunized mice by oral inoculation with B. abortus RB51, and we challenged them with the virulent strain B. abortus 2308 by an oral or intraperitoneal route 42 days after vaccination. Oral inoculation of B. abortus RB51 was able to give protection to mice infected with the virulent strain B. abortus 2308 by the oral route but not to mice infected intraperitoneally. Our results indicate that oral inoculation of mice with B. abortus RB51 is able to give a protective immunity against an oral infection with virulent strains, and this protection seems to rely on an immune response at the mucosal level. AD - Laboratory of Veterinary Medicine, Istituto Superiore di Sanita, Rome, Italy. pasquali@iss.it FAU - Pasquali, Paolo AU - Pasquali P FAU - Rosanna, Adone AU - Rosanna A FAU - Pistoia, Claudia AU - Pistoia C FAU - Petrucci, Paola AU - Petrucci P FAU - Ciuchini, Franco AU - Ciuchini F LA - eng PT - Journal Article PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Brucella Vaccine/*immunology MH - Brucella abortus/*immunology MH - Brucellosis/*prevention & control MH - Female MH - Gastric Acidity Determination MH - Mice MH - Mice, Inbred BALB C MH - Vaccination PMC - PMC153221 OID - NLM: PMC153221 EDAT- 2003/04/22 05:00 MHDA- 2003/05/16 05:00 CRDT- 2003/04/22 05:00 PST - ppublish SO - Infect Immun. 2003 May;71(5):2326-30. PMID- 13162836 OWN - NLM STAT- MEDLINE DA - 19541201 DCOM- 20030501 LR - 20061115 IS - 0002-9955 (Print) IS - 0002-9955 (Linking) VI - 155 IP - 11 DP - 1954 Jul 10 TI - Human sickness caused by Brucella abortus, strain 19. PG - 970-1 FAU - BARDENWERPER, H W AU - BARDENWERPER HW LA - eng PT - Journal Article PL - Not Available TA - J Am Med Assoc JT - Journal of the American Medical Association JID - 7507176 SB - OM MH - *Brucellosis OID - CLML: 5426:25536:86 OTO - NLM OT - *BRUCELLOSIS EDAT- 1954/07/10 MHDA- 1954/07/10 00:01 CRDT- 1954/07/10 00:00 PST - ppublish SO - J Am Med Assoc. 1954 Jul 10;155(11):970-1. PMID- 13201511 OWN - NLM STAT- MEDLINE DA - 19551201 DCOM- 20030501 LR - 20080603 IS - 0003-1488 (Print) IS - 0003-1488 (Linking) VI - 125 IP - 932 DP - 1954 Nov TI - The immunogenicity for cattle of Brucella abortus strain 19 and M vaccine (Huddleson). PG - 401-5 FAU - BERMAN, D T AU - BERMAN DT FAU - IRWIN, M R AU - IRWIN MR LA - eng PT - Journal Article PL - Not Available TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 RN - 0 (Vaccines) SB - OM MH - Brucellosis/*prevention & control MH - *Cattle Diseases MH - *Vaccination MH - *Vaccines OID - CLML: 5527:13163:88:99:485 OTO - NLM OT - *BRUCELLOSIS/prevention and control OT - *CATTLE/diseases OT - *VACCINES AND VACCINATION EDAT- 1954/11/01 MHDA- 1954/11/01 00:01 CRDT- 1954/11/01 00:00 PST - ppublish SO - J Am Vet Med Assoc. 1954 Nov;125(932):401-5. PMID- 13416171 OWN - NLM STAT- MEDLINE DA - 19571201 DCOM- 20020501 LR - 20091118 IS - 0021-9193 (Print) IS - 0021-9193 (Linking) VI - 73 IP - 2 DP - 1957 Feb TI - Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. PG - 211-7 FAU - ELBERG, S S AU - ELBERG SS FAU - FAUNCE, K Jr AU - FAUNCE K Jr LA - eng PT - Journal Article PL - Not Available TA - J Bacteriol JT - Journal of bacteriology JID - 2985120R SB - OM MH - Brucellosis/*immunology PMC - PMC289776 OID - CLML: 5732:14090 OID - NLM: PMC289776 OTO - NLM OT - *BRUCELLOSIS/immunology EDAT- 1957/02/01 MHDA- 1957/02/01 00:01 CRDT- 1957/02/01 00:00 PST - ppublish SO - J Bacteriol. 1957 Feb;73(2):211-7. PMID- 13756096 OWN - NLM STAT- MEDLINE DA - 19611201 DCOM- 19981101 LR - 20061115 IS - 0003-1488 (Print) IS - 0003-1488 (Linking) VI - 139 DP - 1961 Jul 1 TI - Effect of age on resistance and retention of titer in cattle vaccinated with strain 19 Brucella abortus vaccine. PG - 100-3 FAU - KING, N B AU - KING NB FAU - FRANK, N A AU - FRANK NA LA - eng PT - Journal Article PL - Not Available TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 SB - OM MH - Brucellosis, Bovine/*immunology OTO - NLM OT - *BRUCELLOSIS, BOVINE/immunology EDAT- 1961/07/01 MHDA- 1961/07/01 00:01 CRDT- 1961/07/01 00:00 PST - ppublish SO - J Am Vet Med Assoc. 1961 Jul 1;139:100-3. PMID- 14998310 OWN - NLM STAT- MEDLINE DA - 20040304 DCOM- 20040604 LR - 20061115 IS - 0049-4747 (Print) IS - 0049-4747 (Linking) VI - 36 IP - 2 DP - 2004 Feb TI - Protection against brucellosis in goats, five years after vaccination with reduced-dose Brucella melitensis Rev 1 vaccine. PG - 117-21 AB - The protection conferred by the reduced-dose Rev 1 Brucella melitensis vaccine in goats that had been immunized 5 years previously was evaluated. Sixteen goats vaccinated 5 years before with Rev 1 (1 x 10(5) cfu) and 5 non-vaccinated goats were challenged with B. melitensis 16M (4 x 10(5) cfu) using the conjunctival route. After giving birth or aborting, the goats were sacrificed and tissue samples were taken for bacteriological study. The challenge strain was recovered in 12%, of the animals from the vaccinated group, and in (80% of the control group. It is concluded, therefore that the use of reduced-dose Rev 1 protects goats vaccinated in endemic areas for at least 5 years after immunization. AD - CENID Microbiologia, Instituto Nacional de Investigaciones Agricolas, Forestales y Pecuarias, Carretera Federal Mexico-Toluca Km. 15.5, Cuajimalpa, Mexico. diaz@ciml.univ-mrs.fr FAU - Diaz-Aparicio, E AU - Diaz-Aparicio E FAU - Hernandez, L AU - Hernandez L FAU - Suarez-Guemes, F AU - Suarez-Guemes F LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Trop Anim Health Prod JT - Tropical animal health and production JID - 1277355 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Brucella Vaccine/*administration & dosage/immunology MH - Brucella melitensis/*immunology MH - Brucellosis/prevention & control/*veterinary MH - Colony Count, Microbial/veterinary MH - Conjunctiva MH - Dose-Response Relationship, Immunologic MH - Female MH - Goat Diseases/*prevention & control MH - Goats MH - Time Factors EDAT- 2004/03/05 05:00 MHDA- 2004/06/05 05:00 CRDT- 2004/03/05 05:00 PST - ppublish SO - Trop Anim Health Prod. 2004 Feb;36(2):117-21. PMID- 15005547 OWN - NLM STAT- MEDLINE DA - 20040309 DCOM- 20050426 IS - 0253-1933 (Print) IS - 0253-1933 (Linking) VI - 22 IP - 3 DP - 2003 Dec TI - The immune response of guinea pigs and buffalo calves to the locally prepared Brucella abortus strain 19 vaccine. PG - 893-7 AB - Brucella abortus vaccine was prepared from strain 19 imported from Germany. The vaccine induced a good immune response in guinea pigs as evidenced by a serological titre of 328 international units (IU)/ml 10 days post-vaccination. Vaccinated guinea pigs also withstood an experimental challenge of 5,000 colony-forming units of a locally isolated virulent B. abortus strain. This vaccine, containing 7 x 10(10) viable organisms, induced a significant immune response in 8 to 10.5 month old female buffalo calves. Significant serum agglutination test (SAT) titres were seen on day 7 following vaccination. The highest SAT titres were observed on day 14 post-vaccination and the titres started declining thereafter. The rate of decrease was slow from day 14 to day 49 post-vaccination; however, a rapid decrease in titres was seen from day 49 to day 91 post-vaccination. Negligible SAT titres were observed on day 91 post-vaccination. Specific immunoglobulin G titres, as measured by 2-mercaptoethanol treated SAT, also followed a similar trend and the titre of all five of the calves that were vaccinated became zero on day 91 post-vaccination. AD - Department of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan. FAU - Jamal, S M AU - Jamal SM FAU - Afzal, M AU - Afzal M FAU - Ahmed, S AU - Ahmed S LA - eng PT - Journal Article PL - France TA - Rev Sci Tech JT - Revue scientifique et technique (International Office of Epizootics) JID - 8712301 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Immunoglobulin G) RN - 0 (Vaccines, Attenuated) SB - IM MH - Animals MH - Antibodies, Bacterial/*biosynthesis/blood MH - Brucella Vaccine/*immunology MH - Brucella abortus/*immunology/pathogenicity MH - Brucellosis/prevention & control/*veterinary MH - Buffaloes/*immunology MH - Female MH - Guinea Pigs MH - Immunoglobulin G/biosynthesis/blood MH - Spleen/pathology MH - Vaccines, Attenuated/immunology MH - Virulence EDAT- 2004/03/10 05:00 MHDA- 2005/04/27 09:00 CRDT- 2004/03/10 05:00 PST - ppublish SO - Rev Sci Tech. 2003 Dec;22(3):893-7. PMID- 15039330 OWN - NLM STAT- MEDLINE DA - 20040324 DCOM- 20040507 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 72 IP - 4 DP - 2004 Apr TI - Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. PG - 2081-7 AB - In the development of vaccines capable of providing immunity against brucellosis, Cu-Zn superoxide dismutase (SOD) has been demonstrated to be one of the protective immunogens of Brucella abortus. In an earlier study, we provided strong evidence that intramuscular injection with a plasmid DNA carrying the SOD gene (pcDNA-SOD) was able to induce a protective immune response. The present study was designed to characterize T-cell immune responses after an intraspleen (i.s.) vaccination of BALB/c mice with pcDNA-SOD. Animals vaccinated with pcDNA-SOD did not develop SOD-specific antibodies, at least until week 4 after immunization (the end of the experiment), and in vitro stimulation of their splenocytes with either recombinant Cu-Zn SOD or crude Brucella protein induced the secretion of gamma interferon (IFN-gamma), but not interleukin-4, and elicited the induction of cytotoxic-T-lymphocyte activity. Upon analyzing the SOD-specific T-cell responses, the pcDNA-SOD vaccination was found to be stimulating both CD4(+)- and CD8(+)-T-cell populations. However, only the CD4(+) population was able to produce IFN-gamma and only the CD8(+) population was able to induce cytotoxic activity. Nevertheless, although i.s. route vaccination induces a significant level of protection in BALB/c mice against challenge with the virulent B. abortus strain 2308, vaccination by the intramuscular route with a similar amount of plasmid DNA does not protect. Based on these results, we conclude that i.s. immunization with pcDNA-SOD vaccine efficiently induced a Th1 type of immune response and a protective response that could be related to IFN-gamma production and cytotoxic activity against infected cells by SOD-specific CD4(+) and CD8(+) T cells, respectively. AD - Molecular Immunology Laboratory, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepcion, Concepcion, Chile. FAU - Munoz-Montesino, Carola AU - Munoz-Montesino C FAU - Andrews, Edilia AU - Andrews E FAU - Rivers, Rodolfo AU - Rivers R FAU - Gonzalez-Smith, Andres AU - Gonzalez-Smith A FAU - Moraga-Cid, Gustavo AU - Moraga-Cid G FAU - Folch, Hugo AU - Folch H FAU - Cespedes, Sandra AU - Cespedes S FAU - Onate, Angel A AU - Onate AA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Bacterial Vaccines) RN - 0 (Vaccines, DNA) RN - 82115-62-6 (Interferon-gamma) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - Bacterial Vaccines/administration & dosage/immunology MH - Brucella abortus/enzymology/genetics/*immunology/pathogenicity MH - Brucellosis/immunology/microbiology/prevention & control MH - CD4-Positive T-Lymphocytes/*immunology MH - CD8-Positive T-Lymphocytes/*immunology MH - Colony Count, Microbial MH - Female MH - Interferon-gamma/biosynthesis MH - Lymphocyte Activation MH - Mice MH - Mice, Inbred BALB C MH - Spleen/*microbiology MH - Superoxide Dismutase/genetics/*immunology MH - Vaccination MH - Vaccines, DNA/administration & dosage/*immunology PMC - PMC375181 OID - NLM: PMC375181 EDAT- 2004/03/25 05:00 MHDA- 2004/05/08 05:00 CRDT- 2004/03/25 05:00 PST - ppublish SO - Infect Immun. 2004 Apr;72(4):2081-7. PMID- 15213148 OWN - NLM STAT- MEDLINE DA - 20040623 DCOM- 20040806 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 72 IP - 7 DP - 2004 Jul TI - Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M. PG - 4031-9 AB - Human brucellosis can be acquired from infected animal tissues by ingestion, inhalation, or contamination of conjunctiva or traumatized skin by infected animal products. In addition, Brucella is recognized as a biowarfare threat agent. Although a vaccine to protect humans from natural or deliberate infection could be useful, vaccines presently used in animals are unsuitable for human use. We tested orally administered live, attenuated, purine auxotrophic B. melitensis WR201 bacteria for their ability to elicit cellular and humoral immune responses and to protect mice against intranasal challenge with B. melitensis 16M bacteria. Immunized mice made serum antibody to lipopolysaccharide and non-O-polysaccharide antigens. Splenocytes from immunized animals released interleukin-2 and gamma interferon when grown in cultures with Brucella antigens. Immunization led to protection from disseminated infection and enhanced clearance of the challenge inoculum from the lungs. Optimal protection required administration of live bacteria, was related to immunizing dose, and was enhanced by booster immunization. These results establish the usefulness of oral vaccination against respiratory challenge with virulent Brucella and suggest that WR201 should be further investigated as a vaccine to prevent human brucellosis. AD - Department of Infectious and Parasitic Diseases, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA. mina.izadjoo@na.amedd.army.mil FAU - Izadjoo, Mina J AU - Izadjoo MJ FAU - Bhattacharjee, Apurba K AU - Bhattacharjee AK FAU - Paranavitana, Chrysanthi M AU - Paranavitana CM FAU - Hadfield, Ted L AU - Hadfield TL FAU - Hoover, David L AU - Hoover DL LA - eng PT - Journal Article PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Vaccines, Attenuated) SB - IM MH - Administration, Oral MH - Animals MH - Brucella melitensis/*immunology MH - Brucellosis/immunology/*prevention & control MH - Dose-Response Relationship, Immunologic MH - Female MH - Mice MH - Mice, Inbred BALB C MH - Vaccines, Attenuated/administration & dosage/immunology/*pharmacology PMC - PMC427460 OID - NLM: PMC427460 EDAT- 2004/06/24 05:00 MHDA- 2004/08/07 05:00 CRDT- 2004/06/24 05:00 AID - 10.1128/IAI.72.7.4031-4039.2004 [doi] AID - 72/7/4031 [pii] PST - ppublish SO - Infect Immun. 2004 Jul;72(7):4031-9. PMID- 15327798 OWN - NLM STAT- MEDLINE DA - 20040825 DCOM- 20050414 LR - 20081121 IS - 0378-1135 (Print) IS - 0378-1135 (Linking) VI - 102 IP - 3-4 DP - 2004 Sep 8 TI - Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. PG - 237-45 AB - Brucella abortus strain RB51 is an attenuated rough strain, currently being used as the official live vaccine for bovine brucellosis in the USA and several other countries. In strain RB51, the wboA gene, encoding a glycosyltransferase required for the O-side chain synthesis, is disrupted by an IS711 element. Recently, we have demonstrated that strain RB51WboA, RB51 complemented with a functional wboA gene, remains rough but expresses low quantities of O-side chain in the cytoplasm. Mice vaccinated with strain RB51WboA develop greatly enhanced resistance against challenge with B. abortus virulent strain 2308. We have also demonstrated that overexpression of Cu/Zn superoxide dismutase (SOD) in strain RB51 (RB51SOD) significantly increases its vaccine efficacy against strain 2308 challenge. In this study, we constructed a new recombinant strain, RB51SOD/WboA, that over expresses SOD with simultaneous expression of O-side chain in the cytoplasm. We tested the vaccine potential of strains RB51SOD, RB51WboA, RB51SOD/WboA against challenge with virulent Brucella melitensis 16M and B. abortus 2308 in mice. In comparison with strain RB51, strain RB51SOD induced better protection against strain 2308, but not strain 16M, challenge. Similar to strain RB51WboA, vaccination with strain RB51SOD/WboA resulted in complete protection of the mice from infection with strain 2308. When challenged with strain 16M, mice vaccinated with either strain RB51WboA or strain RB51SOD/WboA were significantly better protected than those vaccinated with strain RB51 or RB51SOD. These results suggest that strains RB51WboA and RB51SOD/WboA are good vaccine candidates for inducing enhanced protection against B. melitensis infection. AD - Department of Veterinary Pathobiology, School of Veterinary Medicine, Purdue University, 725 Harrison Street, West Lafayette, IN 47907, USA. rvemulap@purdue.edu FAU - Vemulapalli, Ramesh AU - Vemulapalli R FAU - Contreras, Andrea AU - Contreras A FAU - Sanakkayala, Neelima AU - Sanakkayala N FAU - Sriranganathan, Nammalwar AU - Sriranganathan N FAU - Boyle, Stephen M AU - Boyle SM FAU - Schurig, Gerhardt G AU - Schurig GG LA - eng PT - Journal Article PL - Netherlands TA - Vet Microbiol JT - Veterinary microbiology JID - 7705469 RN - 0 (Bacterial Vaccines) RN - 0 (Brucella Vaccine) RN - 0 (O Antigens) RN - 0 (Recombinant Proteins) RN - 0 (Vaccines, Attenuated) RN - 82115-62-6 (Interferon-gamma) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - EC 2.4.- (Glycosyltransferases) SB - IM MH - Animals MH - Bacterial Vaccines MH - Brucella Vaccine/genetics/*immunology MH - Brucella abortus/genetics/*immunology MH - *Brucella melitensis/genetics/immunology/pathogenicity MH - Brucellosis/microbiology/prevention & control/*veterinary MH - Cattle MH - Genes, Bacterial MH - Glycosyltransferases/genetics MH - Interferon-gamma/biosynthesis MH - Mice MH - O Antigens/biosynthesis/genetics MH - Phenotype MH - Recombinant Proteins/genetics/immunology MH - Serologic Tests/veterinary MH - Superoxide Dismutase/genetics MH - Treatment Outcome MH - Vaccines, Attenuated/immunology MH - Virulence EDAT- 2004/08/26 05:00 MHDA- 2005/04/15 09:00 CRDT- 2004/08/26 05:00 PHST- 2004/01/07 [received] PHST- 2004/06/21 [revised] PHST- 2004/07/01 [accepted] AID - 10.1016/j.vetmic.2004.07.001 [doi] AID - S0378-1135(04)00234-2 [pii] PST - ppublish SO - Vet Microbiol. 2004 Sep 8;102(3-4):237-45. PMID- 15427016 OWN - NLM STAT- MEDLINE DA - 19501201 DCOM- 20040930 LR - 20091118 IS - 0316-5957 (Print) IS - 0316-5957 (Linking) VI - 14 IP - 6 DP - 1950 Jun TI - Vaccination of sexually mature cows with Brucella abortus strain 19 vaccine. PG - 209-13 FAU - MOORE, T AU - MOORE T FAU - MITCHELL, C A AU - MITCHELL CA LA - eng PT - Journal Article PL - Not Available TA - Can J Comp Med Vet Sci JT - Canadian journal of comparative medicine and veterinary science JID - 0151757 SB - OM MH - *Abortion, Veterinary MH - *Bacteria MH - *Brucellosis PMC - PMC1791129 OID - CLML: 5019:17318:1:19 OID - NLM: PMC1791129 OTO - NLM OT - *ABORTION, INFECTIOUS OT - *BACTERIA EDAT- 1950/06/01 MHDA- 1950/06/01 00:01 CRDT- 1950/06/01 00:00 PST - ppublish SO - Can J Comp Med Vet Sci. 1950 Jun;14(6):209-13. PMID- 16187538 OWN - NLM STAT- MEDLINE DA - 20050928 DCOM- 20051220 LR - 20060501 IS - 0019-5189 (Print) IS - 0019-5189 (Linking) VI - 43 IP - 9 DP - 2005 Sep TI - Cloning and sequencing of 28 kDa outer membrane protein gene of Brucella melitensis Rev. 1. PG - 838-40 AB - Brucella melitensis is an organism of paramount zoonotic importance. The 28 kDa outer membrane protein (OMP) is one of the immunodominant antigens of B. melitensis. The gene encoding 28 kDa OMP (omp28) has been amplified from B. melitensis Rev. 1 strain. A PCR product of 753 bp, encoding complete omp28 gene of B. melitensis, was obtained. The gene was further cloned and sequenced. The nucleotide sequence of B. melitensis Rev. 1 strain showed substitution of 2 nucleotides from that of 16M strain. AD - National Biotechnology Centre, Indian Veterinary Research Institute, Izatnagar 243 122, India. pallab@ivri.up.nic.in FAU - Chaudhuri, Pallab AU - Chaudhuri P FAU - Kumar, S Vinoth AU - Kumar SV FAU - Prasad, Rajeev AU - Prasad R FAU - Srivastava, S K AU - Srivastava SK FAU - Yadav, M P AU - Yadav MP LA - eng PT - Journal Article PL - India TA - Indian J Exp Biol JT - Indian journal of experimental biology JID - 0233411 RN - 0 (Antigens, Bacterial) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Recombinant Proteins) SB - IM MH - Antigens, Bacterial MH - Bacterial Outer Membrane Proteins/metabolism MH - Base Sequence MH - Brucella Vaccine/metabolism MH - Brucella melitensis/*metabolism MH - Cell Membrane/metabolism MH - Cloning, Molecular MH - Molecular Sequence Data MH - Plasmids/metabolism MH - Polymerase Chain Reaction MH - Protein Structure, Tertiary MH - Recombinant Proteins/chemistry EDAT- 2005/09/29 09:00 MHDA- 2005/12/21 09:00 CRDT- 2005/09/29 09:00 PST - ppublish SO - Indian J Exp Biol. 2005 Sep;43(9):838-40. PMID- 16481077 OWN - NLM STAT- MEDLINE DA - 20060508 DCOM- 20060825 LR - 20080814 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 24 IP - 19 DP - 2006 May 8 TI - Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. PG - 4179-87 AB - The aim of this study was to evaluate the effect of the excipients used to facilitate the encapsulation of high hydrophobic antigenic complex extracted from Brucella ovis (HS) on the physico-chemical properties of the resulting microparticles. Poly(epsilon-caprolactone) (PEC) microparticles containing HS were prepared by the solvent extraction/evaporation method using total recirculation one-machine system (TROMS). Different excipients, beta-cyclodextrin (beta-CD), Pluronic F68, Tween 20 or Tween 80, were used in order to facilitate the encapsulation and conserve the bioactivity of the encapsulated antigenic complex. HS was efficiently loaded in all the different PEC-microparticle formulations, although the combined use of beta-cyclodextrin and Pluronic F68 permitted an increase in the amount of antigenic extract in the core of the resulting microparticles without loss of its antigenic properties. Finally, the protective ability of this F68-CD-MP formulation was evaluated against an experimental challenge with the virulent Brucella melitensis H38 strain in BALB/c mice. This innocuous subcellular vaccine induced a similar protection to that of the live attenuated Rev 1 vaccine; these are promising results that would merit further investigation in target animals. AD - Immunoadjuvant Unit, Department of Microbiology, University of Navarra, 31008 Pamplona, Spain. FAU - Estevan, Maite AU - Estevan M FAU - Gamazo, Carlos AU - Gamazo C FAU - Grillo, Maria Jesus AU - Grillo MJ FAU - Del Barrio, Guillermo Garcia AU - Del Barrio GG FAU - Blasco, Jose M AU - Blasco JM FAU - Irache, Juan M AU - Irache JM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060131 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antigens, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Excipients) RN - 0 (Polyesters) RN - 0 (Vaccines, Subunit) RN - 24980-41-4 (polycaprolactone) SB - IM MH - Animals MH - Antigens, Bacterial/administration & dosage MH - Brucella Vaccine/*administration & dosage MH - Brucella abortus/immunology MH - Brucella melitensis/*immunology/pathogenicity MH - Brucellosis/immunology/*prevention & control MH - Excipients/administration & dosage MH - Female MH - Mice MH - Mice, Inbred BALB C MH - Microscopy, Electron, Scanning MH - Microspheres MH - Particle Size MH - Polyesters MH - Vaccines, Subunit/administration & dosage EDAT- 2006/02/17 09:00 MHDA- 2006/08/26 09:00 CRDT- 2006/02/17 09:00 PHST- 2006/01/17 [received] PHST- 2006/01/18 [accepted] PHST- 2006/01/31 [aheadofprint] AID - S0264-410X(06)00060-0 [pii] AID - 10.1016/j.vaccine.2006.01.038 [doi] PST - ppublish SO - Vaccine. 2006 May 8;24(19):4179-87. Epub 2006 Jan 31. PMID- 16519974 OWN - NLM STAT- MEDLINE DA - 20060329 DCOM- 20060615 LR - 20061115 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 24 IP - 17 DP - 2006 Apr 24 TI - Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination. PG - 3461-8 AB - The CGV26 and CGV2631 strains are novel engineered Brucella melitensis Rev.1 mutant strains deleted for the bp26 gene or for both bp26 and omp31 genes, respectively, coding for proteins of diagnostic significance. The residual virulence and immunogenicity of both mutants were compared to the parental Rev.1 strain in sheep after subcutaneous or conjunctival vaccination. The deletion of the bp26 gene or both bp26 and omp31 genes had no significant effect on the intracellular survival of the Rev.1 strain in ovine macrophage cultures. The kinetics of infection induced by both mutants in sheep was similar to the Rev.1 strain, and inoculation by the subcutaneous route produced wider and more generalized infections than the conjunctival route. All strains were cleared from lymph nodes and organs within 3 months after inoculation. The CGV26 and CGV2631 mutants induced both specific systemic antibody response and lymphoproliferation in sheep. The kinetics of the responses induced by the mutants was quite similar to that of the parental Rev.1 strain, except for the intensity of the lymphoproliferative response, which was attenuated for the CGV2631 mutant. In conclusion, the residual virulence of both CGV26 and CGV2631 mutants in sheep was similar to that of the parental Rev.1 vaccine strain. These mutants induced also significant specific antibody and cell-mediated immunity in sheep and are suitable to be evaluated as potential vaccine candidates against B. melitensis and B. ovis infections in sheep. AD - Laboratoire de Pathologie Infectieuse et Immunologie, Institut National de Recherche Agronomique, Centre de Tours-Nouzilly, F-37380 Nouzilly, France. laurence.guilloteau@tours.inra.fr FAU - Guilloteau, Laurence A AU - Guilloteau LA FAU - Laroucau, Karine AU - Laroucau K FAU - Olivier, Michel AU - Olivier M FAU - Grillo, Maria Jesus AU - Grillo MJ FAU - Marin, Clara M AU - Marin CM FAU - Verger, Jean-Michel AU - Verger JM FAU - Blasco, Jose-Maria AU - Blasco JM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060220 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Vaccines, Synthetic) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Brucella Vaccine/*administration & dosage/adverse effects/immunology MH - Brucella ovis/*immunology/pathogenicity MH - Brucellosis/prevention & control/*veterinary MH - Conjunctiva MH - Female MH - Injections, Subcutaneous MH - Lymphocyte Activation MH - Macrophages/microbiology MH - Mutation MH - Sheep MH - Sheep Diseases/*prevention & control MH - Vaccination/*veterinary MH - Vaccines, Synthetic/*administration & dosage/adverse effects/immunology MH - Virulence EDAT- 2006/03/08 09:00 MHDA- 2006/06/16 09:00 CRDT- 2006/03/08 09:00 PHST- 2005/12/01 [received] PHST- 2006/01/31 [revised] PHST- 2006/02/06 [accepted] PHST- 2006/02/20 [aheadofprint] AID - S0264-410X(06)00157-5 [pii] AID - 10.1016/j.vaccine.2006.02.007 [doi] PST - ppublish SO - Vaccine. 2006 Apr 24;24(17):3461-8. Epub 2006 Feb 20. PMID- 16537031 OWN - NLM STAT- MEDLINE DA - 20060315 DCOM- 20060330 LR - 20081121 IS - 0366-6999 (Print) IS - 0366-6999 (Linking) VI - 119 IP - 4 DP - 2006 Feb 20 TI - DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. PG - 331-4 AD - Institute of Microbioiogy and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China. FAU - Luo, De-yan AU - Luo DY FAU - Li, Peng AU - Li P FAU - Xing, Li AU - Xing L FAU - Zhao, Guang-yu AU - Zhao GY FAU - Shi, Wei AU - Shi W FAU - Zhang, Song-le AU - Zhang SL FAU - Wang, Xi-liang AU - Wang XL LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Chin Med J (Engl) JT - Chinese medical journal JID - 7513795 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Periplasmic Binding Proteins) RN - 0 (Ribosomal Proteins) RN - 0 (Vaccines, DNA) RN - 0 (p39 protein, Brucella) RN - 70815-33-7 (ribosomal protein L7-L12) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Bacterial Proteins/*genetics/immunology MH - Brucella Vaccine/*immunology MH - Brucella abortus/*immunology MH - Female MH - Immunization MH - Interferon-gamma/biosynthesis MH - Lymphocyte Activation MH - Mice MH - Mice, Inbred BALB C MH - Periplasmic Binding Proteins/*genetics/immunology MH - Ribosomal Proteins/*genetics/immunology MH - Vaccines, DNA/*immunology EDAT- 2006/03/16 09:00 MHDA- 2006/03/31 09:00 CRDT- 2006/03/16 09:00 PST - ppublish SO - Chin Med J (Engl). 2006 Feb 20;119(4):331-4. PMID- 16622210 OWN - NLM STAT- MEDLINE DA - 20060419 DCOM- 20060523 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 74 IP - 5 DP - 2006 May TI - Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. PG - 2734-41 AB - This study was designed to evaluate the immunogenicity and the protective efficacy of a divalent fusion DNA vaccine encoding both the Brucella abortus L7/L12 protein (ribosomal protein) and Omp16 protein (outer membrane lipoprotein), designated pcDNA3.1-L7/L12-Omp16. Intramuscular injection of this divalent DNA vaccine into BALB/c mice elicited markedly both humoral and cellular immune responses. The specific antibodies exhibited a dominance of immunoglobulin G2a (IgG2a) over IgG1. In addition, the dual-gene DNA vaccine elicited a strong T-cell proliferative response and induced a large amount of gamma interferon-producing T cells upon restimulation in vitro with recombinant fusion protein L7/L12-Omp16, suggesting the induction of a typical T-helper-1-dominated immune response in vivo. This divalent DNA vaccine could also induce a significant level of protection against challenge with the virulent strain B. abortus 544 in BALB/c mice. Furthermore, the protection level induced by the divalent DNA vaccine was significantly higher than that induced by the univalent DNA vaccines pcDNA3.1-L7/L12 or pcDNA3.1-Omp16. Taken together, the results of this study verify for the first time that the Omp16 gene can be a candidate target for a DNA vaccine against brucellosis. Additionally, a divalent genetic vaccine based on the L7/L12 and Omp16 genes can elicit a stronger cellular immune response and better immunoprotection than the relevant univalent vaccines can. AD - State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Science, Beijing, China. FAU - Luo, Deyan AU - Luo D FAU - Ni, Bing AU - Ni B FAU - Li, Peng AU - Li P FAU - Shi, Wei AU - Shi W FAU - Zhang, Songle AU - Zhang S FAU - Han, Yue AU - Han Y FAU - Mao, Liwei AU - Mao L FAU - He, Yangdong AU - He Y FAU - Wu, Yuzhang AU - Wu Y FAU - Wang, Xiliang AU - Wang X LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Recombinant Fusion Proteins) RN - 0 (Ribosomal Proteins) RN - 0 (Vaccines, DNA) RN - 70815-33-7 (ribosomal protein L7-L12) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Bacterial Outer Membrane Proteins/*genetics/immunology MH - Brucella Vaccine/*immunology MH - Brucella abortus/*immunology MH - COS Cells MH - Cercopithecus aethiops MH - Female MH - Immunization MH - Interferon-gamma/biosynthesis MH - Lymphocyte Activation MH - Mice MH - Mice, Inbred BALB C MH - Recombinant Fusion Proteins/*immunology MH - Ribosomal Proteins/*genetics/immunology MH - Th1 Cells/immunology MH - Vaccines, DNA/*immunology PMC - PMC1459688 OID - NLM: PMC1459688 EDAT- 2006/04/20 09:00 MHDA- 2006/05/24 09:00 CRDT- 2006/04/20 09:00 AID - 74/5/2734 [pii] AID - 10.1128/IAI.74.5.2734-2741.2006 [doi] PST - ppublish SO - Infect Immun. 2006 May;74(5):2734-41. PMID- 16700714 OWN - NLM STAT- MEDLINE DA - 20060516 DCOM- 20071010 IS - 1198-743X (Print) IS - 1198-743X (Linking) VI - 12 IP - 6 DP - 2006 Jun TI - A new variant of Brucella melitensis. PG - 593-6 AB - Brucella melitensis is highly pathogenic and constitutes a serious risk to public health. In Argentina, biovar 1 has been isolated from infected animals, but the Rev.1 strain vaccine is not authorised for use. This report describes nine atypical B. melitensis isolates obtained from humans. These isolates grew slowly, produced small colonies and were susceptible to penicillin and dyes, similar to the B. melitensis Rev.1 vaccine strain, but were inhibited by streptomycin 2.5 mg/L. The isolation of such atypical B. melitensis variants has never been reported from animals in Argentina, and could indicate the emergence of a new mutant variant. AD - Brucellosis Laboratory, Administracion Nacional de Laboratorios e Institutos de Salud Dr C.G. Malbran, ANLIS, Buenos Aires, Argentina. nidia@elsitio.net FAU - Lucero, N E AU - Lucero NE FAU - Ayala, S M AU - Ayala SM FAU - Escobar, G I AU - Escobar GI FAU - Grayon, M AU - Grayon M FAU - Jacques, I AU - Jacques I LA - eng PT - Comparative Study PT - Journal Article PL - France TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 RN - 0 (Penicillins) SB - IM MH - Adolescent MH - Adult MH - Bacterial Typing Techniques/methods MH - Brucella melitensis/*classification/drug effects/genetics/*isolation & purification MH - Brucellosis/*microbiology MH - Child MH - Child, Preschool MH - Female MH - Humans MH - Male MH - Microbial Sensitivity Tests MH - Penicillins/pharmacology MH - Polymerase Chain Reaction/methods MH - Polymorphism, Restriction Fragment Length EDAT- 2006/05/17 09:00 MHDA- 2007/10/11 09:00 CRDT- 2006/05/17 09:00 AID - CLM1386 [pii] AID - 10.1111/j.1469-0691.2006.01386.x [doi] PST - ppublish SO - Clin Microbiol Infect. 2006 Jun;12(6):593-6. PMID- 16713034 OWN - NLM STAT- MEDLINE DA - 20060612 DCOM- 20060816 LR - 20061115 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 24 IP - 25 DP - 2006 Jun 19 TI - Efficacy of strain RB51 vaccine in heifers against experimental brucellosis. PG - 5327-34 AB - With the goal of providing an additional tool for controlling bovine brucellosis in Brazil and evaluating the full calf dose in adult cattle, the efficacy of the rough Brucella abortus strain RB51 vaccine was tested in heifers. Thirty-three females of approximately 24 months of age were divided in two groups: one group (n=20) received the RB51 vaccine and the other group (n=13) were used as non-vaccinated control. Animals in the vaccinated group were split in two sub-groups. One sub-group (n=12) was vaccinated subcutaneously with 1.5x10(10) colony forming units (CFU) of RB51 at Day 0 of the experiment and the other sub-group (n=8) was vaccinated subcutaneously with 1.6x10(10) CFU of RB51 at 60 days of gestation (Day 260 of the experiment). All cattle were challenged between 6 and 7 months of pregnancy with 3x10(8) CFU of the virulent strain 2308 of B. abortus by the conjunctival route. Vaccination with RB51 vaccine did not result in the production of any antibodies against the O-side chain of lipopolysaccharide (LPS), as measured by conventional serological tests (rose bengal plate agglutination test (RBPAT), standard tube agglutination test (STAT), and 2-mercaptoethanol test (2ME)). A total of 25% cumulative incidence of abortions was found in the vaccinated group, whereas in the control group the cumulative incidence was 62%. B. abortus RB51 was not isolated from any sample, and no abortions were produced by RB51 vaccination of females at 60 days of pregnancy. The results indicate that vaccination with RB51 prevented 59.4% of abortions, 58.6% of cow infections, and 61.0% of fetal infections. The relative risk (RR) revealed that non-vaccinated animals have 2.462 (95% CI 1.029-5.889) times higher risk of aborting than RB51-vaccinated animals. AD - Escola de Veterinaria, Universidade Federal de Minas Gerais, Belo Horizonte - MG, Brazil. FAU - Poester, Fernando P AU - Poester FP FAU - Goncalves, Vitor S P AU - Goncalves VS FAU - Paixao, Tatiane A AU - Paixao TA FAU - Santos, Renato L AU - Santos RL FAU - Olsen, Steven C AU - Olsen SC FAU - Schurig, Gerhardt G AU - Schurig GG FAU - Lage, Andrey P AU - Lage AP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060427 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) SB - IM MH - Abortion, Veterinary/*prevention & control MH - Animals MH - Antibodies, Bacterial/blood MH - *Brucella Vaccine/administration & dosage/adverse effects/immunology MH - Brucella abortus/*immunology/pathogenicity MH - Brucellosis, Bovine/*immunology/*prevention & control MH - Cattle MH - Female MH - Pregnancy MH - Pregnancy Complications, Infectious/*veterinary MH - Vaccination/veterinary EDAT- 2006/05/23 09:00 MHDA- 2006/08/17 09:00 CRDT- 2006/05/23 09:00 PHST- 2006/02/01 [received] PHST- 2006/04/04 [revised] PHST- 2006/04/09 [accepted] PHST- 2006/04/27 [aheadofprint] AID - S0264-410X(06)00452-X [pii] AID - 10.1016/j.vaccine.2006.04.020 [doi] PST - ppublish SO - Vaccine. 2006 Jun 19;24(25):5327-34. Epub 2006 Apr 27. PMID- 16790759 OWN - NLM STAT- MEDLINE DA - 20060622 DCOM- 20060824 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 74 IP - 7 DP - 2006 Jul TI - Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge. PG - 3874-9 AB - znuA is known to be an important factor for survival and normal growth under low Zn(2+) concentrations for Escherichia coli, Haemophilus spp., Neisseria gonorrhoeae, and Pasteurella multocida. We hypothesized that the znuA gene present in Brucella melitensis 16 M would be similar to znuA in B. abortus and questioned whether it may also be an important factor for growth and virulence of Brucella abortus. Using the B. melitensis 16 M genome sequence, primers were designed to construct a B. abortus deletion mutant. A znuA knockout mutation in B. abortus 2308 (DeltaznuA) was constructed and found to be lethal in low-Zn(2+) medium. When used to infect macrophages, DeltaznuA B. abortus showed minimal growth. Further study with DeltaznuA B. abortus showed that its virulence in BALB/c mice was attenuated, and most of the bacteria were cleared from the spleen within 8 weeks. Protection studies confirmed the DeltaznuA mutant as a potential live vaccine, since protection against wild-type B. abortus 2308 challenge was as effective as that obtained with the RB51 or S19 vaccine strain. AD - Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717-3610, USA. FAU - Yang, Xinghong AU - Yang X FAU - Becker, Todd AU - Becker T FAU - Walters, Nancy AU - Walters N FAU - Pascual, David W AU - Pascual DW LA - eng GR - P20 RR-020185/RR/NCRR NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Bacterial Vaccines) RN - 0 (Virulence Factors) RN - 7440-66-6 (Zinc) SB - IM MH - Animals MH - Bacterial Vaccines/administration & dosage/genetics/immunology MH - Brucella abortus/*genetics/growth & development/*immunology/pathogenicity MH - Brucellosis/immunology/microbiology/*prevention & control MH - Cell Line MH - Female MH - *Gene Deletion MH - Macrophages/immunology/microbiology MH - Mice MH - Mice, Inbred BALB C MH - Virulence Factors/*genetics/isolation & purification MH - Zinc/metabolism PMC - PMC1489696 OID - NLM: PMC1489696 EDAT- 2006/06/23 09:00 MHDA- 2006/08/25 09:00 CRDT- 2006/06/23 09:00 AID - 74/7/3874 [pii] AID - 10.1128/IAI.01957-05 [doi] PST - ppublish SO - Infect Immun. 2006 Jul;74(7):3874-9. PMID- 16988260 OWN - NLM STAT- MEDLINE DA - 20060921 DCOM- 20061128 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 74 IP - 10 DP - 2006 Oct TI - Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. PG - 5820-5 AB - Groups of mice were immunized either subcutaneously or intranasally with purified Brucella melitensis lipopolysaccharide (LPS) or with LPS as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (LPS-GBOMP). Control mice were inoculated with sterile saline. Two doses of vaccine were given 4 weeks apart. Mice were challenged intranasally with virulent B. melitensis strain 16M 4 weeks after the second dose of vaccine. Sera, spleens, lungs, and livers of mice were harvested 8 weeks after challenge. The bacterial loads in the organs were determined by culture on brucella agar plates. Protective efficacy was determined by comparing the clearance of bacteria from organs of immunized mice with the clearance of bacteria from organs of control mice. At 8 weeks postchallenge there was significant protection from disseminated infection of spleens and livers of mice intranasally immunized with either vaccine compared to infection of control mice (P < 0.01). There was no significant difference in clearance of bacteria from the lungs of immunized mice and control mice. However, mice immunized subcutaneously with either LPS or LPS-GBOMP vaccine showed significant protection against infection of the spleen (P < 0.001), liver (P < 0.001), and lungs (P < 0.05). These results show that intranasal immunization of mice with either vaccine provided significant protection against disseminated infection of the spleen and liver but subcutaneous immunization of mice with the vaccines conferred significant protection against infection of the spleen, liver, and lungs. AD - Department of Bacterial Diseases, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500, USA. Apurba.Bhattacharjee@us.army.mil FAU - Bhattacharjee, Apurba K AU - Bhattacharjee AK FAU - Izadjoo, Mina J AU - Izadjoo MJ FAU - Zollinger, Wendell D AU - Zollinger WD FAU - Nikolich, Mikeljon P AU - Nikolich MP FAU - Hoover, David L AU - Hoover DL LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Brucella Vaccine) RN - 0 (Lipopolysaccharides) RN - 0 (Porins) RN - 0 (Vaccines, Subunit) RN - 0 (porin proteins, Neisseria) SB - IM MH - Administration, Cutaneous MH - Administration, Intranasal MH - Animals MH - Brucella Vaccine/*administration & dosage/immunology MH - Brucella melitensis/*immunology/isolation & purification MH - Brucellosis/*prevention & control MH - Immunization MH - Lipopolysaccharides/*administration & dosage/immunology MH - Liver/microbiology MH - Lung/microbiology MH - Mice MH - Mice, Inbred BALB C MH - Porins/administration & dosage/immunology MH - Spleen/microbiology MH - Vaccination/*methods MH - Vaccines, Subunit/administration & dosage/immunology PMC - PMC1594895 OID - NLM: PMC1594895 EDAT- 2006/09/22 09:00 MHDA- 2006/12/09 09:00 CRDT- 2006/09/22 09:00 AID - 74/10/5820 [pii] AID - 10.1128/IAI.00331-06 [doi] PST - ppublish SO - Infect Immun. 2006 Oct;74(10):5820-5. PMID- 17028213 OWN - NLM STAT- MEDLINE DA - 20061009 DCOM- 20070108 LR - 20091118 IS - 1556-6811 (Print) VI - 13 IP - 10 DP - 2006 Oct TI - Immune responses of elk to initial and booster vaccinations with Brucella abortus strain RB51 or 19. PG - 1098-103 AB - Previous studies have suggested that currently available brucellosis vaccines induce poor or no protection in elk (Cervus elaphus nelsoni). In this study, we characterized the immunologic responses of elk after initial or booster vaccination with Brucella abortus strains RB51 (SRB51) and 19 (S19). Elk were vaccinated with saline or 10(10) CFU of SRB51 or S19 (n=seven animals/treatment) and booster vaccinated with a similar dosage of the autologous vaccine at 65 weeks. Compared to nonvaccinates, elk vaccinated with SRB51 or S19 had greater (P<0.05) antibody responses to SRB51 or S19 after initial vaccination and after booster vaccination. Compared to nonvaccinated elk, greater (P<0.05) proliferative responses to autologous antigen after initial vaccination occurred at only a few sample times in SRB51 (6, 14, and 22 weeks) and S19 (22 weeks) treatment groups. In general, proliferative responses of vaccinates to nonautologous antigens did not differ (P>0.05) from the responses of nonvaccinated elk. Gamma interferon production in response to autologous or nonautologous Brucella antigens did not differ (P>0.05) between controls and vaccinates after booster vaccination. Flow cytometric techniques suggested that proliferation occurred more frequently in immunoglobulin M-positive cells, with differences between vaccination and control treatments in CD4+ and CD8+ subset proliferation detected only at 22 weeks after initial vaccination. After booster vaccination, one technique ([3H]thymidine incorporation) suggested that proliferative responses to SRB51 antigen, but not S19 antigen, were greater (P<0.05) in vaccinates compared to the responses of nonvaccinates. However, in general, flow cytometric and other techniques failed to detect significant anamnestic responses to autologous or nonautologous Brucella antigens in S19 or SRB51 vaccinates after booster vaccination. Although some cellular immune responses were detected after initial or booster vaccination of elk with SRB51 or S19, our data suggest that responses tend to be transient and much less robust than previously reported in SRB51-vaccinated cattle (Bos taurus) or bison (Bison bison). These data may explain why the vaccination of elk with S19 and SRB51 induces poor protection against brucellosis. AD - Bacterial Diseases of Livestock Research Unit, National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, IA 50010, USA. Solsen@nadc.ars.usda.gov FAU - Olsen, S C AU - Olsen SC FAU - Fach, S J AU - Fach SJ FAU - Palmer, M V AU - Palmer MV FAU - Sacco, R E AU - Sacco RE FAU - Stoffregen, W C AU - Stoffregen WC FAU - Waters, W R AU - Waters WR LA - eng PT - Journal Article PL - United States TA - Clin Vaccine Immunol JT - Clinical and vaccine immunology : CVI JID - 101252125 RN - 0 (Bacterial Vaccines) SB - IM MH - Animals MH - Bacterial Vaccines/*administration & dosage/*immunology MH - Brucella abortus/*immunology MH - Brucellosis/immunology/*prevention & control MH - Cells, Cultured MH - Deer/*immunology MH - Dose-Response Relationship, Immunologic MH - Humans MH - *Immunization, Secondary PMC - PMC1595328 OID - NLM: PMC1595328 EDAT- 2006/10/10 09:00 MHDA- 2007/01/09 09:00 CRDT- 2006/10/10 09:00 AID - 13/10/1098 [pii] AID - 10.1128/CVI.00213-06 [doi] PST - ppublish SO - Clin Vaccine Immunol. 2006 Oct;13(10):1098-103. PMID- 17050051 OWN - NLM STAT- MEDLINE DA - 20070319 DCOM- 20070911 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 25 IP - 15 DP - 2007 Apr 12 TI - Assessment of genetic stability of Brucella melitensis Rev 1 vaccine strain by multiple-locus variable-number tandem repeat analysis. PG - 2858-62 AB - The assessment of the genetic stability is one of the essential elements to guarantee the biological quality of live anti-bacteria vaccines. Live attenuated Brucella melitensis Rev 1 is the most effective vaccine against brucellosis in small ruminants. Thirty-six B. melitensis Rev 1 vaccine strains isolated from human or animal sources from different geographic regions, from different commercial batches or laboratory collections were typed by the multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA) recently described for Brucella spp. Our results demonstrated that B. melitensis Rev 1 group as assayed by MLVA is genetically very homogeneous. We believe that MLVA methodology could be an essential assay to guarantee the quality and stability of live anti-bacterial vaccines being produced worldwide and can be included as in vitro control. AD - Departamento de Microbiologia y Parasitologia, Universidad de Navarra, c/Irunlarrea no. 1, 31008 Pamplona, Spain. FAU - Garcia-Yoldi, David AU - Garcia-Yoldi D FAU - Le Fleche, Philippe AU - Le Fleche P FAU - Marin, Clara M AU - Marin CM FAU - De Miguel, Maria J AU - De Miguel MJ FAU - Munoz, Pilar M AU - Munoz PM FAU - Vergnaud, Gilles AU - Vergnaud G FAU - Lopez-Goni, Ignacio AU - Lopez-Goni I LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20061005 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Bacterial Vaccines) RN - 0 (Rev.1 vaccine, Brucella melitensis) SB - IM MH - Animals MH - Bacterial Vaccines/*genetics MH - Brucella/*genetics/immunology MH - Brucellosis/*virology MH - Cluster Analysis MH - *Genomic Instability MH - Genotype MH - Humans MH - *Minisatellite Repeats MH - Ruminants EDAT- 2006/10/20 09:00 MHDA- 2007/09/12 09:00 CRDT- 2006/10/20 09:00 PHST- 2006/07/28 [received] PHST- 2006/09/18 [revised] PHST- 2006/09/21 [accepted] PHST- 2006/10/05 [aheadofprint] AID - S0264-410X(06)01067-X [pii] AID - 10.1016/j.vaccine.2006.09.063 [doi] PST - ppublish SO - Vaccine. 2007 Apr 12;25(15):2858-62. Epub 2006 Oct 5. PMID- 17196866 OWN - NLM STAT- MEDLINE DA - 20070129 DCOM- 20070801 LR - 20081121 IS - 1286-4579 (Print) IS - 1286-4579 (Linking) VI - 9 IP - 1 DP - 2007 Jan TI - Brucella abortus bacA mutant induces greater pro-inflammatory cytokines than the wild-type parent strain. PG - 55-62 AB - The inner-membrane protein BacA affects Brucella LPS structure. A bacA deletion mutant of Brucella abortus, known as KL7 (bacA(mut)-KL7), is attenuated in BALB/c mice and protects against challenge. Thus, bacA mutation was a candidate for incorporation into live attenuated vaccines. We assessed bacA(mut)-KL7 in 2 additional mouse strains: the more resistant C57BL/6 that produces interferon-gamma throughout the infection and the highly susceptible interferon-gamma-deficient C57BL/6 in which brucellae exhibit continual exponential growth. While it was hypothesized that bacA(mut)-KL7 would exhibit even greater attenuation relative to its parent strain B. abortus 2308 in C57BL/6 mice than it did in BALB/c mice, this was not the case. Moreover, it was more pathogenic in C57BL/6 interferon-gamma-deficient mice than 2308 causing abscesses and wasting even though the splenic loads of bacA(mut)-KL7 were significantly lower. These 2 observations were correlated, respectively, with an ability of IFNgamma-activated macrophages to equivalently control strains 2308 and bacA(mut)-KL7 and the ability of bacA(mut)-KL7 organism and its LPS to induce greater amounts of pro-inflammatory cytokines than 2308. We conclude that attenuation properties of bacA mutation are dependent upon the nature of the host but more importantly that bacterial gene deletion can result in increased host pathology without an increase in bacterial load, crucial considerations for vaccine design. AD - Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA 01003, USA. FAU - Parent, Michelle A AU - Parent MA FAU - Goenka, Radhika AU - Goenka R FAU - Murphy, Erin AU - Murphy E FAU - Levier, Kristen AU - Levier K FAU - Carreiro, Nuno AU - Carreiro N FAU - Golding, Basil AU - Golding B FAU - Ferguson, Gail AU - Ferguson G FAU - Roop, R Martin 2nd AU - Roop RM 2nd FAU - Walker, Graham C AU - Walker GC FAU - Baldwin, Cynthia L AU - Baldwin CL LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20061211 PL - France TA - Microbes Infect JT - Microbes and infection / Institut Pasteur JID - 100883508 RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Cytokines) RN - 0 (Lipopolysaccharides) RN - 0 (Membrane Transport Proteins) RN - 82115-62-6 (Interferon-gamma) RN - 9007-36-7 (Complement System Proteins) SB - IM MH - Animals MH - Bacterial Proteins/*genetics/immunology MH - Brucella Vaccine/genetics/immunology MH - Brucella abortus/*genetics/*immunology/pathogenicity MH - Brucellosis/*immunology/microbiology MH - Complement System Proteins/immunology MH - Cytokines/*biosynthesis/immunology MH - Gene Deletion MH - Interferon-gamma/deficiency/immunology MH - Lipopolysaccharides/pharmacology MH - Macrophage Activation MH - Macrophages/immunology MH - Membrane Transport Proteins/*genetics/immunology MH - Mice MH - Mice, Inbred BALB C MH - Mice, Inbred C57BL EDAT- 2007/01/02 09:00 MHDA- 2007/08/02 09:00 CRDT- 2007/01/02 09:00 PHST- 2006/05/15 [received] PHST- 2006/09/12 [revised] PHST- 2006/10/12 [accepted] PHST- 2006/12/11 [aheadofprint] AID - S1286-4579(06)00371-6 [pii] AID - 10.1016/j.micinf.2006.10.008 [doi] PST - ppublish SO - Microbes Infect. 2007 Jan;9(1):55-62. Epub 2006 Dec 11. PMID- 17239499 OWN - NLM STAT- MEDLINE DA - 20070216 DCOM- 20070815 LR - 20071203 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 25 IP - 12 DP - 2007 Mar 8 TI - Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. PG - 2261-8 AB - bp26 and trigger factor (Tf) DNA vaccines have previously been shown to protect against Brucella infection. In this study, purified bp26 and Tf proteins were tested in BALB/c mice for immunity and protection. The results showed that intranasal (i.n.) immunization with bp26 and Tf in conjunction with cholera toxin (CT) adjuvant elicit both elevated mucosal and systemic immune responses. While nasal immunization with either bp26 or Tf elicited elevated antibody responses, co-immunization with both enhanced anti-Tf immunity, suggesting bp26 adjuvant activity. Evaluation of serum IgG subclass responses showed elevated IgG1 titers. Further analysis to discern the source of immune B cells revealed effective immunization of respiratory tissues. However, Tf stimulated a significantly higher level of cytokine-forming cells (CFC) than bp26. These results imply that co-immunization of bp26 and Tf proteins elicits synergistic cooperation to stimulate the immune system. When immunized mice were challenged with B. melitensis 16M, bp26-plus Tf-immunized mice showed no difference in splenic weights but harbored three-fold less bacterial CFU when compared to sPBS-immunized control mice. AD - Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717-3610, USA. FAU - Yang, Xinghong AU - Yang X FAU - Walters, Nancy AU - Walters N FAU - Robison, Amanda AU - Robison A FAU - Trunkle, Theresa AU - Trunkle T FAU - Pascual, David W AU - Pascual DW LA - eng GR - P20 RR-020185/RR/NCRR NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20061215 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (BP26 protein, Brucella) RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Immunoglobulin G) RN - 0 (Membrane Proteins) RN - 9012-63-9 (Cholera Toxin) SB - IM MH - Administration, Intranasal MH - Animals MH - Antibodies, Bacterial/blood MH - Bacterial Proteins/*immunology MH - Brucella Vaccine/administration & dosage/*immunology MH - Brucella melitensis/drug effects/growth & development/*immunology MH - Brucellosis/blood/immunology/prevention & control MH - Cholera Toxin/*immunology MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Immunity, Mucosal/immunology MH - Immunization/*methods MH - Immunoglobulin G/blood MH - Lymphocytes/immunology MH - Membrane Proteins/*immunology MH - Mice MH - Mice, Inbred BALB C MH - Spleen/immunology/microbiology EDAT- 2007/01/24 09:00 MHDA- 2007/08/19 09:00 CRDT- 2007/01/24 09:00 PHST- 2006/09/26 [received] PHST- 2006/11/27 [revised] PHST- 2006/12/02 [accepted] PHST- 2006/12/15 [aheadofprint] AID - S0264-410X(06)01320-X [pii] AID - 10.1016/j.vaccine.2006.12.004 [doi] PST - ppublish SO - Vaccine. 2007 Mar 8;25(12):2261-8. Epub 2006 Dec 15. PMID- 17428946 OWN - NLM STAT- MEDLINE DA - 20070709 DCOM- 20071102 LR - 20091118 IS - 1556-6811 (Print) VI - 14 IP - 7 DP - 2007 Jul TI - Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. PG - 869-74 AB - In the present study, we report an attempt to improve the immunogenicity of the Omp31 antigen by a DNA prime-protein boost immunization regimen. We immunized BALB/c mice with an Omp31 DNA vaccine (pCIOmp31) followed by boosting with recombinant Omp31 (rOmp31) in incomplete Freund's adjuvant and characterized the resulting immune responses and the protective efficacy against Brucella ovis and B. melitensis infection. Immunoglobulin G1 (IgG1) and IgG2a titers were higher in sera from pCIOmp31/rOmp31-immunized mice than in sera from mice immunized with pCIOmp31 or rOmp31 alone. Splenocytes from pCIOmp31/rOmp31-immunized mice produced significantly higher levels of gamma interferon than did those from mice given rOmp31 alone. In contrast, interleukin 2 (IL-2) production levels were comparable between the two groups of immunized mice. Cells from all immunized mice produced undetectable levels of IL-4. Notably, rOmp31 stimulated IL-10 production in the pCIOmp31/rOmp31-immunized group but not in the pCIOmp31- or rOmp31-immunized group. Although the prime-boost regimen induced specific cytotoxic responses, these responses could not reach the levels achieved by the pCIOmp31 immunization. In conclusion, pCIOmp31 priming followed by rOmp31 boosting led to moderately improved protection against a challenge with B. ovis or B. melitensis. AD - Laboratorio de Inmunogenetica, Hospital de Clinicas Jose de San Martin, Facultad de Medicina, UBA, Cordoba 2351, 3er Piso Sala 4, Buenos Aires, Argentina. jucassat@ffyb.uba.ar FAU - Cassataro, Juliana AU - Cassataro J FAU - Velikovsky, Carlos A AU - Velikovsky CA FAU - Bruno, Laura AU - Bruno L FAU - Estein, Silvia M AU - Estein SM FAU - de la Barrera, Silvia AU - de la Barrera S FAU - Bowden, Raul AU - Bowden R FAU - Fossati, Carlos A AU - Fossati CA FAU - Giambartolomei, Guillermo H AU - Giambartolomei GH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070411 PL - United States TA - Clin Vaccine Immunol JT - Clinical and vaccine immunology : CVI JID - 101252125 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Immunoglobulin G) RN - 0 (Interleukin-2) RN - 0 (Omp31 protein, Brucella melitensis) RN - 0 (Vaccines, DNA) RN - 207137-56-2 (Interleukin-4) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Bacterial Outer Membrane Proteins/*immunology MH - Brucella Vaccine/*immunology/pharmacology MH - Brucella ovis/*immunology MH - Brucellosis/immunology/*prevention & control MH - Female MH - Immunization, Secondary MH - Immunoglobulin G/blood MH - Interferon-gamma/blood MH - Interleukin-2/blood MH - Interleukin-4/blood MH - Mice MH - Mice, Inbred BALB C MH - Th1 Cells/immunology/microbiology MH - Vaccines, DNA/*immunology/pharmacology PMC - PMC1951060 OID - NLM: PMC1951060 EDAT- 2007/04/13 09:00 MHDA- 2007/11/06 09:00 CRDT- 2007/04/13 09:00 PHST- 2007/04/11 [aheadofprint] AID - CVI.00472-06 [pii] AID - 10.1128/CVI.00472-06 [doi] PST - ppublish SO - Clin Vaccine Immunol. 2007 Jul;14(7):869-74. Epub 2007 Apr 11. PMID- 17442465 OWN - NLM STAT- MEDLINE DA - 20070508 DCOM- 20070719 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 25 IP - 22 DP - 2007 May 30 TI - A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. PG - 4437-46 AB - The development of an effective subunit vaccine against brucellosis is a research area of intense interest. The enzyme lumazine synthase from Brucella spp. (BLS) is highly immunogenic, presumably due to its decameric arrangement and remarkable stability. In this work we decided to develop a chimera with the scaffold protein BLS decorated with 10 copies of a known protective epitope derived from an outer membrane protein of 31kDa (Omp31) from Brucella spp. Vaccination of BALB/c mice with the chimera as a recombinant protein (rBLSOmp31) provided the best protection level against Brucella ovis, which was higher than the given by the co-delivery of both recombinant proteins (rBLS + rOmp31) and similar than the control vaccine Brucella melitensis strain Rev.1. Moreover rBLSOmp31 induced protection against Brucella melitensis but to a lesser degree than Rev.1. The chimera induced a strong humoral response against the inserted peptide. It also induced peptide- and BLS-specific T helper 1 and cytotoxic T responses. In conclusion, our results indicate that BLSOmp31 could be a useful candidate for the development of subunit vaccines against brucellosis since it elicits humoral, T helper and cytotoxic immune responses and protection against smooth and rough species of Brucella. AD - Laboratorio de Inmunogenetica, Hospital de Clinicas Jose de San Martin, Facultad de Medicina, Universidad de Buenos Aires UBA, Cordoba 2351, Buenos Aires, Argentina. jucassat@ffyb.uba.ar FAU - Cassataro, Juliana AU - Cassataro J FAU - Pasquevich, Karina A AU - Pasquevich KA FAU - Estein, Silvia M AU - Estein SM FAU - Laplagne, Diego A AU - Laplagne DA FAU - Velikovsky, Carlos A AU - Velikovsky CA FAU - de la Barrera, Silvia AU - de la Barrera S FAU - Bowden, Raul AU - Bowden R FAU - Fossati, Carlos A AU - Fossati CA FAU - Giambartolomei, Guillermo H AU - Giambartolomei GH FAU - Goldbaum, Fernando A AU - Goldbaum FA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070402 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Immunoglobulin G) RN - 0 (Omp31 protein, Brucella melitensis) RN - 0 (Vaccines, Synthetic) SB - IM MH - Animals MH - Antibodies, Bacterial/*blood MH - *Bacterial Outer Membrane Proteins/chemistry/genetics/immunology MH - *Brucella/chemistry/classification/genetics/immunology MH - *Brucella Vaccine/administration & dosage/genetics/immunology MH - Brucella melitensis/chemistry/genetics/immunology MH - Brucella ovis/chemistry/genetics/*immunology MH - Brucellosis/immunology/microbiology/*prevention & control MH - Female MH - Humans MH - Immunoglobulin G/blood MH - Mice MH - Mice, Inbred BALB C MH - T-Lymphocytes, Cytotoxic/immunology MH - Th1 Cells/immunology MH - Vaccination MH - Vaccines, Synthetic/genetics EDAT- 2007/04/20 09:00 MHDA- 2007/07/20 09:00 CRDT- 2007/04/20 09:00 PHST- 2006/12/21 [received] PHST- 2007/03/07 [revised] PHST- 2007/03/13 [accepted] PHST- 2007/04/02 [aheadofprint] AID - S0264-410X(07)00335-0 [pii] AID - 10.1016/j.vaccine.2007.03.028 [doi] PST - ppublish SO - Vaccine. 2007 May 30;25(22):4437-46. Epub 2007 Apr 2. PMID- 17570767 OWN - NLM STAT- MEDLINE DA - 20070615 DCOM- 20070730 IS - 1044-5498 (Print) IS - 1044-5498 (Linking) VI - 26 IP - 6 DP - 2007 Jun TI - A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. PG - 435-43 AB - We constructed a combined DNA vaccine comprising genes encoding the antigens BCSP31, superoxide dismutase (SOD), and L7/L12 and evaluated its immunogenicity and protective efficacy. Immunization of mice with the combined DNA vaccine offered high protection against Brucella abortus (B. abortus) infection. The vaccine induced a vigorous specific immunoglobulin G (IgG) response, with higher IgG2a than IgG1 titers. Cytokine profiling performed at the same time showed a biased Th1-type immune response with significantly increased interferon-gamma and tumor necrosis factor-alpha stimulation. CD8(+), but not CD4(+), T cells accumulated at significantly higher levels after administration of the vaccine. Granzyme B-producing CD8(+) T cells were significantly higher in number in samples prepared from combined DNA-vaccinated mice compared with S19-vaccinated mice, demonstrating that the cytotoxicity lysis pathway is involved in the response to Brucella infection. The success of our combined DNA vaccine in a mouse model suggests its potential efficacy against brucellosis infection in large animals. AD - The National Laboratory of Protein Engineering and Plant Genetic Engineering, Peking University, Beijing, China. FAU - Yu, Da-Hai AU - Yu DH FAU - Hu, Xi-Dan AU - Hu XD FAU - Cai, Hong AU - Cai H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - DNA Cell Biol JT - DNA and cell biology JID - 9004522 RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Cytokines) RN - 0 (DNA, Bacterial) RN - 0 (Immunoglobulin G) RN - 0 (Vaccines, DNA) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - Antibodies, Bacterial/biosynthesis MH - Antigens, Bacterial/genetics MH - Bacterial Proteins/genetics/immunology MH - Base Sequence MH - Brucella Vaccine/*genetics/*pharmacology MH - Brucella abortus/enzymology/*genetics/*immunology MH - Brucellosis/*immunology/*prevention & control MH - Cytokines/biosynthesis MH - DNA, Bacterial/genetics MH - Female MH - Genes, Bacterial MH - Immunoglobulin G/biosynthesis MH - Lymphocyte Subsets/immunology MH - Mice MH - Mice, Inbred C57BL MH - Superoxide Dismutase/genetics/immunology MH - T-Lymphocytes, Cytotoxic/*immunology MH - Vaccines, DNA/*genetics/*pharmacology EDAT- 2007/06/16 09:00 MHDA- 2007/07/31 09:00 CRDT- 2007/06/16 09:00 AID - 10.1089/dna.2006.0552 [doi] PST - ppublish SO - DNA Cell Biol. 2007 Jun;26(6):435-43. PMID- 17600596 OWN - NLM STAT- MEDLINE DA - 20070724 DCOM- 20071003 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 25 IP - 32 DP - 2007 Aug 10 TI - A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. PG - 5958-67 AB - In the present study, we reported an attempt to improve the immunogenicity and protective capacity of the chimera BLSOmp31 using a different antigen delivery: DNA vaccination. Vaccination of BALB/c mice with the DNA vaccine coding for the chimera BLSOmp31 (pCIBLSOmp31) provided the best protection level against Brucella ovis, which was significantly higher than the given by the co-delivery of both plasmids coding for the whole proteins (pcDNABLS+pCIOmp31) and even higher than the control vaccine Rev.1. Moreover, pCIBLSOmp31 induced higher protection against Brucella melitensis than pcDNABLS+pCIOmp31 but similar protection than Rev.1. The chimera induced a strong humoral response against the inserted peptide. It also induced peptide- and BLS-specific cytotoxic T responses. The insertion of this peptide on BLS induced stronger T helper 1 responses specific for the carrier (BLS), thus our results represent a case of synergic strengthening between two Brucella antigens. Hitherto, this is the first indication that a recombinant subunit vaccine elicits greater protection than whole Brucella. AD - Laboratorio de Inmunogenetica, Hospital de Clinicas Jose de San Martin, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. jucassat@ffyb.uba.ar FAU - Cassataro, Juliana AU - Cassataro J FAU - Pasquevich, Karina A AU - Pasquevich KA FAU - Estein, Silvia M AU - Estein SM FAU - Laplagne, Diego A AU - Laplagne DA FAU - Zwerdling, Astrid AU - Zwerdling A FAU - de la Barrera, Silvia AU - de la Barrera S FAU - Bowden, Raul AU - Bowden R FAU - Fossati, Carlos A AU - Fossati CA FAU - Giambartolomei, Guillermo H AU - Giambartolomei GH FAU - Goldbaum, Fernando A AU - Goldbaum FA LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070612 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Bacterial Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Omp31 protein, Brucella melitensis) RN - 0 (Recombinant Proteins) RN - 0 (Rev.1 vaccine, Brucella melitensis) RN - 0 (Vaccines, DNA) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Bacterial Outer Membrane Proteins/*immunology MH - Bacterial Vaccines/*immunology MH - Brucella melitensis/*immunology MH - Brucella ovis/*immunology MH - Brucellosis/*immunology/*prevention & control MH - Immunoglobulin G/blood MH - Mice MH - Mice, Inbred BALB C MH - Recombinant Proteins/immunology MH - T-Lymphocytes, Cytotoxic/immunology MH - Time Factors MH - Vaccines, DNA/*immunology EDAT- 2007/06/30 09:00 MHDA- 2007/10/04 09:00 CRDT- 2007/06/30 09:00 PHST- 2007/04/27 [received] PHST- 2007/05/21 [revised] PHST- 2007/05/23 [accepted] PHST- 2007/06/12 [aheadofprint] AID - S0264-410X(07)00629-9 [pii] AID - 10.1016/j.vaccine.2007.05.049 [doi] PST - ppublish SO - Vaccine. 2007 Aug 10;25(32):5958-67. Epub 2007 Jun 12. PMID- 17686554 OWN - NLM STAT- MEDLINE DA - 20070907 DCOM- 20071108 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 25 IP - 37-38 DP - 2007 Sep 17 TI - Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. PG - 6721-9 AB - The immunogenicity and protective efficacy of recombinant SurA (rSurA) and rDnaK from Brucella spp. were evaluated in BALB/c mice. Immunization with rSurA in adjuvant induced a vigorous immunoglobulin G (IgG) response, with higher IgG2a than IgG1 titers. In addition, after in vitro stimulation with rSurA, spleen cells from rSurA-immunized mice produced interleukin-2 (IL-2), interferon (IFN)-gamma, IL-4 and IL-5. Immunization with rDnaK plus adjuvant induced a strong humoral response resulting in similar anti-rDnaK IgG titers than immunization with rDnaK alone. IgG2a titers predominated over IgG1 in mice injected with rDnaK alone or rDnaK plus adjuvant. Spleen cells from mice immunized with rDnaK plus adjuvant secreted IFN-gamma and IL-2 upon stimulation with rDnaK and induced a specific cytotoxic response. On the contrary, mice immunized with rDnaK alone did not exhibit a specific T helper or cytotoxic response in vitro. Mice given rSurA or rDnaK with adjuvant exhibited a significant degree of protection whereas immunization with rDnaK alone induced a low but still statistically significant level of protection against B. abortus infection. All studied vaccines were less protected than mice immunized with H38 or B. abortus strain 19 control vaccines. Altogether these results suggest that rSurA or rDnaK induce partial protection against B. abortus infection and could be useful candidates for the development of subunit vaccines against brucellosis. AD - Instituto de Estudios de la Inmunidad Humoral (IDEHU-CONICET), Facultad de Farmacia y Bioquimica, UBA, Buenos Aires, Argentina. FAU - Delpino, Maria Victoria AU - Delpino MV FAU - Estein, Silvia Marcela AU - Estein SM FAU - Fossati, Carlos Alberto AU - Fossati CA FAU - Baldi, Pablo Cesar AU - Baldi PC FAU - Cassataro, Juliana AU - Cassataro J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070723 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Brucella Vaccine) RN - 0 (Carrier Proteins) RN - 0 (Recombinant Proteins) RN - EC 3.6.1.- (Adenosine Triphosphatases) RN - EC 5.2.1.8 (Peptidylprolyl Isomerase) SB - IM MH - Adenosine Triphosphatases/genetics/*immunology/metabolism MH - Animals MH - Antibody Formation/immunology MH - Brucella Vaccine/*immunology MH - Brucella abortus/*immunology MH - Brucellosis/*immunology/*prevention & control MH - Carrier Proteins/genetics/*immunology/metabolism MH - Female MH - Mice MH - Mice, Inbred BALB C MH - Peptidylprolyl Isomerase/genetics/*immunology/metabolism MH - Recombinant Proteins/genetics/immunology/metabolism MH - T-Lymphocytes, Cytotoxic/immunology MH - Th1 Cells/immunology MH - Th2 Cells/immunology EDAT- 2007/08/10 09:00 MHDA- 2007/11/09 09:00 CRDT- 2007/08/10 09:00 PHST- 2007/05/16 [received] PHST- 2007/06/28 [revised] PHST- 2007/07/04 [accepted] PHST- 2007/07/23 [aheadofprint] AID - S0264-410X(07)00778-5 [pii] AID - 10.1016/j.vaccine.2007.07.002 [doi] PST - ppublish SO - Vaccine. 2007 Sep 17;25(37-38):6721-9. Epub 2007 Jul 23. PMID- 17715332 OWN - NLM STAT- MEDLINE DA - 20071009 DCOM- 20071113 LR - 20091118 IS - 1556-6811 (Print) VI - 14 IP - 10 DP - 2007 Oct TI - Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria. PG - 1296-301 AB - Previous findings indicate that Brucella antigens and those from nonpathogenic alphaproteobacteria (NPAP) are cross-recognized by the immune system. We hypothesized that immunization with NPAP would protect mice from Brucella infection. Mice were immunized subcutaneously with heat-killed Ochrobactrum anthropi, Sinorhizobium meliloti, Mesorhizobium loti, Agrobacterium tumefaciens, or Brucella melitensis H38 (standard positive control) before intravenous challenge with Brucella abortus 2308. Cross-reacting serum antibodies against Brucella antigens were detected at the moment of challenge in all NPAP-immunized mice. Thirty days after B. abortus challenge, splenic CFU counts were significantly lower in mice immunized with O. anthropi, M. loti, and B. melitensis H38 than in the phosphate-buffered saline controls (protection levels were 0.80, 0.66, and 1.99 log units, respectively). In mice immunized intraperitoneally with cytosoluble extracts from NPAP or Brucella abortus, protection levels were 1.58 for the latter, 0.63 for O. anthropi, and 0.40 for M. loti. To test whether the use of live NPAP would increase protection further, mice were both immunized and challenged by the oral route. Immunization with NPAP induced a significant increase in serum immunoglobulin G (IgG), but not serum or fecal IgA, against Brucella antigens. After challenge, anti-Brucella IgA increased significantly in the sera and feces of mice orally immunized with O. anthropi. For all NPAP, protection levels were higher than those obtained with systemic immunizations but were lower than those obtained by oral immunization with heat-killed B. abortus. These results show that immunization with NPAP, especially O. anthropi, confers partial protection against Brucella challenge. However, such protection is lower than that conferred by immunization with whole Brucella or its cytosoluble fraction. AD - Instituto de Estudios de la Immunidad Humoral (IDEHU, CONICET-UBA), Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, 1113 Buenos Aires, Argentina. FAU - Delpino, M Victoria AU - Delpino MV FAU - Estein, Silvia M AU - Estein SM FAU - Fossati, Carlos A AU - Fossati CA FAU - Baldi, Pablo C AU - Baldi PC LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070822 PL - United States TA - Clin Vaccine Immunol JT - Clinical and vaccine immunology : CVI JID - 101252125 RN - 0 (Brucella Vaccine) RN - 0 (Vaccines, Inactivated) SB - IM MH - Animals MH - Brucella Vaccine/*immunology MH - Brucella abortus/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/*immunology/*prevention & control MH - Hot Temperature MH - Mice MH - Ochrobactrum anthropi/*immunology MH - Rhizobium radiobacter/*immunology MH - Sinorhizobium meliloti/*immunology MH - Vaccines, Inactivated/immunology PMC - PMC2168122 OID - NLM: PMC2168122 EDAT- 2007/08/24 09:00 MHDA- 2007/11/14 09:00 CRDT- 2007/08/24 09:00 PHST- 2007/08/22 [aheadofprint] AID - CVI.00459-06 [pii] AID - 10.1128/CVI.00459-06 [doi] PST - ppublish SO - Clin Vaccine Immunol. 2007 Oct;14(10):1296-301. Epub 2007 Aug 22. PMID- 17894637 OWN - NLM STAT- MEDLINE DA - 20070926 DCOM- 20071127 IS - 1863-1959 (Print) VI - 54 IP - 8 DP - 2007 TI - An aerosolized Brucella spp. challenge model for laboratory animals. PG - 281-5 AB - To characterize the optimal aerosol dosage of Brucella abortus strain 2308 (S2308) and B. melitensis (S16M) in a laboratory animal model of brucellosis, dosages of 10(3)-10(10) colony forming units (CFU) were nebulized to mice. Although tissue weights were minimally influenced, total CFU per tissues increased beginning at 10(6)-10(7) CFU dosages, with 10(9) CFU appearing to be an optimal dosage for S16M or S2308 aerosol delivery. At 12 weeks after vaccination with 10(7) CFU of B. abortus strain RB51 (SRB51) or saline (control), mice were challenged intraperitoneally (i.p.) (6.4 x 10(4) CFU) or via aerosol (1.76 x 10(9) CFU) with S2308. Mice vaccinated with SRB51 had reduced (P < 0.05) splenic, liver and lung colonization (total CFU and CFU/g) after i.p. challenge with S2308 as compared with control mice after i.p. S2308 challenge. Control and SRB51-vaccinated mice did not differ (P > 0.05) in splenic, liver or lung colonization after aerosol S2308 challenge. Failure to demonstrate vaccine protection was not because of a high aerosol challenge dosage as colonization of spleen and liver tissues was lower (P < 0.05) after aerosol challenge when compared with control mice after i.p. S2308 challenge. AD - Bacterial Diseases Research Unit, National Animal Disease Center, USDA, Agriculture, Research Service, Ames, IA 50010, USA. Solsen@NADC.ARS.USDA.GOV FAU - Olsen, S C AU - Olsen SC FAU - Waters, W R AU - Waters WR FAU - Stoffregen, W S AU - Stoffregen WS LA - eng PT - Journal Article PL - Germany TA - Zoonoses Public Health JT - Zoonoses and public health JID - 101300786 RN - 0 (Aerosols) SB - IM MH - Aerosols MH - Animals MH - Brucella abortus/*pathogenicity MH - Brucella melitensis/*pathogenicity MH - Brucellosis/immunology/*microbiology MH - Disease Models, Animal MH - Female MH - Humans MH - Injections, Intraperitoneal MH - Liver/microbiology MH - Lung/microbiology MH - Mice MH - Mice, Inbred BALB C MH - Spleen/microbiology MH - Stem Cells MH - Zoonoses/microbiology EDAT- 2007/09/27 09:00 MHDA- 2007/12/06 09:00 CRDT- 2007/09/27 09:00 AID - JVB1063 [pii] AID - 10.1111/j.1863-2378.2007.01063.x [doi] PST - ppublish SO - Zoonoses Public Health. 2007;54(8):281-5. PMID- 17931756 OWN - NLM STAT- MEDLINE DA - 20071030 DCOM- 20080117 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 25 IP - 46 DP - 2007 Nov 14 TI - Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. PG - 7873-84 AB - Brucellosis is an important zoonotic disease that causes abortion in cattle and undulant fever, arthritis, endocarditis and meningitis in human. In spite of the fact that immunization could be an efficient measure to control brucellosis, not a single ideal vaccine against this important disease has been developed so far. In order to develop an effective vaccine against Brucella abortus (B. abortus), various protective immunodominant gene/protein products of the pathogen have been studied in combination with different adjuvants. For example, recombinant ribosomal protein L7/L12 (rL7/L12) although an interesting T-cell antigen, normally failed to evoke protective immune response when used in free form. In the present study we have demonstrated that Escherischia coli (E. coli) lipid liposome (escheriosome)-mediated cytosolic delivery of recombinant rL7/L12 protein can elicit strong immunological responses in the Balb/c mice. In contrast, egg PC/Chol liposome entrapped rL7/L12, in a manner similar to its free form, was found to impart relatively poor immune response. Furthermore, escheriosome entrapped rL7/L12 protein elicited high IgG2a isotype response suggestive of its relevance in imparting protection against brucellosis in mice. Altogether the present study is a clear indicative of the possible use of escheriosome-based delivery of rL7/L12 protein to induce protective immune responses against experimental murine brucellosis. AD - Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202002, India. FAU - Mallick, A I AU - Mallick AI FAU - Singha, H AU - Singha H FAU - Khan, S AU - Khan S FAU - Anwar, T AU - Anwar T FAU - Ansari, M A AU - Ansari MA FAU - Khalid, R AU - Khalid R FAU - Chaudhuri, P AU - Chaudhuri P FAU - Owais, M AU - Owais M LA - eng PT - Journal Article DEP - 20070920 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antigens, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Liposomes) RN - 0 (Recombinant Proteins) RN - 0 (Ribosomal Proteins) SB - IM MH - Abortion, Septic/genetics/immunology/prevention & control MH - Adjuvants, Immunologic/genetics/pharmacology MH - Animals MH - Antigens, Bacterial/genetics/*immunology/pharmacology MH - Arthritis/genetics/immunology/prevention & control MH - Brucella Vaccine/genetics/*immunology/pharmacology MH - Brucella abortus/genetics/*immunology MH - Brucellosis/genetics/immunology/*prevention & control MH - Cattle MH - Disease Models, Animal MH - Endocarditis/genetics/immunology/prevention & control MH - Escherichia coli/chemistry/genetics/*immunology MH - Female MH - Fever/genetics/immunology/prevention & control MH - Humans MH - Liposomes/chemistry/*immunology/pharmacology MH - Mice MH - Mice, Inbred BALB C MH - Pregnancy MH - Recombinant Proteins/genetics/*immunology/pharmacology MH - Ribosomal Proteins/genetics/*immunology/pharmacology MH - T-Lymphocytes/immunology MH - Zoonoses EDAT- 2007/10/13 09:00 MHDA- 2008/01/18 09:00 CRDT- 2007/10/13 09:00 PHST- 2007/07/15 [received] PHST- 2007/08/31 [revised] PHST- 2007/09/03 [accepted] PHST- 2007/09/20 [aheadofprint] AID - S0264-410X(07)01027-4 [pii] AID - 10.1016/j.vaccine.2007.09.008 [doi] PST - ppublish SO - Vaccine. 2007 Nov 14;25(46):7873-84. Epub 2007 Sep 20. PMID- 18319583 OWN - NLM STAT- MEDLINE DA - 20080305 DCOM- 20080411 IS - 0916-7250 (Print) IS - 0916-7250 (Linking) VI - 70 IP - 2 DP - 2008 Feb TI - Cytokine responses in camels (Camelus bactrianus) vaccinated with Brucella abortus strain 19 vaccine. PG - 197-201 AB - In the present study, we determined the levels of cytokines produced by camel (Camelus bactrianus) peripheral blood mononuclear cells (PBMCs) in response to live attenuated Brucella abortus (B. abortus) S19 vaccine. Seven camels were vaccinated with commercial B. abortus S19 vaccine, and their cytokine responses were determined using a real-time PCR assay. Cytokine responses to B. abortus S19 were examined at 6 hr, 48 hr and 1, 2 and 3 weeks post-vaccination. Serological tests were performed to further confirm these immune responses. The results revealed that IFN-gamma and IL-6 were upregulated during the first week post-vaccination. Low level expressions of IL-1alpha, IL-1beta, TNFalpha and IL-10 and no expression of IL-2 and IL-4 were observed compared with the control camels. The findings showed that B. abortus stimulates cell-mediated immunity by directly activating camel Th1 cells to secrete IFN-gamma. This quantification of cytokine expression in camels is essential for understanding of Camelidae disease development and protective immune responses. This is the first report of in vivo camel cytokine quantification after vaccination. AD - Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Hokkaido, Japan. FAU - Odbileg, Raadan AU - Odbileg R FAU - Purevtseren, Byambaa AU - Purevtseren B FAU - Gantsetseg, Dorj AU - Gantsetseg D FAU - Boldbaatar, Bazartseren AU - Boldbaatar B FAU - Buyannemekh, Tumurjav AU - Buyannemekh T FAU - Galmandakh, Zagd AU - Galmandakh Z FAU - Erdenebaatar, Janchivdorj AU - Erdenebaatar J FAU - Konnai, Satoru AU - Konnai S FAU - Onuma, Misao AU - Onuma M FAU - Ohashi, Kazuhiko AU - Ohashi K LA - eng PT - Controlled Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Japan TA - J Vet Med Sci JT - The Journal of veterinary medical science / the Japanese Society of Veterinary Science JID - 9105360 RN - 0 (Brucella Vaccine) RN - 0 (Cytokines) RN - 0 (RNA, Messenger) SB - IM MH - Animals MH - Brucella/classification/*immunology MH - Brucella Vaccine/*immunology MH - Brucellosis/immunology/*veterinary MH - Camels/*immunology/metabolism MH - Cytokines/genetics/*immunology MH - Gene Expression Regulation MH - RNA, Messenger/genetics/metabolism MH - Time Factors EDAT- 2008/03/06 09:00 MHDA- 2008/04/12 09:00 CRDT- 2008/03/06 09:00 AID - JST.JSTAGE/jvms/70.197 [pii] PST - ppublish SO - J Vet Med Sci. 2008 Feb;70(2):197-201. PMID- 18362129 OWN - NLM STAT- MEDLINE DA - 20080520 DCOM- 20080703 LR - 20091118 IS - 1098-5522 (Electronic) IS - 0019-9567 (Linking) VI - 76 IP - 6 DP - 2008 Jun TI - Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. PG - 2448-55 AB - The development of safe and efficacious immunization systems to prevent brucellosis is needed to overcome the disadvantages of the currently licensed vaccine strains that restrict their use in humans. Alginate microspheres coated with a protein of the parasite Fasciola hepatica (vitelline protein B [VpB]) and containing live Brucella melitensis attenuated mutant vjbR::Tn5 (BMEII1116) were evaluated for vaccine efficacy and immunogenicity in mice. A single immunization dose in BALB/c mice with the encapsulated vjbR mutant improved protection against wild-type B. melitensis 16M challenge compared to the nonencapsulated vaccine strain (P < 0.05). The encapsulated mutant was also shown to induce a sustained elevation of Immunoglobulin G levels. Cytokine secretion from spleen cells of mice vaccinated with the encapsulated vjbR::Tn5 revealed elevated secretion of gamma interferon and interleukin-12, but no interleukin-4, suggesting an induction of a T helper 1 response reflecting the enhanced immunity associated with microencapsulation. Together, these results suggest that microencapsulation of live attenuated organisms offers the ability to increase the efficacy of vaccine candidates. AD - Veterinary Pathobiology, Texas A&M University and Texas Agricultural Experiment Station, College Station, TX 77845-1114, USA. FAU - Arenas-Gamboa, Angela M AU - Arenas-Gamboa AM FAU - Ficht, Thomas A AU - Ficht TA FAU - Kahl-McDonagh, Melissa M AU - Kahl-McDonagh MM FAU - Rice-Ficht, Allison C AU - Rice-Ficht AC LA - eng GR - IU54AI 057156/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20080324 PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Vaccines) RN - 0 (Capsules) RN - 0 (Cytokines) RN - 0 (Delayed-Action Preparations) RN - 0 (Immunoglobulin G) RN - 0 (Vaccines, Attenuated) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Bacterial Vaccines/administration & dosage/*immunology MH - Brucella melitensis/genetics/*immunology/pathogenicity MH - Brucellosis/immunology/*prevention & control MH - Capsules MH - Cytokines/biosynthesis MH - Delayed-Action Preparations MH - Female MH - Immunization MH - Immunoglobulin G/blood MH - Injections, Intraperitoneal MH - Macrophages/microbiology MH - Mice MH - Mice, Inbred BALB C MH - Mutation MH - Random Allocation MH - Spleen/immunology/microbiology MH - Vaccines, Attenuated/administration & dosage/immunology MH - Virulence PMC - PMC2423109 OID - NLM: PMC2423109 EDAT- 2008/03/26 09:00 MHDA- 2008/07/04 09:00 CRDT- 2008/03/26 09:00 PHST- 2008/03/24 [aheadofprint] AID - IAI.00767-07 [pii] AID - 10.1128/IAI.00767-07 [doi] PST - ppublish SO - Infect Immun. 2008 Jun;76(6):2448-55. Epub 2008 Mar 24. PMID- 18423950 OWN - NLM STAT- MEDLINE DA - 20080509 DCOM- 20080708 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 26 IP - 21 DP - 2008 May 19 TI - Immunopathological responses and kinetics of Brucella melitensis Rev 1 infection after subcutaneous or conjunctival vaccination in rams. PG - 2562-9 AB - The innocuousness of the Brucella melitensis Rev 1 live attenuated vaccine strain has never been fully assessed in rams. The immunopathological responses and the kinetics and distribution of the infection induced by this strain were determined after subcutaneous or conjunctival vaccination in both young (3-4 months old) and adult (12 months old) rams. At regular intervals after vaccination the animals were bled for serological studies, and slaughtered for both pathological and bacteriological examinations. The serological response after conjunctival inoculation was of lower intensity and duration than that induced subcutaneously, being the differences more evident in young rams. No genital lesions were produced and genital organs and accessory sexual glands were never found infected, being Rev 1 infection restricted to lymph nodes and spleen. Immunostained Rev 1 bacteria were located intracellularly in plasmablasts, dendritic follicular cells and macrophages in the target lymph nodes, in which cellular hyperplasia was the dominant pathological response. Subcutaneous vaccination induced a generalized infection by 2 weeks after vaccination, being then restricted to the prescapular target lymph node. Infection after conjunctival vaccination was less generalized, being restricted essentially to the cranial lymph nodes. Rev 1 infection was fully cleared by 3 months after vaccination in all animals. These results confirm the innocuousness of B. melitensis Rev 1 vaccine in rams. AD - Unidad de Sanidad Animal, Centro de Investigacion y Tecnologia Agroalimentaria de Aragon, Gobierno de Aragon, Zaragoza, Spain. FAU - Munoz, Pilar-Maria AU - Munoz PM FAU - de Miguel, Maria-Jesus AU - de Miguel MJ FAU - Grillo, Maria-Jesus AU - Grillo MJ FAU - Marin, Clara-Maria AU - Marin CM FAU - Barberan, Montserrat AU - Barberan M FAU - Blasco, Jose-Maria AU - Blasco JM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080403 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Vaccines, Attenuated) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Brucella Vaccine/*adverse effects/immunology MH - Brucella melitensis/immunology/*pathogenicity MH - Brucellosis/immunology/*microbiology/*pathology MH - Dendritic Cells, Follicular/microbiology MH - Genitalia, Male/microbiology/pathology MH - Injections, Subcutaneous MH - Lymph Nodes/microbiology/pathology MH - Macrophages/microbiology MH - Male MH - Plasma Cells/microbiology MH - Sheep MH - Sheep Diseases/immunology/*microbiology/*pathology MH - Spleen/microbiology/pathology MH - Vaccines, Attenuated/adverse effects/immunology EDAT- 2008/04/22 09:00 MHDA- 2008/07/09 09:00 CRDT- 2008/04/22 09:00 PHST- 2008/01/22 [received] PHST- 2008/03/04 [revised] PHST- 2008/03/12 [accepted] PHST- 2008/04/03 [aheadofprint] AID - S0264-410X(08)00330-7 [pii] AID - 10.1016/j.vaccine.2008.03.030 [doi] PST - ppublish SO - Vaccine. 2008 May 19;26(21):2562-9. Epub 2008 Apr 3. PMID- 18462974 OWN - NLM STAT- MEDLINE DA - 20080602 DCOM- 20080826 IS - 1286-4579 (Print) IS - 1286-4579 (Linking) VI - 10 IP - 6 DP - 2008 May TI - Expression of Babesia bovis rhoptry-associated protein 1 (RAP1) in Brucella abortus S19. PG - 635-41 AB - Brucella abortus strain 19 (live vaccine) induces a strong humoral and cellular immune response and therefore, it is an attractive vector for the delivery of heterologous antigens. The objective of the present study was to express the rhoptry-associated protein (RAP1) of Babesia bovis in B. abortus S19, as a model for heterologous expression of immunostimulatory antigens from veterinary pathogens. A plasmid for the expression of recombinant proteins fused to the aminoterminal of the outer membrane lipoprotein OMP19 was created, pursuing the objective of increasing the immunogenicity of the recombinant antigen being expressed by its association to a lipid moiety. Recombinant strains of B. abortus S19 expressing RAP1 as a fusion protein either with the first amino acids of beta-galactosidase (S19pBB-RAP1) or B. abortus OMP19 (S19pBB19-RAP1) were generated. Plasmid stability and the immunogenicity of the heterologous proteins were analyzed. Mice immunized with S19pBB-RAP1 or S19pBB19-RAP1 developed specific humoral immune response to RAP1, IgG2a being the predominant antibody isotype. Furthermore, a specific cellular immune response to recombinant RAP1 was elicited in vitro by lymphocytes from mice immunized with both strains. Therefore, we concluded that B. abortus S19 expressing RAP1 is immunostimulatory and may provide the basis for combined heterologous vaccines for babesiosis and brucellosis. AD - Instituto de Biotecnologia, CICVyA, INTA-Castelar, Las Cabanas y Los Reseros s/n (B1712WAA) Castelar, Buenos Aires, Argentina. FAU - Sabio y Garcia, Julia V AU - Sabio y Garcia JV FAU - Farber, Marisa AU - Farber M FAU - Carrica, Mariela AU - Carrica M FAU - Cravero, Silvio AU - Cravero S FAU - Macedo, Gilson C AU - Macedo GC FAU - Bigi, Fabiana AU - Bigi F FAU - Oliveira, Sergio C AU - Oliveira SC FAU - Rossetti, Osvaldo AU - Rossetti O FAU - Campos, Eleonora AU - Campos E LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080223 PL - France TA - Microbes Infect JT - Microbes and infection / Institut Pasteur JID - 100883508 RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Protozoan Proteins) RN - 0 (Recombinant Fusion Proteins) RN - 0 (Vaccines, Combined) RN - 0 (rhoptry-associated protein-1, Babesia) SB - IM MH - Animals MH - Babesia bovis/*genetics MH - Babesiosis/immunology/prevention & control MH - Bacterial Outer Membrane Proteins/immunology MH - Brucella Vaccine/immunology MH - Brucella abortus/genetics/*metabolism MH - Brucellosis/immunology/prevention & control MH - Genetic Vectors MH - Mice MH - Protozoan Proteins/genetics/*metabolism MH - Recombinant Fusion Proteins/*metabolism MH - Vaccines, Combined/administration & dosage/immunology EDAT- 2008/05/09 09:00 MHDA- 2008/08/30 09:00 CRDT- 2008/05/09 09:00 PHST- 2007/10/04 [received] PHST- 2008/02/12 [revised] PHST- 2008/02/14 [accepted] PHST- 2008/02/23 [aheadofprint] AID - S1286-4579(08)00055-5 [pii] AID - 10.1016/j.micinf.2008.02.010 [doi] PST - ppublish SO - Microbes Infect. 2008 May;10(6):635-41. Epub 2008 Feb 23. PMID- 18763048 OWN - NLM STAT- MEDLINE DA - 20090318 DCOM- 20090618 IS - 0049-4747 (Print) IS - 0049-4747 (Linking) VI - 41 IP - 4 DP - 2009 Apr TI - Seroprevalence of brucellosis in yaks (Poephagus grunniens) in India and evaluation of protective immunity to S19 vaccine. PG - 587-92 AB - The present study was carried out to explore the seroprevalence of brucellosis in yaks of North-Eastern hilly yak tracts of Arunachal Pradesh, India. Of 374 animals tested, 23.79, 21.11 and 18.98% were found positive for brucellosis using avidin-biotin ELISA (AB-ELISA), Rose-Bengal plate test (RBPT) and standard tube-agglutination test (STAT), respectively. The relative sensitivity and specificity for STAT were 79.77 and 100%, respectively and the same for RBPT were 88.76 and 100%, respectively in comparison to AB-ELISA. The alarming prevalence as recorded was highest among the yak cows (31.42%) followed by heifers (23.85%) and bulls (8.88%). The immune response in yaks following standard dose of calfhood vaccination with Brucella abortus strain 19 vaccine showed that protective antibody level persisted up to 210 days. This is the first report from India on prevalence of brucellosis and immunization with B abortus strain 19 vaccine in yaks. The present investigation would be a valuable guideline for future control measure and eradication programme of brucellosis in yaks. AD - National Research Centre on Yak, Dirang, Arunachal Pradesh 790 101, India. FAU - Bandyopadhyay, Samiran AU - Bandyopadhyay S FAU - Sasmal, Debasis AU - Sasmal D FAU - Dutta, Tapan Kumar AU - Dutta TK FAU - Ghosh, Monoj Kumar AU - Ghosh MK FAU - Sarkar, Mihir AU - Sarkar M FAU - Sasmal, Nihar Kanta AU - Sasmal NK FAU - Bhattacharya, Mohan AU - Bhattacharya M LA - eng PT - Clinical Trial PT - Journal Article DEP - 20080902 PL - United States TA - Trop Anim Health Prod JT - Tropical animal health and production JID - 1277355 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Brucella Vaccine/*immunology MH - Brucellosis, Bovine/epidemiology/*immunology MH - *Cattle MH - Female MH - India/epidemiology MH - Male MH - Sensitivity and Specificity MH - Seroepidemiologic Studies MH - Time Factors EDAT- 2008/09/03 09:00 MHDA- 2009/06/19 09:00 CRDT- 2008/09/03 09:00 PHST- 2008/04/29 [received] PHST- 2008/08/19 [accepted] PHST- 2008/09/02 [aheadofprint] AID - 10.1007/s11250-008-9228-0 [doi] PST - ppublish SO - Trop Anim Health Prod. 2009 Apr;41(4):587-92. Epub 2008 Sep 2. PMID- 18836016 OWN - NLM STAT- MEDLINE DA - 20081112 DCOM- 20081211 LR - 20091118 IS - 1098-5336 (Electronic) IS - 0099-2240 (Linking) VI - 74 IP - 22 DP - 2008 Nov TI - Brucella abortus strain RB51 leucine auxotroph as an environmentally safe vaccine for plasmid maintenance and antigen overexpression. PG - 7051-5 AB - To avoid potentiating the spread of an antibiotic resistance marker, a plasmid expressing a leuB gene and a heterologous antigen, green fluorescent protein (GFP), was shown to complement a leucine auxotroph of cattle vaccine strain Brucella abortus RB51, which protected CD1 mice from virulent B. abortus 2308 and elicited GFP antibodies. AD - Department of Biomedical Sciences and Pathobiology and Center for Molecular Medicine and Infectious Diseases, Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, VA 24061-0342, USA. FAU - Rajasekaran, Parthiban AU - Rajasekaran P FAU - Seleem, Mohamed N AU - Seleem MN FAU - Contreras, Andrea AU - Contreras A FAU - Purwantini, Endang AU - Purwantini E FAU - Schurig, Gerhardt G AU - Schurig GG FAU - Sriranganathan, Nammalwar AU - Sriranganathan N FAU - Boyle, Stephen M AU - Boyle SM LA - eng PT - Journal Article DEP - 20081003 PL - United States TA - Appl Environ Microbiol JT - Applied and environmental microbiology JID - 7605801 RN - 0 (Brucella Vaccine) RN - 147336-22-9 (Green Fluorescent Proteins) RN - 61-90-5 (Leucine) SB - IM MH - Animals MH - Brucella Vaccine/*genetics/*immunology MH - Brucella abortus/*genetics/*immunology MH - Brucellosis/*prevention & control MH - Gene Dosage MH - Genes, Reporter MH - Genetic Complementation Test MH - Green Fluorescent Proteins/biosynthesis/genetics MH - Leucine/*biosynthesis/*genetics MH - Mice MH - Plasmids PMC - PMC2583484 OID - NLM: PMC2583484 EDAT- 2008/10/07 09:00 MHDA- 2008/12/17 09:00 CRDT- 2008/10/07 09:00 PHST- 2008/10/03 [aheadofprint] AID - AEM.01511-08 [pii] AID - 10.1128/AEM.01511-08 [doi] PST - ppublish SO - Appl Environ Microbiol. 2008 Nov;74(22):7051-5. Epub 2008 Oct 3.